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Abstract
TITLE: Health Risk Perceptions Regarding Electronic Nicotine Delivery Systems
(ENDS) Among Individuals with Respiratory Illnesses
AUTHOR: Sarah Ann Sebban, M.S.
MAJOR ADVISOR: Vida. L. Tyc, Ph.D.
Electronic nicotine delivery systems (ENDS), also known as electronic cigarettes,
are portable battery-powered devices used to smoke or “vape” a flavored solution which
usually contains nicotine. Many national organizations (CDC, AMA, AAFP, ALA, AHA)
have recognized the alarmingly increased rates of ENDS use in the United States,
especially among certain populations. Those most likely to engage in ENDS use are
youth and young adults, and adults who already smoke combustible cigarettes. Many
people perceive ENDS use as a healthier alternative to smoking regular cigarettes and
thus, are more willing to initiate ENDS use. However, research has indicated that ENDS
use is associated with negative health effects, especially to those already diagnosed with a
respiratory illness or disease such as asthma, chronic obstructive pulmonary disease
(COPD), interstitial lung disease, and lung cancer. The purpose of this study was to
determine the rates of ENDS use among those with respiratory illnesses and to examine
their health risk perceptions associated with ENDS. Other risk factors, including
demographic, psychosocial, and health-related factors associated with ENDS risk
perceptions were also examined.
This study included 270 adult participants with respiratory illnesses who were
current/past smokers (n = 28, 10%), current/past vapers (n = 7, 3%), current/past dual
users (n = 208, 77%), and ever dual users (n = 27, 10%). The sample included 146 men,
101 women, 19 transwomen, 3 transmen, and one individual who identified as gender
fluid. Most respondents were between the ages of 25-34 years old.
Results demonstrated that risk perceptions associated with ENDS use were
significantly greater for those smoking or vaping a single product compared to those who
were current dual users, U = 3988, z = -6.18, p < .001. ENDS risk perceptions were also
significantly associated with gender, ethnicity, geographic region, and race. Particularly,
participants who identified as male/transman, Hispanic/Latino, from the South and
Midwest U.S. regions, and of a minority race were more likely to report lower risk
perceptions associated with ENDS use. Likewise, those who had one or more friends who
vaped were more likely to have lower ENDS risk perceptions compared to those who had
no friends who vaped.
More than half of this sample endorsed ENDS use as an effective coping method
for stress management (n = 146, 54%). Similarly, 66% (n = 179) agreed that ENDS use is
an effective tool for smoking cessation and 76% (n = 206) agreed that ENDS products
could help with reducing the number of cigarettes smoked (i.e., harm reduction strategy).
Although more than half of the participants (n = 159, 59%) endorsed that their health care
providers have never advised the use of ENDS products for smoking cessation, 33% (n =
90) endorsed being advised this once or twice, and 8% (n = 21) of participants endorsed
being advised frequently from a healthcare provider to use ENDS products for smoking
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cessation. In terms of respiratory-health risk factors, an individual's overall health status
significantly predicted ENDS Risk Perceptions, B = 0.70, t (265) = 3.42, p < .001,
indicating that on average, a one standard deviation-unit increase in Health Status score
increased the value of ENDS Risk Perception scores by 0.70 standard deviation units.
Those with a poorer health status were more likely to have higher risk perceptions related
to ENDS use.
Based on the results from this study, medical practitioners can be more mindful in
sharing the negative health outcomes of dual using among those who have a chronic
respiratory condition and currently smoke and vape. Since this population often requires
frequent medical care and hospital visits, it would be worthwhile to modify respiratory
medical standards to include education about the negative health effects of vaping to be
regularly discussed with patients. The association between health perceptions and
smoking/vaping status demonstrated in this study, and the fact that health perceptions are
modifiable, suggests that provider advice about smoking/vaping-related health risks may
influence behavioral change.
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Review of the Literature
Prevalence of Tobacco, ENDS, and Dual Use Among the General U.S. Population
Electronic Nicotine Delivery Systems (ENDS) are defined as portable,
noncombustible smoking products in contrast to conventional tobacco, combustible
cigarettes. These products use an “e-liquid” that may contain nicotine, as well as varying
mixtures of flavorings, propylene glycol, vegetable glycerin, water, and other ingredients
(FDA, 2020). The e-liquid is then heated to create an aerosol that the user inhales into
their lungs. Bystanders can also breathe in this aerosol when the user exhales it into the
atmosphere. ENDS may be manufactured to look like conventional cigarettes, cigars, or
pipes. Some devices resemble pens or USB flash drives. Larger devices, such as tank
systems or mods, generally do not resemble cigarettes. ENDS are known by various
names colloquially: vapes, vaporizers, vape pens, hookah pens, electronic cigarettes (ecigarettes or e-cigs), and e-pipes. Although each ENDS device varies in design, the
products generally contain similar components: a mouthpiece, cartridge tank that holds
the e-liquid, heating element that turns the e-liquid into vapor, microprocessor, switch to
activate the heating element, and a battery (FDA, 2020).
ENDS were first introduced in the United States in 2007; the availability and use
of ENDS devices have increased exponentially in more recent years (Gravely et al., 2014;
McMillen, et al., 2015). The significant increase in ENDS use has been especially notable
among youth in the U.S., whose ENDS use has surpassed combustible cigarettes as the
most used tobacco product in the past two years (Wang et al., 2018). According to the
CDC, in 2018 more than 3.6 million U.S. middle and high school students used ecigarettes in the past 30 days, including approximately 5% of middle school students and
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20% of high school students. According to analysis done by the American Lung
Association (ALA, 2021) on the CDC’s National Youth Tobacco Survey, from years
2011 to 2019, “current use” of e-cigarettes (vaping on most or some days over the past
month) increased 1650% among middle school students, from 0.6% to 10.5%; it has also
increased 1733% among high school students, from 1.5% to 27.5%. In 2019, close to 2.9
million youth started using e-cigarettes, demonstrating a significant increase from
previous years (ALA, 2021).
While rates of ENDS use among adults are relatively low compared to youth,
ENDS use has similarly increased among a select group of adults- young adults. A
review of the rates in all ages (adults 18 years and older), based on data from The
National Health Interview Survey conducted in 2018, showed that 14.9% had ever used
an electronic cigarette and 3.2% were current e-cigarette users (Villarroel et al., 2020).
The highest prevalence among adults who had ever used or was a current e-cigarette user
was among those aged 18–24 years, or what is known as the ‘young adult’ demographic.
Specifically, 25.8% of young adults reported ever using e-cigarettes, the highest amongst
all other age groups. This shows a 3% increase from the rates collected in 2016 (CDC,
2017). In another analysis conducted by the American Lung Association (ALA, 2021) on
trends of the National Health Interview Survey, the number of young adults (aged 18-24)
who currently used e-cigarettes increased by 49% from years 2014 to 2018. To put that
into perspective, all other adult age groups demonstrated a slight decrease in e-cigarette
use over those same years (ALA, 2021).
The term “dual use” describes using different forms of tobacco products such as
electronic cigarettes (e-cigarettes), smokeless tobacco, or other tobacco products in
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addition to combustible cigarettes (CDC- Dual Use, 2020). For example, an individual
who smokes regular combustible cigarettes and e-cigarettes would be considered a “dual
user.” Based on the data from The National Health Interview Survey conducted in 2018,
the percentage of adults who had ever used an e-cigarette varied significantly based on
individuals’ cigarette smoking status (Villarroel et al. 2020). The percentage of adults
who had ever used an e-cigarette and were current e-cigarette users was highest among
former cigarette smokers who quit within the past year. The percentage of adults who
were current e-cigarette users was lower for current cigarette smokers (9.7%) than for
former cigarette smokers who quit within the past year (25.2%) and former cigarette
users who quit between 1–4 years ago (17.3%). These findings suggest that people who
smoke combustible cigarettes are more likely to begin using e-cigarettes, shortly after
quitting combustible cigarettes.
In a recent study conducted by Kava et al. (2020), the authors measured and
compared the use of conventional cigarettes, e-cigarettes, and dual use among adult
employees in the workplace. Out of the 221,264 survey respondents, approximately 17%
were current smokers of any product, 14% used conventional cigarettes, 5% used ecigarettes, and 2% were dual users. E-cigarette only and dual use were generally highest
among young adults (18–24 years), male, and less-educated respondents and lowest for
respondents who identified as black, Asian/Native Hawaiian/Pacific Islander, or Hispanic
than for white respondents. Interestingly, rates of cigarette-only and dual use were higher
for respondents who did not have health care coverage (Kava et al. 2020).
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Prevalence of Tobacco Smoking Among Those with Respiratory Illness
While vaping rates among individuals who have respiratory illnesses have not
been determined for various reasons, rates for cigarette smoking among this medically
compromised group are available. Prevalence rates for cigarette smoking among
asthmatics in the U.S. averages around 21% and ranges by state, from lowest being 12%
in Minnesota/Utah to the highest being 32% in Kentucky, according to the BRFSS (CDC,
2010). Furthermore, rates from the BRFSS (CDC, 2017) showed that among those with
Chronic Obstructive Pulmonary Disease (COPD) in the U.S., 15.2% are current smokers,
7.6% are past smokers, and 2.8% are never smokers (CDC, 2017). In comparison to other
medically comprised groups, studies have shown a range between 50%-83% of cancer
patients that continue to smoke even after receiving a cancer diagnosis (Cataldo et al.
2010; Duff et al., 2008; Sardari Nia et al., 2005). A longitudinal study including over
10,000 individuals which measured smoking habits of people with cardiovascular disease
(CVD) and coronary heart disease (CHD), found that for the daily smokers, 11.2% had
CVD and 10.3% had CHD. For the ever smokers, 6.3% had CVD and 5.4% had CHD, for
the former smokers, 13.4% had CVD while 10.8% had CHD (Amiri et al., 2019).
Notably, this suggested that people with respiratory or other chronic medical conditions
often continue to smoke despite continued medical problems.
Geographic location in the U.S. also plays a role in the prevalence rates of
smoking among individuals with respiratory illnesses (CDC, 2017). Among current
smokers, age-adjusted COPD prevalence ranged from 7.8% in Hawaii to 25.9% in West
Virginia. Among former smokers, age-adjusted COPD prevalence ranged from 4.7% in
Hawaii to 15.1% in West Virginia. Among never smokers, age-adjusted COPD
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prevalence ranged from 1.6% in Minnesota to 6.0% in West Virginia. Rates of current
asthma in the U.S. vary by region, the Northeast having the highest prevalence at 8.6%
and the Midwest with the lowest prevalence at 7.7.% (NHIS, 2019). Similarly, rates of
asthma attacks are more prevalent in the Northeast region of the U.S. at 3.5% and lowest
in the Midwest region of the U.S. at 3.0% (NHIS, 2019). Alternatively, COPD presents
highest prevalence rates in the South region of the U.S. at 5.3% and lowest prevalence
rates in the Northeast and Western regions of the U.S. at 3.7% (NHIS, 2019). This
information demonstrates higher prevalence rates in certain geographic areas.
Regions throughout the U.S. show varying prevalence rates of smoking as well.
The U.S. Census Bureau divides the country into 4 major regions as follows: Northeast,
Midwest, South, and the West. Among current smokers, COPD prevalence was highest in
the South and Midwest regions; and higher prevalence of COPD was identified in
Southern states, regardless of smoking status (CDC, 2017). According to the Surgeons
General Report on The Health Consequences of Smoking- 50 Years of Progress
(USDHHS, 2014), people living in certain regions more often suffer from poor health,
including chronic respiratory ailments, due to higher rates of tobacco use and cigarette
smoking in those areas. According to the results from the National Survey on Drug Use
and Health (SAMHSA, 2017), rates of cigarette smoking among U.S. adults are highest
among people living in the South (22.7%) and Midwest (22.2%) regions, and lowest
among individuals living in the Northeast (20.1%) and West (16.3%) regions. People in
the South and Midwest also tend to use several types of tobacco products including
smokeless tobacco (i.e., chewing tobacco, snuff, snus, dissolvable tobacco) and
cigarettes, increasing their risks of developing serious illnesses/diseases (USDHHS,
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2014).
Furthermore, the Truth Initiative (2019) released a report describing specific
states in the South and Midwest regions of the U.S. that have consistently exceeded
national adult smoking rates over the past decade. Because of the disproportionately
higher rates found in Alabama, Arkansas, Indiana, Kentucky, Louisiana, Michigan,
Mississippi, Missouri, Ohio, Oklahoma, South Carolina, Tennessee and West Virginia,
these states have been coined as the “Tobacco Nation” by the Truth Initiative (2019).
Compared to the rest of the U.S., the “Tobacco Nation” showed significant differences in
important life areas beyond just the increased smoking rates, such as disparate income
level, health ratings, and public policies. These 13 states have ranked among the top 25%
of tobacco using states in the U.S. consistently over the past 10 years. Individuals living
in the “Tobacco Nation” earn on average 25% less per year than individuals living in
other states. Furthermore, access to healthcare is limited and perceived health ratings
among residents are reported to be more than 20% worse than the average Americans’
rating. This can be reasonably understood given that the rates of serious diseases, such as
lung cancer, heart disease, and COPD, are higher in the “Tobacco Nation” compared to
the rest of the U.S. Finally, public policy laws protecting citizens from second-hand
smoke in the “Tobacco Nation” are lacking; only two states in the “Tobacco Nation”
(Michigan and Ohio) have laws forbidding indoor smoking (i.e., workplaces, restaurants,
and bars) compared to more than 50% of the rest of the country. Buying a pack of
cigarettes is on average 19% cheaper in the “Tobacco Nation” as well (Truth Initiative,
2019).
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Perceived Benefits of Using E-Cigarettes
There is substantial debate in the literature regarding the health risks of ENDS
use, with most studies reporting insufficient evidence to establish a conclusive finding
(CDC, 2020). Alternative viewpoints in the current literature have deemed the use of ecigarettes as ‘safe’ in comparison to cigarette smoking when analyzing potential risks
among current smokers; however, when analyzing potential risks among non-smokers,
the safety perception of using e-cigarettes varies (Fairchild et al., 2019). Many studies
have reported on the effectiveness of e-cigarettes in smoking cessation via a harm
reduction model as well (Beaglehole et al., 2019; Hajek et al., 2019; McNeill et al., 2018;
National Academies of Sciences, Engineering, and Medicine [NASEM], 2018; Royal
College of Physicians of London, 2016). However, most of these studies focus on the
relative benefits of e-cigarettes compared to the risks involved in continued cigarette
smoking, while the absolute value inherent in e-cigarettes remains unverified (Fairchild et
al., 2019).
In a Cochrane Review of using electronic cigarettes for smoking cessation,
Hartmann-Boyce and colleagues (2016) evaluated results from various randomized
controlled trials (RCTs) published from 2004 to 2016. The main outcome measure
assessed across the studies was abstinence from smoking after at least six months followup. The combined results, involving 662 participants, showed that using e-cigarettes
containing nicotine increased the chances to stop smoking by 45% compared to using ecigarettes without nicotine. However, due to limitations in various study designs, it could
not be determined if the e-cigarettes were better than a nicotine patch in helping people
with smoking cessation. Stated limitations included having a small number of trials, wide
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confidence intervals, and a low number of participants. Due to this, confidence in the
results was rated as ‘low’ according to the GRADE system. This means that “further
research is very likely to have an important impact on our confidence in the estimate of
effect and is likely to change the estimate,” ultimately indicating that any potential
smoking cessation benefit seen in this review was inconclusive (Hartmann-Boyce et al.,
2016, p.2).
In another RCT conducted by Bullen and colleagues (2013), similar results were
reported. The study involved 657 individuals who were randomly assigned to 3 groups:
nicotine e-cigarettes (289 participants), nicotine patches (295 participants), or placebo ecigarettes (73 participants). The primary outcome measure was continuous abstinence at
six months that was biochemically verified via exhaled carbon monoxide measurement
less than 10 ppm. At the six-month mark, verified abstinence was 7.3% (21 of 289) for
nicotine e-cigarettes, 5.8% (17 of 295) for nicotine patches, and 4.1% (3 of 73) for
placebo e-cigarettes. The authors reported insufficient statistical power to conclude an
advantage of nicotine e-cigarettes over nicotine patches or the placebo e-cigarettes since
the abstinence levels were substantially lower than anticipated given the power
calculation. Thus, final conclusions from the study suggested that e-cigarettes, with or
without nicotine, were mildly effective at helping smokers quit, with similar abstinence
levels seen with nicotine patches (Bullen et al., 2013).
Another well-known study conducted by Hajek and colleagues (2019), showed
that e-cigarettes reduced smoking rates, however, participants continued to use ecigarettes after terminating cigarette smoking. A total of 886 participants were
randomized into 2 groups to assist with smoking cessation: using nicotine-replacement
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products (patch, gum, lozenge, nasal spray, inhalator, mouth spray, mouth strip, and
microtabs) or using e-cigarettes with nicotine. The treatment also included weekly
behavioral support for at least one month. The primary outcome measure was
biochemically validated sustained abstinence for one year which was verified via exhaled
carbon monoxide level of less than 8 ppm. Data was recorded at baseline, after one
month, and then at the one-year mark. Other outcome measures included self-reported
adherence to the treatment protocol and respiratory symptoms. Results revealed that at
the one-year abstinence mark, 18% were abstinent in the e-cigarette group compared to
9.9% abstinent in the nicotine-replacement group. Furthermore, among these participants
who reached one-year abstinence, those in the e-cigarette group were more likely to
continue the use of their assigned e-cigarette product (80%) than those in the nicotinereplacement group (9%); this is concerning as this may pose health risks if participants
transition to using e-cigarettes for long term use. Both e-cigarettes and nicotinereplacement products were perceived to be less satisfying in comparison to regular
cigarettes; however, participants reported greater satisfaction from e-cigarettes than
nicotine-replacement products. In terms of respiratory symptoms, throat/mouth irritation
was more frequently reported in the e-cigarette group (65.3%) than in the nicotinereplacement group (51.2%). Conversely, the occurrence of cough and phlegm production
showed a decline in both groups at the one-year mark. Additionally, nausea was more
frequently reported in the nicotine-replacement group (37.9%) than in the e-cigarette
group (31.3%). Overall conclusions indicated that e-cigarettes were more effective than
nicotine-replacement therapy, when accompanied by behavioral intervention, and when
e-cigarettes were used for smoking cessation in heavily dependent cigarette smokers
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(Hajek et al., 2019).
In a longitudinal study of 322 adult daily smokers and dual users, researchers
examined the course of dual smoking and likelihood for discontinuation of either
combustible cigarettes, e-cigarettes, or both (Piper et al., 2020). Results revealed that
most dual users transitioned to exclusive smoking of one product. Sustained e-cigarette
use was related to baseline e-cigarette dependence. Largely, the research suggested that
dual use was not sustainable for most, but a sustained pattern was more likely evident if
the user was more dependent on e-cigarettes to begin with. There was also evidence that
dual users were more likely to quit than exclusive smokers of one product; however, this
may be due to factors other than their dual use (Piper et al., 2020).
A meta-analytic review comprised of 65 studies indicated various perceived
benefits and reasons for vaping among e-cigarette users, cigarette smokers, dual users,
and non-users (Romijnders, Osch, Vries, & Talhout, 2018b). Among adult smokers and
e-cigarette users, e-cigarettes were used primarily for purposes of smoking cessation and
the perceived benefits revolved around convenience and attractiveness of the product.
These benefits included positive experiences such as improved taste/smell, social
acceptance, avoidance of smoking restrictions/bans, and using a cool/fashionable product.
Additionally, dual users indicated vaping for the perceived benefit of reducing cigarette
smoking cravings and improving their health. Adult e-cigarette users, dual users, and
non-users also reported a perceived benefit for bystanders’ health when e-cigarettes were
used instead of traditional combustible cigarettes. Non-users indicated reasons for
potentially initiating e-cigarette use would be the expected benefits (enjoyable taste and a
variety of flavors), experienced benefits (reduce stress and enables control of weight
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gain), avoidance of smoking restrictions by dual use, convenience of the product,
curiosity, and influence from the social environment (recommended by friends). Smoking
cessation was found to be a major reason why individuals use e-cigarettes; however most
other reported motives revolved around the perceived health benefits e-cigarettes can
provide in comparison to traditional cigarettes (Romijnders, Osch, Vries, & Talhout,
2018b).
While e-cigarettes were initially used as a method of attempting to quit
combustible cigarettes, growing evidence suggests that people may be using e-cigarettes
for other reasons. In a content analysis study of Twitter postings regarding ENDS and
related terms, the data suggested that reasons for vaping have shifted from smoking
cessation towards social image over the span of 2012 to 2016 (Ayers et al., 2017). Early
years included quitting combustible cigarettes as the most cited reason for using ENDS
(e.g., “I couldn’t quit till I tried e-cigs”). Other reasons included social image, indoors
use, favorable odors/flavorings, perceived safety relative to combustible cigarettes, and
cost efficiency. Notably, Twitter postings related to quitting combustible cigarettes and
using e-cigarettes indoors significantly declined throughout the years. Researchers
postulated that this most likely has to do with the increase in consumer knowledge on the
health risks of vaping and new policy restrictions made on indoor vaping (Ayers et al.,
2017).
The U.S. Preventive Services Task Force recently issued a recommendation
which stated, “the current evidence is insufficient to assess the balance of benefits and
harms of e-cigarettes for tobacco cessation in adults” such that patients should continue
using established tobacco cessation interventions (Krist et al., 2021, p. 265). Even when
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comparing the potential health risks of continued tobacco smoking, evidence is
inconclusive on whether e-cigarette smoking is beneficial or not. Additionally, in the
most recent Surgeons General Report which focuses on Smoking Cessation, it was
concluded that there is insufficient evidence to state that e-cigarettes help with smoking
cessation; thus, traditional smoking cessation interventions approved by the FDA should
continue to be used (USDHHS, 2020). The Surgeon General’s Report on smoking
cessation strongly endorses behavioral counseling and FDA-approved medication as
evidence-based methods, proven safe and effective, for smoking cessation. Behavioral
counseling significantly increases the chance of quitting successfully and can be
delivered in a variety of different ways including individual or in group settings. FDAapproved smoking cessation medications include nicotine-replacement therapy such as
nicotine gum, throat lozenge, transdermal patch, nasal spray, oral inhaler, and sublingual
tablet. Other FDA-approved smoking cessation medications include non-nicotine therapy
such as bupropion sustained released (e.g., Zyban, Wellbutrin) and varenicline tartrate
(i.e., Chantix). Despite these explicit recommendations, there remains a widespread
perception among the U.S. population that e-cigarettes are a safer and healthier
alternative to combustible cigarettes, and an effective method of smoking cessation
(Baeza-Loya et al., 2014; Brose et al., 2015; Delnevo et al., 2016; Huang et al., 2019).
These perceived benefits have contributed to the observed increase in e-cigarette use
overall. While e-cigarettes might not be as harmful as combustible cigarettes, e-cigarettes
are not completely without risk.
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Risks of Using E-Cigarettes
Various particles and chemical substances currently found in e-cigarette aerosols,
e-liquid cartridges, and environmental emissions have been known to be toxic,
carcinogenic, and to cause pulmonary/cardiac diseases (National Academies of Sciences,
Engineering, and Medicine [NASEM], 2018). The key ingredients found in e-liquid
mixtures include solvents such as propylene glycol (PG) or vegetable glycerin (glycerol),
a certain percentage of nicotine, concentrated flavors, and water (NASEM, 2018).
Despite this initial simple mixture, over 113 chemicals in 50 different brands of e-liquids
have been found to exist (Kucharska et al., 2016). More substances can be observed in
the aerosol than in the original solution because some chemicals are generated during the
vaporization process. For example, an aerosol generated from a single product tested by
Herrington and Myers (2015) showed 18 additional compounds observed in this solution.
Some of the toxic substances identified in e-liquids and resulting aerosols originate from
the following: nicotine, solvents (PG and glycerol), tobacco-specific nitrosamines
(TSNAs), carbonyl compounds (aldehydes), metals, silicates, volatile organic compounds
(VOCs), phenolic compounds, polycyclic aromatic hydrocarbons (PAHs), flavorings,
tobacco alkaloids, and drugs – all of which can be found in an ENDS device (NASEM,
2018).
The most reported short-term symptom from e-cigarette users is dry mouth/throat,
most likely due to the water-absorbing property of PG and glycerol (NASEM, 2018).
While PG has been generally recognized as safe under conditions of use as a food
additive by the FDA, it has not been verified as safe for other routes of absorptions such
as through inhalation (NASEM, 2018). PG can also be used for other purposes, such as
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artificial smoke and fog used in firefighter training and in theatrical productions
(NASEM, 2018). Occupational exposures to PG have been researched by Varughese et
al. (2005) in a study of 101 employees who were routinely exposed to these fogs.
Measuring the levels of exposure, lung function, and acute/chronic symptoms revealed
that theatrical fog exposures were significantly associated with chronic work-related
wheezing and chest tightness (Varughese et al., 2005). Various organizations (Health
Council of the Netherlands [HCN], National Institute for Occupational Safety and Health
[NIOSH], Occupational Safety and Health Administration [OSHA], and World Health
Organization [WHO]) have established precautionary guidelines for the recommended
exposure limit to PG because of these concerns (NASEM, 2018).
Several other symptoms have been associated with PG use in humans, such as
allergic reactions, eye irritation, irritating cough, upper respiratory irritation, and
increased development of a pulmonary illness (Choi et al., 2010; McCauley et al., 2012;
NASEM, 2018). A systematic literature review conducted by Lim and colleagues (2014)
on the toxicity of large doses of PG administered orally or intravenously to humans
contributed to the identification of a “PG toxidrome” which results in adverse effects
such as hyperosmolarity, lactic acidosis, hemolysis, central nervous system (CNS)
toxicity, and cardiac arrhythmia. PG is processed in the body by the kidney, which
eliminates 45% of the PG and then the liver metabolizes the remainder of lactic acid,
pyruvic acid, or acetone. People with impaired liver or kidney functioning are at a higher
risk for developing PG toxidrome following high inhalation doses (Bjur et al., 2017;
NASEM, 2018).
The other main solvent in e-liquid mixtures, glycerol, can also be found in food,
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nutritional supplements, pharmaceutical products, and oral care products (NASEM,
2018). When glycerol is used at unspecified doses or as a drug, reported adverse effects
include mild headaches, dizziness, nausea, vomiting, thirst, and diarrhea. Most of orally
administered glycerol is metabolized in about 2.5 hours, with 7% to 14% of eliminated
glycerol remaining in urine (NASEM, 2018). There have not been reported glycerol
inhalation studies among human samples. In addition to PG and glycerol, ethylene glycol
has been identified as another solvent used in e-liquids. Ethylene glycol is commonly
used as an industrial solvent, as antifreeze in cooling/heating systems, and in hydraulic
brake fluids (NASEM, 2018). While most e-liquid's do not contain this solvent, some
ENDS devices do. This is a significant concern as inhalation of ethylene glycol is known
to lead to severe eye and respiratory tract infection (Agency for Toxic Substances and
Disease Registry [ATSDR], 2010; NIOSH, 2011) and is associated with distinct toxic
hazards compared to PG and glycerol (Gomes et al., 2002).
Each ENDS device also creates harmful carbonyl compounds through their
heating mechanisms (Jensen et al., 2015; NASEM, 2018). Most ENDS products create
temperatures within the range of 150°–350°C from their heating mechanisms and some
devices allow users to change the output voltage of their battery to increase aerosol
production and thus nicotine delivery. This results in higher heating temperatures of the
e-liquid mixtures. The increased battery output voltage has further been reported to affect
the quantity of carbonyls created. For example, Kosmider and colleagues (2014) studied
the results of altering the voltages in various ENDS devices. The researchers showed that
simply increasing the voltage from 3.2 V to 4.8 V resulted in an increase of more than
200 times the levels of formaldehyde, acetaldehyde, and acetone in the aerosolized
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vapors (Kosmider et al., 2014). The levels of formaldehyde generated from the high
voltage devices were practically identical to those found in combustible cigarette smoke
(Kosmider et al., 2014). Other studies have confirmed these results leading to the
conclusion that as heating temperatures rise in an ENDS device, so too the levels of
formaldehyde will rise, and in a particularly steep manner (Bekki et al., 2014; Flora et al.,
2017; Geiss et al., 2016; Jensen et al., 2015).
Even without modification of an ENDS output voltage and controlling for
temperatures, the inherent interaction between common solvents found in the e-liquids
(PG and glycerol) produce these toxic byproducts (Jenson et al.; 2017; Salamanca et al.,
2017). Several harmful compounds are produced even in the absence of nicotine and
flavor additives to the e-liquid mixtures (NASEM, 2018). Wang and colleagues (2017)
studied this by controlling temperatures and ensuring e-liquid mixtures only contained
PG and glycerol but did not contain nicotine and flavorings. The authors detected
significant amounts of formaldehyde and acetaldehyde in the vapors, only liquids
containing glycerol produced acrolein (Wang et al., 2017). Independent of temperature
and complexity of e-liquid mixtures, when e-liquids are heated and aerosolized, they can
generate chemical reactions that form harmful carbonyl compounds, which have toxic
effects on human health (NASEM, 2018). Therefore, the perceived benefit of using
ENDS as a ‘healthier alternative’ appears unsubstantiated.
In addition to the health risks found with the solvents in e-liquid mixtures, there
remains notable health risks that exist from nicotine intake, a risk that similarly presents
with combustible cigarettes (NASEM, 2018). Nicotine may increase insulin resistance
and increase susceptibility to Type 2 Diabetes (USDHHS, 2010). Nicotine can also
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damage the cardiovascular system by creating endothelial dysfunction (Bhatnagar, 2016)
and affects the endocrine system, particularly contributing to pathogenesis of various
endocrine diseases (Tweed et al., 2012). Nicotine also increases blood pressure,
constricting coronary blood vessels and promoting acute ischemic events in people who
have coronary artery disease (Balakumar & Kaur, 2009; Lippi et al., 2014; Putz-hammer
et al., 2016; Sajja, et al., 2015). In addition, some e-liquids may contain concentrations of
nicotine large enough to cause seizures, anoxic brain injury, vomiting, and lactic acidosis
when inhaled (NASEM, 2018). In fact, calls to poison control centers that involved
individuals suffering potentially fatal poisonings of e-liquids increased from an average
of 1 call per month in 2010 to an average of over 200 calls per month in 2014 (ChathamStephens et al., 2014).
In a meta-analytic publication of 90 peer-reviewed articles analyzing
physiological effects of nicotine on human organ systems, Mishra and colleagues (2015)
reported that nicotine contributed to several health hazards such as increased risk of
cardiovascular, respiratory, and gastrointestinal disorders. Other notable findings
included a decreased immune response and negative impacts on reproductive health.
Nicotine was also shown to negatively affect cell proliferation, contributing to oxidative
stress, apoptosis, and DNA mutation. Significant associations found between nicotine and
cancer were also reported and included tumor proliferation, metastasis, and resistance to
chemotherapy (Mishra et al., 2015).
Various studies on the inherent toxicity of e-cigarettes have been reported and
analyzed and numerous significant findings have emerged. Several hazardous compounds
have been found in e-liquids and in the heated aerosol produced by e-cigarettes, including
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formaldehyde, acetaldehyde, and acrolein, which are known carcinogenic toxins
(NASEM, 2018). The added flavorings that are considered safe for use in food, have not
been extensively tested for sensitizing, toxic, or irritating potency though inhalation.
There is also evidence that e-cigarettes emit fine particles at high doses that seep into the
human respiratory system when PG and glycerol are aerosolized. Given all the
considered research, there is substantial evidence that in addition to nicotine, most ecigarette products contain and produce numerous potentially toxic substances. Other than
nicotine, the characteristics of potentially toxic substances emitted from e-cigarettes are
highly variable and depend on each ENDS device and how the device is operated by the
individual user (NASEM, 2018).
In a review of overall health information linked to vaping, Dr. M.J. Blaha (2021)
stated that while vaping may be less harmful in certain circumstances than smoking, it is
still not safe. As of February 2020, the CDC reported a total of 2,807 hospitalizations and
confirmed 68 deaths due to a national outbreak of E-cigarette or Vaping product use
Associated Lung Injury (EVALI). More than just harm to the lungs, growing evidence
supports that e-cigarette carry many other health risks including increased likelihood of
having a heart attack and cardiovascular disease. Moreover, having Coronavirus Disease
2019 (COVID-19) and being a vaper significantly increased individuals’ health risks and
complications from the virus, making recovery longer and more intensive for these
patients. E-cigarettes can also be just as addictive as traditional cigarettes because of the
nicotine content. Users may receive more nicotine than they would have received from a
tobacco product if using higher potency cartridges or if the user increases the voltage in
their personal ENDS device. Despite being marketed and perceived to be a smoking
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cessation aid by many companies, it lacks approval/endorsement from the FDA, CDC,
and USDHHS as a smoking cessation tool. Most alarmingly, e-cigarette use is gaining
more popularity among those who have never smoked traditional cigarettes (Blaha,
2021). What is concerning here is that individuals who would have never used nicotine
products are now initiating this new habit due to the appeal and perceived positive
experience associated with using e-cigarettes. This new habit might lead to nicotine
addiction and initiation into traditional dual use of smoking products in the future.
E-cigarette flavors also play a role in vaping initiation. In a study conducted by
Landry and colleague (2019), most participants reported beginning to use e-cigarettes due
to the appeal of various flavors, when otherwise they would not be interested in smoking.
The authors analyzed a sample of 1,492 adults, current e-cigarette users drawn from an
online quantitative survey. Most e-cigarette users used flavors other than tobacco.
Notably, flavors were a common reason for initiating e-cigarette use. Particularly the fruit
flavors were more likely to influence young adults (18 to 24 years) to initiate vaping
compared to older adults. Those who used flavors also demonstrated higher odds of
reporting a high satisfaction from vaping and had higher odds of perceived addiction to
vaping than the participants who do not use flavors in their e-cigarettes (Landry et al.,
2019). Increases in dual using (use of traditional cigarettes and e-cigarettes) suggested
that e-cigarettes are not merely substituting for cigarettes anymore, e-cigarettes are now
occurring in individuals who would not otherwise have tried any tobacco product
(Barrington-Trimis et al. 2016).
In a meta-analytic review comprised of close to 7,000 studies including over
17,000 adolescents and young adults, Soneji and colleagues (2017), found that
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individuals using e-cigarettes at baseline measurements were significantly more likely to
initiate use of combustible cigarettes (8%-40%) than individuals not using e-cigarettes at
baseline (3%-10%). Specifically, the probability of initiating tobacco cigarette smoking
was 23% for baseline ever e-cigarette users compared to the 7% for baseline never ecigarette users. Similar discrepant probabilities for initiating tobacco cigarette smoking
were found between baseline 30-day e-cigarette users and baseline non-users. Overall,
results indicated that e-cigarette use was associated with a greater risk for initiating
tobacco cigarette smoking later in life (Soneji et al., 2017). This demonstrated a bidirectional influence, in that combustible cigarette smokers will later initiate e-cigarette
use and e-cigarette users will later initiate combustible cigarette smoking.
These findings were supported in various other studies. In a longitudinal study
following high school students in the UK, Best and colleagues (2017) examined the
likelihood of an individual initiating cigarette smoking if they had ever tried an ecigarette. Results indicated that individuals were more likely to experiment with
combustible cigarettes if they had even tried vaping once before. Similar results were
reported in another UK study (Conner et al., 2017); findings revealed that ever having
used an e-cigarette was robustly associated with initiating cigarette smoking later in life.
In another study comprised of 2,558 young adult students in college, Loukas and
colleagues (2018) evaluated whether e-cigarette use predicted initiation of cigarette
smoking. Findings demonstrated that e-cigarette use in this population was a prominent
risk factor for later initiation of cigarette smoking (Loukas et al., 2018). Another
longitudinal study showed that dual users were more likely to increase their level of
smoking cigarettes compared to those who used fewer e-cigarettes (Doran et al., 2017).
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Specifically, occasional cigarette smokers who reported more frequent use of e-cigarettes
in their baseline measurements later reported greater increases in cigarette quantity over a
12-month period than cigarette only smokers (Doran et al., 2017). These findings suggest
that not only does e-cigarette use potentially lead to cigarette smoking, but it also
increases the quantity and frequency of cigarette smoking when dual using.

Respiratory/Pulmonary Health
Before discussing the smoking/vaping health effects on the respiratory system,
brief information regarding respiratory health is provided. The World Health
Organization (WHO) created the Global Alliance Against Respiratory Diseases (GARD)
in 2006 with the purpose of combining knowledge from national and international
organizations, institutions, and agencies to address the worldwide health burden which
results from chronic and acute respiratory diseases. The Forum of International
Respiratory Societies (FIRS, 2017) adopted this challenge and produced an extensive
report on lung diseases, environmental precursors, prevalence rates, and other important
factors related to respiratory diseases found worldwide. Some of the most common
respiratory diseases reported across the globe included the following: acute lower
respiratory tract infections, asthma, chronic obstructive pulmonary disease (COPD), lung
cancer, occupational lung diseases, pulmonary hypertension, sleep-apnea, and
tuberculosis (TB) (FIRS, 2017).
The following are reported prevalence rates for the most common respiratory
diseases. An estimated 65 million people have moderate to severe COPD, from which
about 3 million die each year, making it the third leading cause of death worldwide
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(FIRS, 2017). COPD rates average from 5-7% found among the U.S. adult population
according to the National Health Interview Survey (NHIS, 2019) and the Behavioral Risk
Factor Surveillance System (BRFSS, 2019). About 334 million people suffer from
asthma, which is the most common chronic disease of childhood, affecting 14% of
children globally (FIRS, 2017). In the U.S., the rates of ever having asthma were reported
at 13.4% and rates of current asthma were recorded as 7.7% (NHIS, 2019). Additionally,
African Americans and Puerto Ricans are at a higher risk of developing asthma than
people of other races or ethnicities (National Institutes of Health [NIH]-National Heart,
Lung, and Blood Institute [NHLBI], 2020). African American and Hispanic children are
also more likely to die from asthma-related causes than non-Hispanic white Americans
(NIH-NHLBI, 2020). Among children, more boys than girls have asthma; however, in
teens/adult populations, asthma is more common among women than men (NIH-NHLBI,
2020).
When any of the functions involved with the respiratory system are not working
properly – due to damage, infection, or inflammation – respiratory illness or disease may
develop (NIH-NHLBI, 2020). Respiratory diseases are defined as “diseases of the
airways and other structures of the lung” by the World Health Organization (2021). There
are several terms in the literature used to described respiratory illnesses such as thoracic
disease, pulmonary disorder, lung disease, respiratory illness, lung illness, and so on. For
this review, any chronic or acute disorder, illness, or disease associated with the
respiratory, pulmonary, or lung system will be included in the discussion on respiratory
disease.
According to the American Lung Association (ALA, 2021), key symptoms which
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demonstrate the presence of a respiratory illness include chronic cough, shortness of
breath, phlegm production, wheezing, coughing up blood, or chest pain/tightness. These
symptoms occur in over 50 pulmonary diseases, such as acute respiratory distress
syndrome (ARDS), asthma, bronchiectasis, bronchiolitis obliterans, chronic obstructive
pulmonary disease (COPD) including emphysema or chronic bronchitis, cystic fibrosis,
diffuse panbronchiolitis, interstitial lung disease, lung cancer, sleep apnea, pulmonary
edema, and tuberculosis (TB), to name a few (ALA, 2021; WHO, 2021).
According to the National Institutes of Health (NIH) U.S. National Library of
Medicine (2021), lung diseases can be classified into three main categories: airway
disease, lung tissue diseases, and lung circulation disease. Airways diseases affect the
tubes in the lungs which carry oxygen into and out of the respiratory system. It involves a
narrowing or blockage of the airways and can be seen in asthma, COPD, and
bronchiectasis. Individuals with these diseases often report sensations of limited
breathing capability (i.e., trying to breathe out of a straw). Lung tissue diseases affect the
structures of the lung tissue. Particularly, scarring or inflammation of the lung tissue
prevents the lungs from fully expanding, making it harder for the lungs to take in oxygen
and release carbon dioxide. As a result, individuals with this condition cannot breathe
deeply and may often report chest tightness. This is frequently seen in pulmonary
fibrosis, sarcoidosis, and interstitial lung diseases. Finally, lung circulation diseases affect
the blood vessels (capillaries) in the lungs and are caused by clotting, scarring, or
inflammation of the blood vessels. This affects the lungs’ ability to take in oxygen and
release carbon dioxide and can also affect heart functioning. A primary example of this
disease is pulmonary hypertension; people with this condition often feel very short of
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breath when exerting themselves. Many lung diseases incorporate a combination of the
above-mentioned factors (NIH-U.S. National Library of Medicine, 2021).
Another primary method of identifying a lung disease is by conducting
Pulmonary Function Tests (PFTs), as reported by John Hopkins Medicine (2021) and the
American Lung Association (ALA, 2020). These tests measure how well someone's lungs
are functioning by defining lung volume, capacity, rates of flow, and gas exchange. The
resulting information from PFTs aid healthcare providers in diagnosing and treating
various respiratory illnesses. PFTs results reveal two types of disorders in the lung:
obstructive or restrictive. Obstructive lung disorders are categorized by a reduction in
airflow where air remains inside of the lungs after full exhalation due to airway
resistance; this is common in COPD, asthma, bronchiectasis, and cystic fibrosis.
Restrictive lung disorders are characterized by a reduction in lung volume and difficulty
with breathing air into the lungs, most likely due to lung tissue damage and restriction in
chest muscle expansions. These issues are common in interstitial lung diseases (ALA,
2020; John Hopkins Medicine, 2021).
Symptom severity from lung disease can be a costly burden on total healthcare
spending (FIRS, 2017). The direct cost of COPD is 6% of total healthcare spending
(€38.6 billion annually) in the European Union and accounts for 56% of the total cost of
treating respiratory diseases. COPD involves persistent respiratory symptoms and airflow
limitation due to bronchioles and alveoli abnormalities (Global Initiative for Chronic
Obstructive Lung Disease [GOLD], 2021). Chronic inflammation in the lungs, narrowing
of the bronchioles, and destruction of parenchyma (lung tissue) contribute to the loss in
alveoli functioning and decreases the lung elasticity in COPD. These changes diminish
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the ability of the airways to remain open during exhalation, retaining harmful carbon
dioxide within the lungs. Abnormalities in the bronchioles may also contribute to
mucociliary dysfunction, preventing the activity in the mucociliary escalator from
removing inhaled toxic particles. Along with air pollution and inhaled tobacco smoke,
genetic syndromes (such as alpha-1 antitrypsin deficiency), childhood pneumonia, and
other diseases that impact the airways (such as chronic asthma and TB) are all risk factors
for the development of COPD (GOLD, 2021).
After encouraging smoking cessation, treatment for COPD typically involves
immediate and long-term relief of respiratory symptoms, slowing the disease progression,
improving exercise tolerance/ability to stay active, preventing medical complications, and
improving overall health status (FIRS, 2017; GOLD, 2021; NIH-NHLBI, 2020).
Bronchodilators, commonly known as inhalers, relax the muscles around the airways.
Together with inhaled corticosteroids and other pharmacological interventions, these
devices help to relieve and prevent exacerbations of severe airflow obstruction.
Furthermore, patients with chronic low blood oxygen levels may require oxygen therapy,
which can increase survival rates and improve quality of life. Maintaining physical
activity is also highly important because difficulty breathing may lead to decreased
activity level and subsequent lung deconditioning. Thus, exercise based pulmonary
rehabilitation is another treatment option for individuals with COPD (FIRS, 2017;
GOLD, 2021).
Another common respiratory illness is asthma which is a lifelong, uncurable
disease. However, treatment with asthma medication can be effective in regulating
symptoms (FIRS, 2017). Asthma accounts for frequent preventable hospital visits,
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particularly among pediatric populations (FIRS, 2017). Notably, recent data indicates that
young children with asthma may develop abnormal lung growth and are therefore at risk
for developing lifelong respiratory conditions such as COPD in adulthood, especially
with increased health risk factors such as poor lifestyle choices (i.e., smoking) (FIRS,
2017). Asthma is characterized by airway obstructions due to inflammation and
narrowing of the bronchioles (NIH-NHLBI, 2020; NIH-U.S. National Library of
Medicine, 2021). Asthma affects individuals across all ages although the onset usually
begins in childhood. Typical symptoms associated with asthma include wheezing,
coughing, chest tightness, and shortness of breath. Symptom severity varies by individual
and how often someone is exposed to asthma triggers. Some individuals may experience
these symptoms frequently throughout the day with great difficulty, while other
individuals may experience these symptoms only a couple of times a year with very
minimal difficulty. Asthma symptoms may cause discomfort, functional difficulties, and
interfere with daily activities. Overtime, uncontrolled asthma can lead to permanent
tissue damage in the bronchioles (NIH-NHLBI, 2020; NIH-U.S. National Library of
Medicine, 2021).
Triggers to worsening asthma symptoms vary by person but usually involve
tobacco smoke, exercise, allergies, cold air, or hyperventilation from laughing or crying
(FIRS, 2017; NIH-NHLBI, 2020; NIH-U.S. National Library of Medicine, 2021). Other
asthma triggers include dust mites, outdoor air pollution, pests such as cockroaches or
mice, animal dander, and cleaning products (CDC, Common Asthma Triggers, 2020).
Additionally, asthma symptoms worsen with infections and are more severe in different
times of the day (i.e., early morning and late evening). Asthma attacks, or exacerbations,
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involve episodes of severe worsening of asthma symptoms. Asthma exacerbations require
immediate rescue inhaler treatment and may require emergency care, as attacks can be
life-threatening if untreated (NIH-NHLBI, 2020; NIH-U.S. National Library of Medicine,
2021).
Moving on to other respiratory illnesses, acute lower respiratory tract infections
have been among the top three causes of death and disability amongst both children and
adults for many decades (FIRS, 2017). Acute lower respiratory tract infections include
pneumonia, acute bronchitis, bronchiolitis, influenza, and whooping cough. Acute lower
respiratory tract infections in childhood increase the likelihood for the development of
chronic respiratory diseases later in life. Respiratory tract infections caused by influenza
kill between 250,000 and 500,000 people worldwide and cost between 71 and 167 billion
U.S. dollars annually. These infections are particularly prevalent in low- and middleincome countries and kill more people worldwide than human immunodeficiency virus
(HIV), TB, and malaria combined. Risk factors for pneumonia include being very young
or elderly, crowded living conditions, malnutrition, HIV infection, lack of breastfeeding
in infants, lack of immunization, chronic health conditions, and exposure to tobacco
smoke or indoor air pollutants (FIRS, 2017).
Interstitial lung disease (ILD) encompasses various pulmonary disorders related
to scarred lung tissue, particularly in the lung interstitium. The interstitium is the space
where alveoli contact the connective tissue throughout the lungs to exchange oxygen and
carbon dioxide (NIH-NBHLI, n.d.). In ILD, the interstitial tissue becomes thick and
stiffens, making it harder for oxygen to move out of the lungs and into the bloodstream
and equally difficult for carbon dioxide to move out of the bloodstream and into the lungs
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to be exhaled. The causes for ILD include genetics factors, certain medications such as
chemotherapy drugs, heart medications, and anti-inflammatory drugs, or other medical
conditions such as sarcoidosis and autoimmune disorders. Exposures to toxic substances
in the environment also contribute to the development of ILD, particularly with asbestosrelated lung diseases and hypersensitivity pneumonitis. For some ILDs, such as
idiopathic pulmonary fibrosis, the cause of the interstitium scarring is unknown. Typical
symptoms include dry cough, shortness of breath, chest discomfort, and fatigue. ILDs are
either mild or severe, with the amount of scarring progressively getting worse with time.
Treatment usually involves avoiding environmental triggers and managing symptoms
with medicines/inhalers, pulmonary rehabilitation, oxygen therapy, or a lung transplant.
Untreated ILD can lead to further medical complications such as venous
thromboembolism (VTE), lung cancer, pulmonary hypertension, heart failure, and
respiratory failure (NIH-NBHLI, n.d.).
Sung and colleagues (2021), examined the cancer burden worldwide based on
global estimates of cancer incidence and mortality produced by the International Agency
for Research on Cancer. Of the major cancers, lung cancer was the most fatal cancer
worldwide. After tobacco smoking, other risk factors for the development of lung cancer
included exposure to secondhand smoke, biomass fuel, diesel exhaust, radon, asbestos,
and other environmental and workplace carcinogens (FIRS, 2017). Lung cancer treatment
varies by stage; early-stage lung cancer is treated with surgery or radiation therapy.
Advanced stage lung cancer is not curable, many patients however may experience
symptom relief via new forms of treatment. These include molecular targeted therapy
against Epidermal Growth Factor Receptor (EGFR) mutations and Anaplastic Lymphoma
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Kinase (ALK) re-arrangements, which have reached tumor response rates of around 70%.
However, cost may be a major barrier preventing patients from obtaining these forms of
treatments (FIRS, 2017).
Respiratory illnesses can affect individuals when asleep as well, particularly with
sleep apnea, which involves breathing interruptions while sleeping (Mayo Clinic, 2020).
There are three main types of sleep apnea: obstructive, central, and mixed. Obstructive
sleep apnea is the most common type and occurs when throat muscles relax, the airways
narrow or completely close when breathing in. This results in an inability to get enough
air into the lungs which then lowers the oxygen level in the bloodstream. The brain
senses the inability to breathe and signals the individual to awaken and resume breathing.
At this point an individual might snort, choke, or gasp as they awake, take a breath, and
return to sleep. These awakenings are quite brief, and individuals might not recall them.
This pattern repeats five to thirty times or more each hour, all night, impairing the ability
to reach the deep and restorative phases of sleep. Central sleep apnea occurs when the
brain does not send proper signals to the muscles around the lungs to regulate breathing.
Individuals with this type usually awaken with shortness of breath or have difficulty
getting to sleep and staying asleep. Mixed type occurs when both obstructive sleep apnea
and central sleep apnea are present. Symptoms for all three categories overlap and can
include loud snoring, brief periods without breathing, gasping for air during sleep,
awakening with a dry mouth, morning headaches, insomnia/hypersomnia, difficulty
paying attention while awake, and irritability. Risk factors include smoking, excess
weight, larger neck circumference, narrow lung airways, alcohol abuse, nasal congestion,
and medical conditions such as congestive heart failure, hypertension, type 2 diabetes,
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asthma, and Parkinson's disease. Treatment can involve a variety of interventions
including adopting a healthier lifestyle (e.g., smoking cessation, losing weight, eating
healthier, etc.), utilizing a continuous positive airway pressure (CPAP) machine, or using
different mouthpieces and implants to help with breathing at night. For severe cases of
sleep apnea, surgical procedures such as a tonsillectomy, maxillary (jaw advancement
surgery), or tracheostomy may be considered (NIH-NHLBI, n.d.).

Health Risk Factors Associated with Respiratory Illnesses
The respiratory system ensures daily survival via oxygen intake and carbon
dioxide exhalation (gas exchange process in the lungs). Human lungs are exposed to
environmental particles and potentially dangerous organisms in the air constantly. As a
result, individuals with compromised respiratory systems are at a higher risk for the
development of other health conditions, functional difficulties, and higher levels of stress.
Cigarette smoking or e-cigarette use may exacerbate the already elevated health risks for
this medically compromised population. Due to these vulnerabilities, it is important to
evaluate specific health risk factors associated with having a respiratory illness.
Lifestyle impairments from respiratory diseases can be quite severe. Respiratory
diseases account for more than 10% of all disability adjusted life years, a measure that
estimates the amount of active and productive life lost due to a medical condition (FIRS,
2017). The prevalence of adults with current asthma in the U.S. who also have disability
status is 16.5% and 18.7% for those with COPD, compared to 9.2% of the general
population, adults aged 18 and over (NCHS, 2019). The National Center for Health
Statistics (NCHS, 2019) defines disability status as having considerable difficulty in at
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least one of the six functional domains listed: seeing, hearing, mobility, communication,
cognition, and self-care. This is notable as those who manage a chronic disease and have
low functional capacity are more likely to develop stress and depression, especially as the
number of medical conditions increase (Swartz & Jantz 2014; Vancampfort et al., 2017).
Furthermore, for those with a chronic medical condition, like a respiratory disease, stress
can intensify symptoms by increasing the frequency and severity of respiratory
symptoms, and by decreasing overall level of functioning (Prior et al. 2016; Vancampfort
et al, 2017). Particularly, high levels of psychological distress can also contribute to
worsening progression of chronic medical conditions (Prior et al., 2016; Russ et al., 2012;
Vancampfort et al., 2017).
Living with a chronic medical condition like asthma or COPD affects the overall
quality of one’s life via lowered functioning ability. In one study by Strine and colleagues
(2008), researchers found that U.S. adults with chronic illnesses were significantly more
likely than those without chronic conditions to report life dissatisfaction due to functional
limitations. In addition, adverse health behaviors (such as smoking and physical
inactivity) contributed to poorer health-related quality of life (Strine et al., 2008). In
another study by Samiei-Siboni and colleagues (2019), the lowest reported level of
functioning and quality of life scores came from participants who had respiratory diseases
(i.e., asthma and COPD). Furthermore, those with respiratory diseases who smoked had
greater functional difficulties than those who do not have a respiratory disease and
smoked (Sales et al., 2019). In comparison to smokers with no history of a respiratory
disease, smokers with an active respiratory disease had additional difficulties with
smoking cessation due to higher levels of nicotine dependence and withdrawal, higher
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levels of exhaled carbon monoxide, low motivation and low self-efficacy, and a higher
prevalence of anxiety and depression. It is unclear why smokers with an active
respiratory disease experienced more difficulties with smoking cessation, however, it is
likely that this may be due to the complications of simultaneously managing chronic
health conditions. Individuals who had a respiratory disease and smoked also required
smoking cessation treatment that involved multidisciplinary intervention and was more
intensive/prolonged than the treatments for smokers without a respiratory illness (Sales et
al. 2019).
Respiratory symptoms can present differently for each patient and for each
specific disease. However, what remains consistent is that with increase in respiratory
symptoms and symptom severity, poorer health outcomes are present (Doyle et al., 2013;
GOLD, 2021; Miravitlles et al., 2007; Monteagudo et al., 2013; Price et al., 2013; Roche
et al., 2013; Tsiligianni et al., 2011). Using the PERCEIVE study (perception of
exacerbations of chronic obstructive pulmonary disease) involving random sampling
from participants across 6 countries (Germany, France, Italy, Spain, the UK, and the
USA), Miravitlles and colleagues (2007) conducted a survey with 1,100 individuals.
Notable results included the impact COPD had on a patient’s daily-life activities; many
participants reported that they could not complete activities they enjoyed due to their
COPD symptoms. The second most endorsed functional difficulty reported by
participants was sleep disturbances due to their COPD symptoms. A relationship was
found between increased symptom severity and difficulty with completing daily
functional activities. As the number of respiratory symptom exacerbations and
hospital/emergency visits increased, the higher the likelihood that an individual endorsed
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that COPD negatively impacted their daily-life activities and overall wellbeing. This was
the case as many would have to remain in bed resting or lay down during severe
symptom episodes to recover.
Symptom exacerbations also had a strong impact on mood, with many individuals
reported feeling frightened or scared and others feeling frustrated and depressed with
their physical limitations from increased symptoms. In terms of other notable perceptions
endorsed, 17% of participants responded that they were afraid their COPD would cripple
them or eventually kill them. Individuals with more negative perceptions related to their
COPD were older, had a longer duration of the disease, more severe symptomology,
more co-morbidities, and a greater proportion of former smokers. In contrast, 34%
responded that their COPD was mainly a nuisance but not too serious. This group
consisted of individuals who were significantly younger, had shorter duration of the
disease, less severe symptomology, fewer co-morbidities, and a greater proportion of
active smokers (Miravitlles et al., 2007).
In a study involving 791 patients with COPD in a primary care clinic,
Monteagudo and colleagues (2013) analyzed various factors associated with changes in
patients’ health-related quality of life. Health-related quality of life was measured at
baseline and then at a one-year follow-up visit using the Saint George’s Respiratory
Questionnaire (SGRQ). Patients with declining scores on their follow-up measure had
notably worsened symptoms, including significant increase in coughing and
expectoration, and a significant increase in hospital admissions and rehabilitation visits
compared to patients whose follow-up scores improved. Among those patients who had
improved follow-up health-related quality of life scores, a significant proportion included
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former smokers. Factors that were independently and significantly associated with
improved follow-up scores included initiation of pulmonology visits, poly-medication, a
balanced diet, improved respiratory symptoms, ending rehabilitation, and quitting
smoking (Monteagudo et al., 2013).
Price and colleagues (2013) evaluated nocturnal symptom severity and daily
functioning level for 2,807 patients with COPD. Outcomes revealed that patients who
experienced sleep disturbances due to respiratory symptom exacerbations in the evenings,
experienced more respiratory symptoms throughout the daytime and more exacerbations
in a 12-month period than those who typically did not experience symptoms throughout
the evening. Furthermore, for the patients with increased nocturnal symptoms, they were
more likely to have problems in other areas such as daytime breathlessness, frequent
exacerbations, functional difficulties with “getting started in the morning,” poorer sleep
quality, and a poorer quality of life (Price et al., 2013).
In a randomized control trial involving 162 patients with COPD, Doyle and
colleagues (2013) examined associations between mental health symptoms and
pulmonary-specific symptoms. Results indicated that anxiety and depression were
associated with higher levels of fatigue and shortness of breath, and with frequency of
respiratory symptoms. In addition, functional capacity was a moderator of anxiety and
pulmonary-specific COPD symptoms. The association between anxiety and shortness of
breath and the frequency of COPD symptoms was greatest among patients with lower
functional capacity (Doyle et al., 2013). Patients with respiratory diseases, particularly
COPD and asthma, experienced significantly more stress and psychological issues, such
as anxiety and depression, than the general population (Doyle et al., 2013; Miravitlles &
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Ribera, 2017; Wagena et al., 2005). Severity of respiratory symptoms and resulting
limited level of functioning might be the main contributing factors for this stress
(Miravitlles et al., 2007; Miravitlles & Ribera, 2017; Wagena et al., 2005).
Tsiligianni and colleagues (2011) conducted a meta-analytic review on the
different factors which affect the health status of individuals with COPD. Notable
findings included smoking status whereby current smoking and exposure to secondhand
smoke was reported to be associated with poorer health status in patients with COPD.
Most published studies suggested that health status was significantly associated with
symptom presentation (severity and frequency), especially as the disease progressed to
the more severe stages. In fact, one of the most central symptoms in COPD, dyspnea, was
found to be significantly negatively associated with health status and had the highest
correlations with various health status questionnaires among all other factors. Other
typical symptoms, such as sputum production, chronic cough, wheezing, and fatigue,
were also negatively associated with health status among patients with COPD. Comorbidity also had strong associations with negative health status, particularly involving
co-morbid heart disease, hypertension, locomotive disorders, diabetes, sleep disturbances,
depression, and anxiety. Finally, patient’s perception of their illness and overall health
was a factor significantly associated with quality of life across many studies (Tsiligianni
et al., 2011).
In a review of the biomedical literature describing reported relationships between
COPD symptoms and disease burden, Miravitlles and Ribera (2017) identified various
factors negatively impacted by COPD. These factors included quality of life, perceived
health status, daily activities, physical activity, sleep, comorbid anxiety/depression, as
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well as disease prognosis. Overall health status was reported to be significantly lower in
patients who experienced more COPD symptoms throughout the day compared to those
who experienced no COPD symptoms or less severe symptomology. COPD symptoms
progressively compromised a patient’s ability to function normally in terms of their dayto-day activities and severely impaired sleep quality when symptoms presented at night
(Miravitlles & Ribera, 2017).

Impact of Smoking and Vaping on Respiratory/Pulmonary Health
Health risk factors associated with respiratory illnesses have been described
above. How does smoking and vaping impact these health risk factors and ultimately
one’s respiratory health? Nicotine exposure (from both cigarettes and e-cigarettes) affects
pulmonary symptoms and plays a significant role in the development of several
respiratory/pulmonary diseases (Grando, 2014; Martin et al., 2016; Mishra et al., 2015;
Rowell & Tarran, 2015). E-cigarettes have been reported to negatively affect
cardiovascular and pulmonary functioning (Bold et al., 2018). Exposure to nicotine
through smoking or vaping is an automatic irritant to lung tissue (Mishra et al., 2015).
Nicotine plays a role in the development of emphysema in smokers, by decreasing elastin
in the lung parenchyma and increasing the alveolar volume. Nicotine stimulates vagal
reflex and parasympathetic ganglia and causes an increased airway resistance by causing
bronchoconstriction. Nicotine also transforms respiration through its effects on the CNS.
The simultaneous effect of bronchoconstriction and apnea increases the tracheal tension
and causes several pulmonary disorders (Mishra et al., 2015). In a study conducted by
Jaiswal and colleagues (2013), researchers microinjected nicotine to the preBotzinger
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complex and adjacent nuclei in the brain. The firing pattern of the brain signals and
breathing pattern were then monitored. Results demonstrated a shallow and rapid rhythm
of respiration, indicating strained breathing similar to what is observed with nicotine
exposure (Jaiswal et al., 2013).
One of the most common diseases resulting from long-term cigarette smoking is
COPD (FIRS, 2017; GOLD, 2021). Outdoor, indoor, and occupational air contamination
are major risk factors for the development of COPD. However, the leading contributing
risk factor for the development of COPD is smoking (FIRS, 2017; GOLD, 2021; NIHNHLBI, 2020; NIH-U.S. National Library of Medicine, 2021; WHO, 2021). Up to 75%
of individuals who have COPD currently smoke or previously smoked. Tobacco smoke
causes destruction of lung tissue (emphysema) and obstruction of the small airways with
inflammation and mucus (chronic bronchitis), leading to the development of the main
symptoms of COPD – dyspnea (shortness of breath), frequent coughing, wheezing, chest
tightness, and sputum production (coughing out phlegm from the respiratory tract). The
primary means of prevention for COPD involves complete smoking cessation. After
diagnosis, it is imperative that healthcare providers deliver effective FDA-approved
smoking cessation interventions (behavioral counseling and pharmacotherapy) to patients
and encourage them to quit since symptom severity and disease progression are highly
correlated with continued tobacco use (FIRS, 2017; GOLD, 2021).
Another disease associated with tobacco smoking and inhalation of secondhand
tobacco smoke is asthma. In a meta-analytic review, Wang and colleagues (2015)
reported that children with asthma had worse symptom severity when exposed to
secondhand smoke exposure. Specifically, these children were twice as likely to have
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been hospitalized than children with asthma who are not exposed to secondhand smoke.
Having been exposed to secondhand smoke was also significantly associated with
emergency department or urgent care visits, wheezing symptoms, and lower PFT results
(Wang et al., 2015). Many other studies have linked secondhand smoke exposure to
increased asthma rates, symptom severity, and worsening lung functioning (Awasthi et al.
2012; CDC-pulmonary diseases, 2010; Kanchongkittiphon et al., 2014; Quinto 2013;
Schlueter et al., 2011; Van Den Bosch et al., 2012). Despite the lack of exact preventive
measures for the development of asthma, there are still vital ways to slow down the
progression of debilitating lung function such as reducing cigarette smoking or exposure
to secondhand tobacco smoke (FIRS, 2017). Moreover, those with asthma who smoke
have significantly more impaired lung functioning than those with asthma who do not
smoke (FIRS, 2017; NIH-NHLBI, 2020; NIH-U.S. National Library of Medicine, 2021).
Of the major cancers, lung cancer has been the most diagnosed cancer over the
past decades and remains the leading cause of cancer-related death (Sung et al. 2021).
Tobacco smoke contributes to more than two-thirds of the cases of lung cancer by
damaging DNA and mutating genes in the lung cells (FIRS, 2017). The more years an
individual smokes, the higher the risk of developing lung cancer, as it takes time for the
DNA-damaged genes to accumulate and create progressive damage. Therefore, even
former smokers are at risk for developing lung cancer if they have smoked for many
years prior. The simplest and most effective preventative measure of lung cancer is
through tobacco control (FIRS, 2017; Sung et al., 2021).
The impact of tobacco smoking on other respiratory conditions is extensive.
Cigarette smoking increases the likelihood of developing Interstitial Lung Disease (ILD)
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in addition to making the condition worse if smoking is continued once diagnosed (FIRS,
2017). People who smoke cigarettes are three times more likely to have obstructive sleep
apnea than those who have never smoked (Mayo Clinic, 2020). Individuals with chronic
bronchitis who smoke, worsen lung functioning by deregulating the healing process in
lung tissue due to continuous damage caused by inhalation of tobacco smoke (CDCpulmonary diseases, 2010). A relationship between number of years/packs of cigarettes
smoked and severity of emphysema was established in a study evaluating more than 400
lungs removed from patients being treated for lung cancer (Hogg 2004). The more years
a patient smoked and the higher number of packs of cigarettes smoked per day, the more
severe the pulmonary emphysema was (Hogg 2004).
Many studies report that using e-cigarettes can also damage lung cells and lead to
worsening respiratory functioning, contributing to severe respiratory symptoms or even
the development of a respiratory illness if not already present (Bhatta & Glantz, 2020;
Ghosh et al. 2019; Muthumalage et al., 2019; Xie et al., 2020). A recent study showed
that long-term vaping can initiate the same harmful lung changes seen in cigarette
smokers (Ghosh et al., 2019). Researchers evaluated bronchoscopies of healthy
nonsmokers, cigarette smokers, and e-cigarette users. Results of the comparison showed
many similarities between cigarette smokers and e-cigarette users. As with smoking,
vaping-induced nicotine dependent protease release from pulmonary immune cells,
resulted in disruption of the protease-antiprotease balance by increasing proteolysis
(protein breakdown into amino acids) in the lungs. This activity increases the risk of
developing chronic lung diseases in comparison to the normal population. Conclusions
from the study indicated that e-cigarettes did not appear to have less harmful respiratory
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effects than tobacco smoking (Ghosh et al 2019). Furthermore, e-cigarette flavoring pods
have been shown to cause significant damage in lung cells and the respiratory system
(Muthumalage et al., 2019). Researchers from this study analyzed JUUL and other
companies’ common pod flavors such as fruit, vanilla, mint, coffee, menthol, etc. with
each pod ranging between 5-6% nicotine. Human bronchial epithelial cells were exposed
to aerosols of the various pods and then the cells were measured for dysfunction and/or
potential damage. Results showed that the substances in flavored pods stimulate oxidative
stress, inflammation, epithelial barrier dysfunction, and DNA damage in the lung cells
(Muthumalage et al., 2019).
In another recent study, researchers reported associations between e-cigarette use
and increased risk for respiratory disease (Xie et al., 2020). Over 20,000 individuals were
included in this sample from the Population Assessment of Tobacco and Health (PATH)
study. Adjustments were made to control for other variables such as combustible tobacco
product use, demographic characteristics, and other chronic health conditions. Results
indicated that among former and current e-cigarette users, there was an increased risk of
developing respiratory diseases such as asthma, chronic bronchitis, emphysema, and
COPD. Another notable result was that those who used e-cigarettes daily and started
before the age of 25 had the highest prevalence rates of respiratory disease later in life
(Xie et al., 2020).
In a longitudinal analysis of associations between e-cigarette use and respiratory
disease, researchers Bhatta and Glantz (2020) found that using e-cigarettes was an
independent risk factor for the development of respiratory diseases and later smoking
combustible cigarettes. Furthermore, dual use was reported as the most common pattern
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and was riskier than sole use of e-cigarettes or smoking cigarette (Bhatta & Glantz,
2020). In studies identifying self-reported negative health symptoms associated with ecigarette use, the most reported symptoms were those related to what is typically seen in
asthma, COPD, pneumonia, and bronchitis (Hua, Alfi, & Talbot, 2013; Hua et al., 2020).
Self-reported symptoms included frequent coughing, wheezing, dyspnea, heavy
breathing, nasal discharge/congestion, dry cough, and gasping for air (Hua, Alfi, &
Talbot, 2013; Hua et al., 2020).
E-cigarettes various flavorings also present several health risks to users when
inhaled. Specifically, diacetyl, acetylpropionyl, and acetoin, the major chemicals in ecigarette products with creamy flavors, were found to be present in more than 90% of
tested e-cigarettes available in the U.S. (Allen et al., 2016). These chemicals have been
associated with increased incidences of chronic cough, bronchitis, asthma, and
bronchiolitis obliterans (Kreiss et al., 2002; NIOSH, 2017). Additionally,
cinnamaldehyde (the major chemical in cinnamon and fruit flavors) was found in high
concentrations toxic to humans in 50% of e-liquids tested (Behar et al., 2016). Even at
low concentrations, cinnamaldehyde can be cytotoxic, genotoxic, and adversely affect
cell processes and cell survival (NASEM, 2018).
In addition, harmful carbonyl compounds such as formaldehyde, acetaldehyde,
acrolein, and glyoxal are created when e-liquids are heated and aerosolized (NASEM,
2018). Formaldehyde is classified as a human carcinogen by the International Agency for
Research on Cancer (IARC) and acetaldehyde is classified as possibly carcinogenic to
humans (Bekki et al., 2014; NASEM, 2018). Acrolein causes nasal cavity irritation and
damages to the lining of the lungs (ATSDR, 2007). Furthermore, glyoxal and
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methylglyoxal show a potential for creating permanent transmissible changes in genetic
material of cells (NASEM, 2018). While there is variability in the level of toxicity of
each ENDS device due to e-liquid concentrations, puffs inhaled by the user, etc., very
high levels of formaldehyde have typically been reported in e-cigarette aerosols almost
comparable to levels found in combustible tobacco cigarette smoke (Canistro et al., 2017;
Gillman et al., 2016; Kosmider et al., 2014).
EVALI (E-cigarette or Vaping product use Associated Lung Injury) is a term
coined by the CDC in response to a multi-state outbreak of severe lung illness associated
with using e-cigarettes/vaping products, first identified in the summer of 2019 (CDCEVALI, 2020). EVALI symptoms can present in otherwise completely healthy
individuals and include shortness of breath, dry cough, fever, chills, vomiting, diarrhea,
chest pain, headache, dizziness, coughing up blood, weight loss, and fast heartbeat (Awad
& Awan, 2020). Because these symptoms can mirror the flu or other respiratory illnesses,
diagnosing EVALI can be challenging (Awad & Awan, 2020). As of February 2020, a
total of 2,807 EVALI cases and 68 confirmed deaths have been reported in the U.S.
(CDC-EVALI, 2020). Despite the steep rise of prevalence in EVALI cases, there has
been a gradual decline in deaths since peaking in September 2019. This could be due to
increased public awareness of the risk associated with THC-containing e-cigarettes,
removal of vitamin E-acetate from products, and/or new law enforcement policies.
Notwithstanding the decline in cases, continued use of e-cigarettes still presents a risk
factor for the development of EVALI or worse conditions as not enough information is
known on the extent of this novel disorder and the potential long term health effects
(CDC-EVALI, 2020).
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Cigarettes/ENDS Health Perceptions and Influence on Smoking Behaviors
It is known, the harmful effects vaping can have on the respiratory system,
especially in those already living with a chronic respiratory condition. Given this reality,
how can vaping behaviors be influenced to prevent use and promote healthier behaviors?
Evidence suggests that an individuals’ values, attitudes, and beliefs can reliably predict
their behaviors (Clark et al., 2017; Fishbein & Ajzen, 1975; González-López, & CuervoArango, 2008; Janz & Becker, 1984; Ponizovskiy et al., 2019; Schwartz 1992).
Moreover, risk perceptions and perceived self-efficacy are important antecedents to
making behavioral changes associated with one’s health, as established by the Theory of
Planned Behavior (TPB) and the Health Belief Model (HBM) (Ajzenm, 1991; Becker,
1974). According to the TPB, perceived behavioral control, or self-efficacy, together with
behavioral intention, can be used directly to predict whether an action will be completed
(Ajzenm, 1991). Moreover, the HBM reports that there are key factors influencing health
behaviors, such as an individual's perceived threat to illness (i.e., perceived
susceptibility), perceived severity of the illness, perceived benefits from taking action,
perceived barriers to action, exposure to stimuli that prompt action (i.e., cues to action),
and confidence in one’s ability to succeed (i.e., self-efficacy) (Becker, 1974; Sheeran &
Abraham, 1996; Sutton, 2002). As it relates to vaping behaviors, perceived risks versus
perceived benefits of e-cigarette use, have been shown to influence individuals’ vaping
behaviors. Prevalence rates of ENDS use are higher among those who perceive ENDS as
less harmful to their health than combustible cigarettes compared to those who do not
hold this perception (Adkison et al., 2013; Choi & Forster, 2013; Cooper et al., 2016;
Loukas et al., 2018; Peters et al., 2015). Similarly, individuals who have ever used e-
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cigarettes are significantly more likely than those who have never used e-cigarettes to
endorse the perception that e-cigarettes should be allowed in public places, presumably
due to e-cigarette users’ belief that e-cigarettes are not associated with the harmful health
effects associated with secondhand cigarette smoke (Peters et al., 2015). In fact, 80% of
current e-cigarette users endorsed the perception that e-cigarettes are less harmful to the
health of passive bystanders than combustible cigarettes (Foulds et al., 2011). In addition,
the perception that e-cigarettes are an effective smoking cessation method is associated
with higher rates of e-cigarette use. One of the most cited reasons for e-cigarette use was
for smoking cessation, reported by 55-88% of adults in multiple nationally representative
samples (Adkison et al., 2013; Rutten et al., 2015; Zhu et al., 2013).
In a study conducted by Popova and colleagues (2018), researchers examined the
relationship between affect, perceived risk, and current use for cigarettes versus vaping in
a nationally representative sample of 5,398 U.S. adults. Results indicated that negative
affect was more highly correlated with cigarettes than with vaping and these associations
were mediated by risk perceptions towards smoking and vaping. Moreover, the higher the
positive affect associated with vaping, the lower the perceived risk, and the higher the
likelihood of being a current vaper. Some methodological limitations of this study,
however, involved limited variety in affective cues presented to the participants to illicit
emotional reactions and perceptions. Additionally, since this involved a cross sectional
survey, all results were correlational and therefore causal inference was limited to the
data consistent with the hypothesized mediation model used in the study. The authors
have acknowledged that alternative models could have possibly fit the data better
(Popova et al. 2018).
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Harrell and colleagues (2018) evaluated how flavored vaping preferences among
various age groups influenced their vaping behaviors. College students and young adults
nationwide reported that their first vaping experience involved a flavor other than tobacco
due to the negative health perceptions associated with smoking tobacco. Alternate flavors
were an especially motivating reason for high school students to begin vaping. While
tobacco flavorings were more preferred among dual users and older adult samples, sweet
flavors like fruit and candy dominated preferences for all age groups as they indicated
more positive affect from smoking with these fruity flavors. The option to make one’s
ENDS device taste like something other than tobacco was reported to be a strong
motivating factor for individuals to initiate vaping (Harrell et al., 2018).
Other health perceptions that entice users to initiate ENDS use have also been
identified. In a cross-sectional study including a sample of 726 adult participants,
smoking beliefs of different product users (non-smokers, cigarette smokers, vapers, and
dual users) were assessed (Romijnders, Beijaert, Osch, Vries, & Talhout, 2018a). Results
indicated that vapers endorsed vaping as less harmful than regular cigarette smoking.
Cigarette smokers were significantly more likely to have an intention to start vaping
compared to non-smokers. Finally, vapers reported their intention to begin vaping
stemmed from perceived safety and perceived social acceptability of vaping among their
peers in comparison to cigarette smoking (Romijnders, Beijaert, Osch, Vries, & Talhout,
2018a).
Another study conducted by Chen and colleagues (2016), examined the
relationship between risk perceptions and cigarette-smoking behaviors among a
nationally representative sample of 1,680 U.S. adults. Findings from this study revealed
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that the absolute and relative risk perceptions were significantly correlated with having
smoked at least 100 cigarettes in one’s lifetime and with the frequency of cigarette
smoking. Absolute risk perception was assessed via a question measuring participants’
individual belief of developing lung cancer as either ‘very low’, ‘somewhat low’,
‘moderate’, ‘somewhat high’, or ‘very high’. Relative risk perception was assessed via
the question: “Compared to the average person your age, would you say that you are
more likely, about as likely, or less likely to get lung cancer?” Finally, the frequency of
cigarette smoking was measured as ‘every day’, ‘some days’, or ‘not at all’. Those who
responded ‘every day’ were then asked how many cigarettes they smoked per day on
average. Respondents generally had a low absolute risk perception of developing lung
cancer; 47% rated their risk as being ‘very low’ while only 12.1% of respondents rated
their risk of getting lung cancer as being ‘somewhat high’ or ‘very high’. Close to 60% of
respondents reported that they were less likely to get lung cancer compared to the average
person their age, about 30% rated their risk as being similar to that of other people their
age, and only 11% of respondents believed their risk of developing lung cancer was
higher than others their age (Chen et al., 2016). Although this study evaluated different
types of risk perceptions (absolute versus relative), these health perceptions were
specifically related to lung cancer. Health perceptions regarding e-cigarette use in relation
to lung cancer or other respiratory diseases were not examined. Additionally, health risk
factors such as general health status, stress level, and level of functioning were not
assessed which could have potentially provided more information on participants’ health
vulnerability.
In another study evaluating the risk perceptions of lung cancer according to
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smoking status, Chen and Kaphingst (2011) revealed that while perceived risk associated
with developing lung cancer was higher for never smokers with a family history of lung
cancer, it was lower for former and current smokers with a family history of lung cancer.
The authors concluded that even when a current or former smoker has a family risk of
developing lung cancer, their perceived individual risk was considerably lower compared
to those who have never initiated smoking (Chen & Kaphingst, 2011). The finding that
those at risk for smoking-related health outcomes continue to smoke may be due to
inaccuracies of risk perceptions associated with smoking – when considering one’s
absolute versus relative risks of smoking (Chen & Kaphingst, 2011; Krosnick et al.,
2017).
Current and former smokers may also considerably underestimate their personal
health risk associated with smoking to cognitively distance themselves from the
possibility of developing negative health consequences from their behaviors (Chen et al.,
2016; Chen & Kaphingst, 2011; Krosnick et al., 2017; Weinstein 1998). This may be
partially mediated through the mental discomfort associated with cognitive dissonance
(Ayanian & Cleary, 1999; Strecher, Kreuter, & Kobrin, 1995; Weinstein 1998). As an
attempt to relieve this inconsistency, individuals must distance themselves from the idea
that their behaviors are contributing to their negative health outcomes, thus personal risk
is perceived to be less intense than the general or absolute risks associated with smoking.
When evaluating the absolute risk associated with smoking, individuals are more willing
to admit harm from smoking behaviors due to the cognitive distance these questions
provide. This may partially account for different outcomes across studies as participants’
risk perceptions may depend on the way risk is assessed (i.e., relative, personal, or
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absolute risk) (Ayanian & Cleary, 1999; Chen et al., 2016; Chen & Kaphingst, 2011;
Hwang et al., 2019; Krosnick et al., 2017; Strecher, Kreuter, & Kobrin, 1995; Weinstein
1998).
Health perception studies among high-risk groups, such as pregnant women,
cancer patients, and medically compromised individuals, also indicate strong associations
between risk perceptions associated with smoking and smoking behaviors. In a sample of
118 pregnant women (54 smokers, 64 non-smokers), smokers were less likely to endorse
that smoking during pregnancy could negatively impact the health of their baby and less
likely to view smoking during pregnancy as a risk factor for the baby’s development
(Bronars et al., 2018). Additionally, out of all the participants, close to three-fourths
justified smoking during pregnancy as a method to help manage negative emotions/stress.
However, the women in the sample lived in urban areas, thereby limiting generalizability
of the results to women living in more rural or other regions in the U.S. (Bronars et al.,
2018).
In a meta-analytic review of research conducted between 2006 and 2016 on
perceptions and use associated with tobacco smoking and e-cigarette use during
pregnancy, McCubbin and colleagues (2017) identified two prevailing perceptions in the
literature regarding vaping during pregnancy. The first perception was that e-cigarettes
were a safer and potentially healthier alternative (for pregnant woman and fetus)
compared to traditional cigarettes. Across all the studies included in this review, the
majority of participants viewed e-cigarettes as less harmful than traditional cigarettes in
general. The second most common perception was that e-cigarettes may be effectively
used as a tool for smoking cessation (McCubbin et al., 2017). In fact, one cross-sectional
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study included in this review conducted research with a gynecology population of 194
current and former female tobacco users; more than half the participants were pregnant
(Ashford et al., 2016). Notable results showed that majority of the women (88%) were
dual users and the top endorsed reason for being a dual user was to “quit cigarette
smoking.” The majority of women initiated the use of e-cigarettes due to the belief that
switching to e-cigarettes would be a safer alternative than cigarette smoking and thus had
a lower harm perception associated with vaping, even while pregnant (Ashford et al.,
2016).
Reflecting views from cancer patients who smoke, Alton and colleagues (2018)
evaluated the risk perceptions of continued smoking among 1,121 patients recently
diagnosed with cancer. Patients who were current smokers around the time of diagnosis
and who perceived greater health risks associated with continued smoking were two to
five times more likely to quit smoking compared with patients who perceived low harm
associated with smoking. Those who were current smokers around the time of diagnosis
were also less likely to perceive that continued smoking was harmful when compared to
former smokers and never smokers. Additionally, perceiving that smoking negatively
affected one's quality of life after diagnosis was strongly associated with the initiation of
smoking cessation behaviors. Among all the participants, those with a longer smoking
history were less likely to believe that smoking was harmful in terms of their quality of
life, rates of survival, and fatigue levels (Alton et al., 2018). While this study sample
included individuals with various forms of cancer, it did not specifically focus on patients
with lung cancer or respiratory diseases. Additionally, other health risk factors that can
influence health perceptions such as health status, symptom severity, stress level, and
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level of functioning, were not examined.
Similarly, a sample of 105 males, aged 40 years and older, who were current
tobacco smokers were involved in a study to measure their perceptions of respiratory
health and diseases typically resulting from long-term smoking (Hwang et al., 2019).
This particular sample was chosen due to their elevated risk factor of developing COPD
(e.g., males, older individuals, current smokers). Out of all participants, approximately
25% knew about COPD, close to 50% of participants did not know what a pulmonary
function test (PFT) was, and only about 30% of participants had previously taken a PFT.
Most respondents perceived their risk of developing COPD to be equal to their friends’
COPD risk or other similarly aged smokers. However, around 40% of the participants
perceived their personal COPD risk to be lower than their friend’s COPD risk and other
similarly aged smokers. The authors suggested that this was due to optimistic bias,
whereby smokers minimized their personal health risks associated with cigarette smoking
by underestimating their risk of developing smoking related conditions (Ayanian &
Cleary, 1999; Hwang et al., 2019; Strecher, Kreuter, & Kobrin, 1995). Each participant
was then tested with a spirometry breathing test. After receiving their individual results,
60% of the respondents indicated they would obtain PFTs in the future and close to 50%
of the participants reported they would quit smoking due to their abnormal spirometry
results (Hwang et al., 2019). While this study chose participants based on “at risk”
population factors for developing COPD (males, older individuals, current smokers),
results were not generalizable to other populations including women, younger
individuals, and former smokers.
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Demographic/Psychosocial Risk and Protective Factors
Identifying demographic and psychosocial influences related to e-cigarette use is
important for predicting future trends in vaping and for developing preventative
interventions for vulnerable populations. E-cigarette use in the U.S. has been found to
vary significantly based on an individual’s sociodemographic characteristics (Levy et al.
2017; Park et al. 2017; Villarroel et al. 2020). Data from the National Health Interview
Survey conducted in 2018 reported that men (17.8%) were more likely than women
(12.3%) to have ever used an e-cigarette and men (4.3%) were almost twice as likely as
women (2.3%) to be current e-cigarette users. The percentage of adults who had ever
used an e-cigarette also decreased as age and income increased. The prevalence of adults
who had ever used an e-cigarette and were current users was highest among non-Hispanic
white males. Moreover, non-Hispanic white adults (16.9%) were more likely than
Hispanic (11.5%), non-Hispanic black (10.0%), and non-Hispanic Asian (10.2%) adults
to have ever used an e-cigarette. Additionally, non-Hispanic white adults (3.7%) were
more likely than Hispanic (2.5%), non-Hispanic black (1.6%), and non-Hispanic Asian
(2.2%) adults to be current e-cigarette users (Villarroel et al. 2020).
In addition, e-cigarette use varies as a function of education level, such that
individuals with higher education are less likely to have ever tried ENDS or to be a
current ENDS user, compared to individuals with lower levels of education (Huang et al.,
2016; Levy et al., 2017; Sharapova et al., 2018; Weaver et al., 2016). Moreover,
socioeconomic status (SES) has likewise been implicated as a predictor of ENDS use,
although studies assessing this factor are mixed. While some studies have found adults
with lower income are more likely to have ever tried ENDS (Regan et al., 2013) or to be
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a current ENDS user (Sharapova et al., 2018), other studies have found adults with higher
income are more likely to be current ENDS users (Huang et al., 2016). Some studies have
found no association between income levels and rates of current or ever ENDS use (King
et al., 2015). Although limited studies have investigated the relationship between ENDS
use and sexual orientation, research has consistently found that LGBT respondents
endorse higher rates of current and ever ENDS use compared to their heterosexual
counterparts (Huang et al., 2016; Sharapova et al., 2018). Finally, prevalence rates also
vary by marital status, with current ENDS use endorsed by 7.6% of those single/never
married/not living with a partner, 5.5% of those widowed, divorced, or separated, and
4.5% of those married or living with a partner (Sharapova et al., 2018), suggesting
romantic relationships may serve as a protective factor against ENDS use. Interestingly,
many of the same demographic factors that influence smoking/vaping behaviors similarly
influence the development and progression of respiratory diseases, such as with asthma
and COPD (FIRS, 2017; GOLD, 2021), thereby compounding potential health problems
for those who choose to smoke or vape.
Having family members and friends who smoke is also associated with greater
use of ENDS (Sutfin et al., 2015). One study found that the second most common reason
endorsed for initiating e-cigarettes included that a friend or family member used, gave, or
offered them an e-cigarette (Pepper et al., 2014). Mental health status has also been
identified as a psychosocial risk factor that influences ENDS use. Individuals with mental
health conditions are more likely to have ever used ENDS (34.2%), to currently use
ENDS (16.3%) and to currently use ENDS daily (3.3%), compared to individuals without
a mental health condition (16.7%, 6.5%, and 1.6%, respectively) (Spears et al., 2019). All
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mental health conditions assessed, except for schizophrenia, were associated with a
higher likelihood of both lifetime and current ENDS use including bipolar disorder
(49.0% lifetime use, 25.4% current use), mood disorders (47.7% lifetime use, 26.3%
current use), schizoaffective disorder (39.6% lifetime use, 24.4% current use), anxiety
disorders (37.8% lifetime use, 19.1% current use), and depression (35.1% lifetime use,
17.5% current use) (Spears et al., 2019). This is notable as it puts individuals with
respiratory illnesses at elevated risk for using ENDS since these populations show an
already elevated risk for having co-occurring mood disorders (Hynninen et al., 2007;
Miravitlles & Ribera, 2017; Rakofsky & Dunlop, 2019; Yi-Fong et al., 2017). Several
studies have also indicated that smoking cigarettes is positively associated with ENDS
use (East et al. 2018; Levy et al., 2017; McMillen et al., 2015; Sharapova et al., 2018;
Soneji et al. 2017).
Park and colleagues (2017) measured the relationship between smoking status and
mental health via assessing psychological distress. Participants were assigned to groups
defined by their product use: exclusive cigarette users, exclusive e-cigarette users, ever ecigarettes and cigarettes user, and current e-cigarettes and cigarettes user. Researchers
found a relationship between high levels of psychological distress and a greater
likelihood of exclusive e-cigarette use, current e-cigarette and cigarette user, and ever ecigarette use. Additionally, as level of distress increased, likelihood to initiate e-cigarettes
increased as well (Park et al. 2017). Similarly, in a survey conducted with the general
population, Spears and colleagues (2019) determined a positive relationship between
psychological distress and ever/current ENDS use. Overall, e-cigarette use was strongly
associated with increased levels of stress (Spears et al., 2019).
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The relationship between e-cigarette use and mental health conditions may be
partially mediated by individuals’ levels of experienced stress. For example, both
episodic and chronic stress have been associated with numerous mental health conditions
(Lupien et al., 2009). Similarly, both stress and negative emotional states influence
individuals’ engagement in negative health-related behaviors such as using e-cigarettes
(Ferrer et al., 2016). In fact, severe psychological stress has been found to increase
likelihood of lifetime ENDS use (Park et al. 2017; Spears et al., 2019), current ENDS use
(Park et al., 2017; Phillips et al., 2017; Spears et al. 2019), and daily ENDS use (Spears et
al., 2019). As stress may play a role in the use of e-cigarettes, it puts individuals with
respiratory illnesses further at risk due to their already elevated stress levels (Doyle et al.,
2013; Miravitlles et al., 2007; Miravitlles & Ribera, 2017; Tsiligianni et al., 2011;
Wagena et al., 2005).
Another risk factor that may influence vaping behaviors among those with
respiratory illnesses is the advice obtained from medical providers identifying ecigarettes as a potential harm-reduction strategy for smokers. In the most recent U.S.
Surgeons General report on smoking cessation (USDHHS, 2020), key findings stated that
more research is required to evaluate whether e-cigarettes are effective for smoking
cessation. However, if e-cigarettes should become an effective method for smoking
cessation, it would need to be used as a complete substitution for smoking cigarettes or
other tobacco products. The eventual treatment goal would be to terminate e-cigarette use
to achieve maximum health benefits (USDHHS, 2020). Even though e-cigarettes are not
currently approved by the FDA as a smoking cessation tool, perceptions among some
medical healthcare providers are that e-cigarettes can be an effective harm-reduction
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strategy in smoking cessation (Dewantoro et al., 2018; Franks et al., 2017; Gravely et al.,
2019; Kanchustambham et al., 2017; McNeill, 2016). On the other hand, survey results
from one study suggested that most family physicians do not endorse or prescribe ecigarettes to their patients for smoking cessation purposes (Ofei-Dodoo et al., 2017).
Also, due to outbreak of EVALI (E-cigarette or Vaping product use Associated Lung
Injury), it appears that physician’s perceptions of e-cigarettes have changed over the
years, moving from neutral to more negative beliefs associated with e-cigarette use for
smoking cessation (Ofei-Dodoo et al., 2020). Therefore, it is important to assess whether
individuals with respiratory illnesses, who smoke cigarettes, have been informed by their
providers of the risks associated with e-cigarettes or have been advised to use e-cigarettes
to stop smoking.
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Study Rationale and Justification
Research has substantiated that inhalation of ENDS vapors can cause significant
damage to an individuals’ health. The most notable health effects include reduced
pulmonary function, as evidenced by problems with respiration (Kumral et al., 2016;
McConnell et al., 2017; Muthumalage et al. 2019; Vardavas et al., 2012), and reduced
cardiac function, as evidenced by endothelial dysfunction and oxidative stress (Alzahrani
et al., 2018; Antoniewicz et al., 2016; Carnevale et al., 2016; Moheimani et al., 2017).
Despite these documented negative health effects, ENDS use is increasing at a substantial
rate among adults in the U.S. To date, no published studies have determined vaping rates
among those with respiratory and pulmonary illnesses. However, a significant proportion
of individuals with a chronic respiratory illness formerly smoked cigarettes or are current
cigarette smokers and may be at risk for e-cigarette use. Furthermore, cigarette smokers
have a higher risk than the general population of developing a respiratory illness. In
addition, managing a chronic respiratory illness can adversely impact one’s perceived
health, stress levels, and overall functioning. The collective stress of these challenges
may place those with respiratory and pulmonary problems at high risk for ENDS use due
to the established relationship between stress and increased likelihood of using ENDS
(Ferrer et al., 2016; Park et al., 2017; Phillips et al., 2017; Spears et al., 2019).
Research is limited in explaining why those with respiratory illness and chronic
lung problems choose to vape. Despite increased vulnerability to the negative health
consequences associated with ENDS use, those with a respiratory illness may perceive
ENDS to be a safer alternative to smoking cigarettes, aid in smoking cessation, and
provide an overall improved smoking experience compared to combustible cigarette
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smoking. However, little is known about the demographic, psychosocial, and other
health-related factors that shape their risk perceptions regarding ENDS use. Unlike
previous studies, this study will add to the literature by examining health risk perceptions
associated with ENDS among a vulnerable population of individuals with chronic
respiratory illnesses. Understanding what factors contribute to ENDS risk perceptions
will help to inform public health policy messaging and improve health related behaviors
among this at-risk group. As the development of respiratory illnesses from cigarette
smoking can take decades to advance (Gotts et al. 2019), early interventions to reduce
smoking and ENDS use may prevent the worsening of respiratory symptoms or even the
development of more severe conditions like lung cancer in the future.
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Objectives and Hypotheses
Objective A: To describe the rates of past and current use of combustible cigarettes,
ENDS use, and dual products (concurrent combustible cigarette and e-cigarette use)
among those with respiratory illnesses.
Hypothesis A.1: The rates of combustible cigarette use, ENDS use, and dual
use among those with respiratory illnesses will be comparable to rates
reported in other medically compromised samples.
Objective B: To examine health risk perceptions related to ENDS use among those
with respiratory illnesses.
Hypothesis B.1: Individuals with respiratory illnesses will perceive the use of
ENDS as less harmful than combustible cigarettes.
Hypothesis B.2: Individuals with respiratory illnesses will have
comparable ENDS health risk perceptions regardless of their
smoking/vaping status (i.e., Current Dual Users vs. All Other Users).
Hypothesis B.3: The majority of participants (>50%) will perceive ENDS
use as an effective tool for smoking cessation and stress management.
Hypothesis B.4: A significant proportion (at least 50%) of participants
will report that their healthcare providers have advised the use of
electronic cigarettes as a method of smoking cessation or harm reduction
strategy.
Objective C: To determine the association between risk factors and ENDS health risk
perceptions among those with respiratory illnesses. These include demographic
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factors, psychosocial factors, and other health risk factors related to respiratory
illnesses.
Hypothesis C.1: Participants who are younger, male, low income, less
educated, single, non-Hispanic, from the South/Midwest regions, and
Caucasian will report lower ENDS health risk perceptions.
Hypothesis C.2: Participants who have friends who smoke/vape will
report lower ENDS health risk perceptions.
Hypothesis C.3: Participants with a higher overall health risk, as
measured by these factors (perceived health status, stress level, symptom
severity, and level of functioning) will report higher ENDS health risk
perceptions.
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Methods
Participants and Recruitment
In order to participate, individuals must have met the following criteria: (a) 18
years of age or older, (b) able to read and write English fluently, (c) have been diagnosed
with a respiratory illness and still have the diagnosis, (d) be a current/former smoker of
any combustible tobacco product (i.e. cigarettes, cigarillos, cigars, blunts, bidis, or any
other tobacco product), or a current/former ENDS user (i.e., electronic cigarettes, ecigarettes, vapes, electronic hookahs, hookah pens, vape pens, electronic pipes, or any
other electronic vaping products), or a dual user (i.e. concurrently use
cigarettes/combustible tobacco products and ENDS or used both products at some point
in time). Participants were recruited through various internet listservs, support groups,
and community boards via requests for voluntary participation in an anonymous survey.
Approval from the Florida Institute of Technology Institutional Review Board was
obtained prior to recruitment. All participants were asked to provide informed consent
prior to data collection.

Data Collection Procedures
Participants were directed to the survey through a link provided on the consent
form. The online survey consisted of 75 items and took approximately 15-20 minutes to
complete. To begin the survey, participants first provided informed consent, following
provision of information regarding what the study entailed. Participants verified their
eligibility by responding to a set of initial qualifying questions as described in Appendix
B. During the survey, participants were able to adjust their answers to previous questions
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by using the “back” button and to decline a response to any question. They were also able
to withdraw at any time. The data collected from the surveys were entered into a HIPPAcompliant database which de-identified all personal information. Finally, participants
were provided the option to enter a drawing to win one out of four $50 gift cards at the
completion of the survey.

Measures
Participants accessed the survey through the Qualtrics website. The core components of
the survey included the following:
I.

Qualifying Information. Questions were asked to verify a participant’s eligibility for
this survey prior to continuing with the full survey. Participants must have been 18
years of age, read and write English fluently, currently have a respiratory illness, and
be a current/former smoker or a current/former vaper, or a dual user.

II.

Demographics. Demographic characteristics obtained included age, sexual
orientation, gender identity, race, ethnicity, geographic region, relationship status,
education level, income, and occupational status.

III.

Psychosocial. Physical health and mental health were assessed via questions
pertaining to medical and mental health diagnoses. A quality-of-life question relevant
to participants’ respiratory health was also asked.

IV.

Cigarette Smoking Status and History. Participants were asked about their past and
current smoking status. “Past smokers” were defined as those who have smoked at
least 100 cigarettes in their lifetime, but not within the last 30 days (NHIS, 2020).
“Current smokers” were defined as those who have smoked at least 100 cigarettes in
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their lifetime and currently smoke cigarettes on “some days” or “nearly every day”
within the past 30 days as defined in prior studies (USDHHS, 2016). “Ever smokers”
were defined as those who endorse smoking in the past or currently (USDHHS,
2016). “Never smokers” were identified as those who have not smoked at least 100
cigarettes in their lifetime and who have not smoked in the past 30 days. “Current
dual users” were defined as those who currently smoke cigarettes and who currently
use ENDS. Participants who currently use either cigarettes or ENDS products and
have used the other product in the past, even if not at the same time, were considered
“Ever dual users.” Participants were asked about the number of smokers with whom
they are close friends. Responses were categorized into 0 smokers, 1-2 smokers, >3
smokers. Participants were also asked to complete questions regarding whether their
spouse/partner currently smokes. Responses were ‘Yes’, ‘No’, and ‘N/A (No
spouse/partner)’ for this question.
V.

ENDS Vaping Status and History. Participants were asked about their past and
current ENDS use status. “Current vapers” were those who reported use of any ENDS
product on “some days” or “nearly every day” within the past 30 days. “Past vapers”
were those who reported use of any ENDS product at least once in their lifetime but
not within the last 30 days. “Ever vapers” included the current and past ENDS users.
“Never vapers” were identified as those who have never used any ENDS product in
their lifetime, including over the past 30 days. A question regarding the level of
nicotine typically used in ENDS devices was included. As this study will include
participants who smoke cigarettes and may or may not currently use ENDS, an item
assessing future intentions to use ENDS was included. Participants were asked about
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the number of vapers with whom they are close friends. Responses were categorized
into 0 vapers, 1-2 vapers, >3 vapers. Participants were also asked to complete
questions regarding whether their spouse/partner currently vapes. Responses were
‘Yes’, ‘No’, and ‘N/A (No spouse/partner)’ for this question.
VI.

Respiratory Health Status and History. Items in this section assessed participants’
respiratory/pulmonary health history and verified participants’ diagnoses of
respiratory, pulmonary, or lung disease/illness. Participants were described as having
a “respiratory illness” if they have been informed by a medical professional of their
diagnosis and still currently have the respiratory illness/disease. The proportion of
participants who endorsed individual items was also reported and analyzed.

VII.

Health Risk Perceptions Regarding ENDS. Participants were asked about their
perceptions of harm from ENDS use as it relates to their overall
respiratory/pulmonary health (14 risk perception items). Items were adapted from the
co-investigator’s previous smoking research (Tyc, Lensing, Vukadinovich, & Hovell,
2013) for the current study. Items were rated on a 4-point scale ranging from
“Strongly Disagree” to “Strongly Agree” or a 3-point scale with options of “less
harmful,” “as harmful," or “more harmful.” A total health risk perception score
ranging from 0-38 was computed. Higher health risk perception scores (22 – 38) were
indicative of greater perceptions of harm regarding ENDS use. Lower health risk
perception scores (0 – 21) were indicative of less perceptions of harm regarding
ENDS use. The proportion of participants who endorsed individual items was also
reported and analyzed.
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VIII.

Smoking Cessation Perceptions. Participants were asked two questions regarding
their perceptions of using e-cigarettes as a smoking cessation or harm reduction
strategy. Items were rated on a 4-point scale ranging from “Strongly Agree” to
“Strongly Disagree.” Total values range from 0 – 6; higher scores indicate a stronger
perception that using ENDS use can be an effective method of smoking cessation or
harm reduction.

IX.

Healthcare Provider Communication. Participants were asked four questions
regarding smoking and vaping risks/warnings received from their healthcare
providers. Additionally, questions were asked regarding what smoking cessation
interventions their healthcare providers have advised them to use. Items were rated on
a 3-point scale: “Never,” “Once or twice,” or “Frequently.” Scores for the 4th question
were reversed. Total values range from 0 – 8; lower scores indicate limited delivery
of information about smoking cessation from healthcare providers.

X.

Health Risk Variables. Overall health risk was examined across four categories: a)
health status; b) stress level; c) symptom severity; and d) level of functioning.
Individual scores were computed for each category and an overall cumulative health
risk score was computed by summing the individual scores across each category.
Total cumulative health risk score ranges from 0 to 139, with higher scores indicative
of a greater health risk.
a. Health Status. This was assessed using 2 adapted questions from the
CDC’s Health Related Quality of Life 14-item measure (HRQOL-14).
Responses include ‘Excellent’, ‘Good’, ‘Fair’, ‘Poor’, and ‘Terrible’.
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Total values range from 0 – 8; higher scores indicate poor overall
perceived health status.
b. Stress Level. This was measured using the Perceived Stress Scale-4 item
questionnaire (PSS-4). This scale is a measurement of global stress which
is often used in primary care clinics for individuals with long-term
medical conditions. Since the sample included individuals with at least
one long-term medical condition (respiratory), it is best suited for
measuring stress levels for this population. Responses were measured on a
Likert scale including ‘Never’, ‘Almost Never’, ‘Sometimes’, ‘Fairly
Often’, and ‘Very Often’. Total values range from 0 – 16; higher scores
indicate higher levels of stress.
c. Symptom Severity. Participants were asked about the severity of their
respiratory/pulmonary symptoms. Items from the Quality-of-Life
Respiratory Illness Questionnaire (QOL-RIQ; Maillé et al. 1997) and the
BRFSS (2017) were adapted for this measure. Relevant symptoms are
defined as the following: chest pain/tightness, coughing, difficulty
breathing in, fatigue, frequent need to clear throat, heavy/rapid breathing,
itchy/dry throat, phlegm production, recurrent colds, shortness of breath,
sleeping issues, stuffed sinus/runny nose, weight loss/gain, and wheezing.
Total values range from 0 – 70; higher scores indicate worse symptom
severity.
d. Level of Functioning. Participants were asked about their level of
difficulty/impairment with completing activities of daily living. Items
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from the QOL-RIQ (Maillé et al. 1997) were included for this measure.
Relevant activities can be defined as bathing/showering,
eating/swallowing, getting dressed, going up stairs, lifting a heavy object,
running a short distance, sleeping/resting, shopping, and toileting. Total
values range from 0 – 45; higher scores indicate significant difficulty with
completing many areas of daily functioning.

Research Design and Data Analysis
This study utilized a cross-sectional design. Descriptive statistics, including
means, standard deviations, and frequencies, were calculated for participant
demographics, primary outcomes (ENDS Health Risk Perceptions), and all covariates.
Differences in health risk perceptions between current dual users and those in the ‘other
smoking/vaping’ group were examined using non-parametric Mann-Whitney U tests. Chi
Square tests were used to assess for differences between groups for categorical variables.
Linear regression analyses were conducted to examine the association between health
status, stress level, symptom severity, level of functioning and ENDS Risk Perceptions.
Preliminary analyses were conducted to examine the relationship between variables and
primary outcomes and tests for assumptions of normality and multicollinearity were
conducted for selected analyses. The data was analyzed using the Statistical Package for
the Social Sciences (SPSS) –version 28. All analyses were considered significant at the p
<.05 level.
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Results
Participants
Demographic Variables: A total of 305 participants agreed to participate in the
study. Of those, 35 were not eligible to take the survey due to not having any respiratory
conditions and not being a smoker or vaper. The final sample consisted of 270
participants, including 146 men, 101 women, 19 transwomen, 3 transmen, and one
individual who identified as gender fluid. Most participants were in the age range of 2534 years old (n = 95, 35%) and most identified as Heterosexual (n = 209, 77%). The
majority of participants were male (n = 146, 54%), identified as White/Caucasian (n =
204, 76%), were Non-Hispanic/Latino (n = 150, 56%), and lived in Urban/City areas (n =
209, 77%). The most frequently endorsed U.S. geographic region of residence was the
South (n = 79, 29%). A total of 23 participants (8.52%) endorsed living outside of the
US, specific counties of residence included United Kingdom, Ireland, Kenya, Qatar,
Canada, New Zealand, and South Africa. In terms of relationship status, the most
prevalent category was Married (n = 117, 43%). The most endorsed level of education
was a Technical Degree/Certificate (n = 72, 27%). Most participants were in the income
level of $20,000-$39,000 (n = 76, 28%) and more than half were employed full-time (n =
148, 55%).
Psychosocial Variables: In reference to participants’ health conditions, arthritis
(n = 96, 36%), chronic pain (n = 60, 22%), and hypertension (n = 57, 21%) were the top
three most frequently endorsed chronic medical conditions. Regarding mental health
conditions, anxiety (n = 126, 47%), depression (n = 78, 29%), and sleep disorders (n =
61, 23%) were the top three most frequently identified mental health conditions. Quality
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of life in relation to living with a respiratory condition was evaluated. The majority of
participants (n = 200, 74%) endorsed that their respiratory illness negatively
impacted/worsened their quality of life. See Table 1 for additional health diagnosis
information.
Smoking/Vaping Status: Smoking and vaping status of participants were
categorized into 7 groups to account for all participants. Current Smoker (n = 7, 3%)
consisted of those who smoked at least 100 cigarettes in their lifetime including over the
past 30 days and have never used a vaping product. Current Vaper (n = 2, 1%) included
those who have not smoked 100 cigarettes in their lifetime and have not smoked within
the past 30 days but have vaped in the past 30 days. Current Dual User (n =190, 70%)
included those who have vaped and smoked within the past 30 days regardless of if they
smoked 100 cigarettes in their lifetime or not. Past Smoker (n = 21, 8%) included those
who have smoked at least 100 cigarettes in their lifetime but have not smoked within the
past 30 days and have never vaped. Past Vaper (n = 5, 2%) includes those who have not
smoked at least 100 cigarettes, have not smoked or vaped within the past 30 days, but
have vaped at least once in their lifetime. Past Dual User (n = 18, 7%) includes those who
have smoked at least 100 cigarettes in their lifetime and have vaped at least once in their
lifetime but have not smoked or vaped within the past 30 days. Ever Dual User (n = 27,
10%) includes individuals who did not meet criteria for any other group.

For

comparative purposes and due to the limited number of participants in some groups, these
groups have been merged to categorize participants into two groups: the ‘Current Dual
Users’ versus ‘All Other Users’ combined.
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Respiratory Illness Variables: The top three most frequently identified
respiratory illnesses among participants included Asthma (n =111, 41%), Chronic
Obstructive Pulmonary Disease (COPD; n = 88, 33%), and Bronchiectasis (n = 78, 29%).
In terms of sequence for the onset of illness in comparison to smoking/vaping initiation,
more than half of participants endorsed smoking or vaping prior to receiving a diagnosis
for their respiratory condition (n = 149, 55%). A little over three-fourths of participants (n
= 205, 76%) endorsed having been given a Pulmonary Function Test (PFT) to assess
breathing concerns. Similarly, majority of participants endorsed currently using a
medically prescribed inhaler (n = 191, 71%) and experiencing an episode of severe
symptom exacerbation during the past 12 months (n = 149, 58%). During the past 12
months, 168 participants (62%) have visited an emergency room or urgent care center
due to their respiratory illness and 212 participants (78%) have seen a medical
professional for a routine checkup regarding their respiratory illness. See Table 2 for
further information.
ENDS Health Risk Perception Variables: The health risk perceptions regarding
ENDS were assessed via 14 questions (i.e., question 48-61). The responses to each
question were totaled to obtain a ‘ENDS Risk Perception Score’ for each participant. The
minimum score was 0 and the maximum score was 38 (Md = 21). Higher scores indicated
a greater perception of harm from ENDS devices. Lower scores indicated less perception
of harm from ENDS devices.
Health Risk Variables: These factors included health status, stress levels,
symptom severity, and level of functioning as measured by difficulty/impairment with
completing daily activities. Total scores for each variable were computed as well as an
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‘Overall Health Risk Score’ composed of health status, stress level, symptoms severity,
and level of functioning. For the Overall Health Risk, range of scores were from 8 to 107.
Higher Overall Health Risk scores indicated a greater health risk for the participant and
Lower Overall Health Risk scores indicated less of a health risk for the participant. The
mean Overall Health Risk score was 57 (SD = 21.65, Md = 61) indicating a moderate
overall health risk status for those with respiratory illness among this sample. See Table 3
for data on the responses to the Health Risk Variables and Table 4 for summary statics of
each Health Risk factor.
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Hypotheses
Hypothesis A.1: The rates of combustible cigarette use, ENDS use, and dual use
among those with respiratory illnesses will be comparable to rates reported in other
medically compromised samples.
Within the current study, it was found that 2.6% of the sample were current
smokers (n = 7), 0.7% were current vapers (n = 2), and 70.4% were current dual users (n
= 190). Similarly, 7.8% of the sample were past smokers (n = 21), 1.9% were past vapers
(n = 5), and 6.7% were past dual users (n = 18). Since there were not any individual
studies which evaluated cigarette use, ENDS use, and dual use within a single medical
population, multiple studies were used to analyze the rates obtained in the current study
to comparison samples. In a nationally representative sample (Behavioral Risk Factor
Surveillance System survey [BRFSS], CDC, 2019), current and past cigarette smoking
rates for those who endorsed having a chronic medical condition were reported. Of those
who endorsed having any type of cancer, the current cigarette smoking rate was 1.7%,
while the past cigarette smoking rate was 4.6%. Likewise, of those who endorsed having
coronary heart disease or myocardial infarction, the current cigarette smoking rate was
1.3%, while the past cigarette smoking rate was 2.6%. In an analysis of the Population
Assessment of Tobacco and Health (PATH) Study, authors Salloum and colleagues
(2019) evaluated the vaping rates of cancer survivors. Current vaping rates among cancer
survivors were reported at 3.8%, past vaping rates were reported at 0.7%, and dual
current use rates (cigarettes and vaping) were reported at 25% (Salloum et al., 2019).
Results of chi square goodness of fit tests demonstrated that current cigarette
smoking rates among individuals with respiratory illnesses in this study (2.6%) were not
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significantly different than the published rates among cancer patients (1.7%), χ2(1) =
1.29, p > .05, and among cardiac patients (1.3%), χ2(1) = 3.51, p > .05 found in the
BRFSS. However, results of chi square goodness of fit tests demonstrated that past
cigarette smoking rates among individuals with respiratory illnesses in this study (7.8%)
were significantly different than the published rates among cancer patients (4.6%), χ2(1)
= 6.21, p < .05, and among cardiac patients (2.6%), χ2(1) = 28.58, p < .001 found in the
BRFSS.
Results of chi square goodness of fit tests demonstrated that current vaping rates
among individuals with respiratory illnesses in the current sample (0.7%) were
significantly different than the published rates among cancer survivors (3.8%), χ2(1) =
6.91, p < .05 found in the PATH Study. Results of chi square goodness of fit tests also
demonstrated that past vaping rates among individuals with respiratory illnesses in the
current sample (1.9%) were significantly different than the published rates among cancer
survivors (0.7%), χ2(1) = 5.15, p < .05 found in the PATH Study. Finally, results of chi
square goodness of fit tests demonstrated that current dual user rates among individuals
with respiratory illnesses in the current study (70.4%) were significantly different than
the published rates of current dual use among cancer survivors (25%), χ2(1) = 296.42, p <
.001 found in the PATH Study.

Hypothesis B.1: Individuals with respiratory illnesses will perceive the use of
ENDS as less harmful than combustible cigarettes.
The frequency of responses to the survey item (“Use of e-cigarettes is: ___”) were
reviewed. Most participants endorsed the response “As harmful to me as regular
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cigarettes” (n = 129, 48%). The response “Less harmful to me than regular cigarettes”
was endorsed by 41% of participants (n = 112), and 11% of participants (n = 29)
endorsed the use of e-cigarettes as “More harmful to me than regular cigarettes.”

Hypothesis B.2: Individuals with respiratory illnesses will have comparable
ENDS health risk perceptions regardless of their smoking/vaping status (i.e., Current
Dual Users vs. All Other Users).
For this analysis, Current Dual Users were compared to all other smoking/vaping
groups combined due to the limited number of participants in some groups and because
the Dual Users were currently using both a smoking and vaping product while
participants in the other groups used only a single product at a time. KolmogorovSmirnov and Shapiro-Wilk tests were conducted to determine whether the distribution of
total ENDS health risk perception scores was significantly different from a normal
distribution. Results from both tests showed that this distribution was not normally
distributed (D = 0.14, p < .001) and (W = 0.96, p < .001), respectively. Therefore, a nonparametric Mann-Whitney U test was conducted to test for differences in ENDS risk
perception scores between the Current Dual Users and ‘Other Smoking/Vaping’ groups.
The Mann-Whitney U Test indicated that the ENDS risk perception scores were
significantly greater for the ‘Other Smoking/Vaping’ group (Md = 27.50, n = 80) than for
the Current Dual Users group (Md = 20.00, n =190), U = 3988, z = -6.18, p < .001.

Hypothesis B.3: The majority of participants (>50%) will perceive use of ENDS
as an effective tool for smoking cessation and stress management.
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In order to evaluate this hypothesis, the frequency of responses to specific survey
items (i.e., questions 62 and 63 for smoking cessation and question 36 for stress
management) were reported. More than half of the sample responded “Yes” (n = 146,
54%) to the question, “Do you feel that you use e-cigarettes/vaping products to manage
or cope with stress?”
Regarding smoking cessation perceptions, 66% (n = 179) ‘agreed’ or ‘strongly
agreed’ with the statement “E-cigarette/vaping products could help me, or others quit
smoking regular cigarettes”. Similarly, 76% of the sample (n = 206) ‘agreed’ or ‘strongly
agreed’ with the statement “E-cigarette/vaping products could help me, or others reduce
the number of cigarettes smoked.” These collective results support the hypothesis that
majority of this sample agreed that ENDS use is an effective stress management coping
method and an effective tool for smoking cessation/harm reduction.

Hypothesis B.4: A significant proportion (at least 50%) of participants will
report that their healthcare providers have advised the use of electronic cigarettes as a
method of smoking cessation or harm reduction strategy.
This hypothesis was evaluated by examining the frequency of responses to a
specific survey item (question 67) “Have any of your health care providers advised the
use of e-cigarettes/vaping products to quit cigarette smoking or reduce the number of
cigarettes smoked?” More than half of the respondents answered ‘Never’ (n = 159, 59%),
33% responded ‘Once or Twice’ (n = 90), and 8% responded ‘Frequently’ (n =21) to this
question. The hypothesis that a significant proportion of participants were advised by
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their healthcare providers to use electronic cigarettes as a smoking cessation or harm
reduction strategy was not supported.

Hypothesis C.1: Participants who are younger, male, low income, less educated,
single, non-Hispanic, from South/Midwest regions, and Caucasian will report lower
ENDS health risk perceptions.
A Chi-square Test of Independence was conducted using Yates continuity
correction values to examine whether age, gender, income, education, relationship status,
ethnicity, geographic region, and race were associated with ENDS Health Risk
Perceptions. For this analysis, high and low health risk perception groups were
determined using the median value of the health risk perception scores (Md = 21). The
first group consisted of the higher risk perception scores (n = 123, 46%) and included
those who obtained a risk perception score between 22 and 38. The lower risk perception
scores (n = 147, 54%) consists of those who obtained a risk perception score between 0
and 21. Age groups were divided into two categories: 18-34 years old (n = 131, 49%) and
35 years and older (n = 139, 51%). Income level groups were categorized as those who
endorsed making $39,000 and below (n = 107, 40%) and those who endorsed making
$40,000 and above (n = 163, 60%). Two groups were created for education level. ‘More
Education’ consisted of Associates Degree, Bachelor’s degree, Master’s Degree, and
Doctoral Degree (n = 104, 39%) and ‘Less Education’ consisted of all other responses (n
= 166, 61%). Relationship status was divided into two groups: Single group consisted of
single, divorced, and widowed (n = 91, 34%) and Relationship group consisted of
married and in a relationship (n = 179, 66%). The results of the Chi-square tests showed
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no significant association between ENDS Health Risk Perceptions and age, income level,
education level, and relationship status. Chi Square values are presented in Table 5.
Gender groups were divided into two categories: female, transwoman, and gender
fluid (n = 121, 45%) in one category and male and transman (n = 149, 55%) in the other
category. The results of the Chi-square test showed a significant association between
ENDS Health Risk Perceptions and gender, χ2(1) = 6.50, p = .011. Those in the higher
risk perception group were more likely to be Female while those in the lower risk
perception group were more likely to be Male. There were two groups created for
ethnicity: Hispanic/Latino (n = 120, 44%) and Non-Hispanic/Latino (n = 150, 56%). The
results of the Chi-square test showed a significant association between ENDS Health
Risk Perceptions and ethnicity, χ2(1) = 4.03, p = .045. Those in the higher risk perception
group were more likely to be Non-Hispanic/Latino while those in the lower risk
perception group were more likely to be Hispanic/Latino. Geographic region of residence
was divided into two groups: South/Midwest (n = 151, 56%) and all other regions,
including outside of the U.S., (n = 119, 44%). A Chi-square test indicated a significant
association between ENDS Health Risk Perceptions and geographic region, χ2(1) = 4.16,
p = .041. Participants in the lower risk perception group were more likely to be from the
South and Midwest regions while those in the higher risk perception group were more
likely to be from other regions. Race groups were divided into two categories: Caucasians
(n = 204, 76%) and all other minorities (n = 66, 24%). Race and ENDS health risk
perceptions were significantly associated, χ2(1) = 7.40, p = .007 showing that those in the
higher risk perception group were more likely to be White/Caucasian while those in the
lower risk perception groups were more likely to be of another race. In summation,
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ENDS risk perception scores were significantly associated with gender, ethnicity,
geographic region, and race. Chi Square values are presented in Table 5.

Hypothesis C.2: Participants who have friends who smoke/vape will report lower
ENDS health risk perceptions.
A Chi-square Test of Independence was conducted using Yates continuity
correction values to examine whether having friends who smoke and vape were
associated with ENDS Risk Perceptions. The High and Low ENDS Risk Perception
groups, as defined above using the median scores to divide the groups, were used in this
analysis. Number of friends who smoke were divided into two groups: none (n = 39,
14%) and one or more friend who smokes (n = 231, 86%). The results of the Chi-square
test indicated no significant association between the number of friends who smoked and
ENDS Risk Perceptions,
Likewise, number of friends who vape were divided into two groups: none (n =
39, 14%) and one or more friend who vapes (n = 231, 86%). A Chi-square test showed a
significant association between the number of friends who vape and ENDS Risk
Perceptions, χ2(1) = 13.92, p < .001. Participants with higher ENDS risk perceptions
were more likely to have no friends who vape while those with lower ENDS risk
perceptions were more likely to have one or more friends that vape. See Table 5 for Chi
Square values.
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Hypothesis C.3: Participants with a higher overall health risk, as measured by
these factors (health status, stress level, symptom severity, and level of functioning) will
report higher ENDS health risk perceptions.
A Chi-square Test of Independence using Yates continuity correction values was
conducted to examine whether overall health risk was associated with ENDS Health Risk
Perception Scores. The High and Low ENDS Risk Perception groups, as defined above,
were used in this analysis. Similarly, high and low overall health risk groups were
determined using the median of the overall health risk scores (Md = 61). The first group
consisted of the higher overall health risk scores (n = 131, 49%) and included those who
obtained a total score between 62 and 107. The lower overall health risk scores (n = 139,
51%) consisted of those who obtained a total score between 8 and 61. The results of the
Chi-square test were not significant, χ2(1) = 0.48, p = .490, suggesting no significant
association between overall health risk and ENDS risks perceptions. See Table 5 for Chi
Square values.
A linear multiple regression analysis was conducted to assess whether Health
Status, Stress Level, Symptom Severity, and Level of Functioning significantly predicted
ENDS Risk Perception Scores. Preliminary analyses indicated no violation of the
assumptions of normality and multicollinearity. The results of the linear regression model
were significant, F (4,265) = 4.01, p = .004, R2 = 0.06, indicating that approximately 6%
of the variance in ENDS Risk Perception Scores was explained by Health Status, Stress
Level, Symptom Severity, and Level of Functioning. Of the variables in the model,
Health Status significantly predicted ENDS Risk Perceptions, B = 0.70, t (265) = 3.42, p
< .001. This indicates that on average, a one standard deviation-unit increase in Health
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Status score will increase the value of ENDS Risk Perception scores by 0.70 standard
deviation units. Stress Level did not significantly predict ENDS Risk Perception scores, B
= -0.01, t (265) = -0.06, p = .956. Symptom Severity also did not significantly predict
ENDS Risk Perception scores, B = 0.03, t (265) = 0.78, p = .437. Level of Functioning
was not a significant predictor of ENDS Risk Perception scores, B = -0.03, t (265) = 0.56, p = .578. Table 6 summarizes the results of the regression model.
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Discussion
Extensive literature has conclusively demonstrated the harmful effects of smoking
on individuals’ health while research investigating the net public health effect of ENDS
has been somewhat more controversial (National Academies of Sciences, Engineering,
and Medicine, 2018). Nonetheless, the increasing popularity of ENDS has contributed to
a surge in research resulting in increased evidence supporting ENDS use as significantly
damaging to users’ health, especially related to cardiovascular and pulmonary
functioning (Bold et al., 2018). Moreover, even second-hand exposure to nicotine
through vaping is an immediate irritant to the lung tissue (Mishra et al., 2015). Despite
notable respiratory concerns and susceptibility to further negative health effects from
vaping, 70% of individuals with respiratory illnesses from this study indicated being a
current dual user. Current dual use compounds the negative health effects that is
associated with combustible cigarette smoking and vaping. The high rates of multiple
product use among individuals with respiratory illnesses suggest an at-risk population
that warrants interventions to address their smoking and vaping behaviors.
A comparison of current cigarette smoking rates in the study sample were similar
to those reported in prior studies (BRFSS-CDC, 2019; PATH Study-Salloum et al., 2019)
with other medically compromised groups (i.e., those with cancer and cardiac
conditions). However past cigarette smoking rates were significantly higher among this
sample compared to the other medically compromised groups. This finding may have
several explanations. While the BRFSS and the PATH studies were published in 2019,
the timing of when participants answered the survey most likely occurred years prior.
Participants in the current study responded in 2021, amidst the COVID-19 pandemic. The
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significant difference in past cigarette smoking rates between the two studies may be
accounted for by the fact that participants in our study had respiratory concerns during a
respiratory pandemic and may have elected to quit smoking because of COVID-19
concerns. The different rates of vaping between the two samples may also be due to the
fact that as rates of vaping increase as smokers attempt to quit smoking, failed smoking
cessation attempts while concurrently vaping may contribute to dual product use.
The reasons that individuals with respiratory illnesses use ENDS products at high
rates may be explained, in part, by their perceived benefits of ENDS use. Our study
found, for example, that 54% of the sample used ENDS to manage their stress.
Additionally, two-thirds of this sample agreed that e-cigarettes were an effective method
to stop smoking while over three-fourths of this sample agreed that e-cigarettes could
assist a smoker in reducing the number of cigarettes smoked. Additionally, when
participants were asked the reasons, they might use or consider using e-cigarettes, the
most frequently endorsed item was “Help with quitting other tobacco products, such as
cigarettes.” These findings, combined with the fact that the majority of the sample
perceived use of e-cigarettes ‘as harmful’ or ‘less harmful’ than combustible cigarettes,
suggests that individuals who smoke and view e-cigarettes as a safer alternative, may
initiate vaping to quit smoking, and instead become nicotine dependent on two products.
This conclusion may account for the high rate of dual use in our sample. However, based
on the nature of our data, it is difficult to determine which product use came first. Future
longitudinal studies could better address the trajectory of smoking and vaping initiation
and track the course of product use.
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Relatedly, a little more than half of the participants responded that they have
never been advised by their healthcare provider to use an ENDS product to quit cigarette
smoking or reduce the number of cigarettes smoked. However, one-third of participants
indicated they have been advised at least once or twice from their healthcare providers to
use an ENDS product to quit smoking. More alarmingly, 8% of participants endorsed
being advised frequently by their healthcare providers to use an ENDS product to quit
smoking. This is despite that fact that there is limited data about the effectiveness of
ENDS as a cessation tool and numerous health agencies do not recommend ENDS use as
a cigarette smoking cessation aid. Instead, patients should be directed by their providers
to implement evidence-based approaches and FDA-approved medications to quit
smoking. If e-cigarettes are used by patients, they should be used as a bridge off of
combustible cigarettes with the patient ultimately quitting all products as an end goal.
When examining health perceptions, results showed that current dual users had
significantly lower risk perceptions (i.e., lower perceptions of harm associated with ecigarette use) than the “all other users” group. This finding is consistent with previous
research that suggests that those who have less perceived health risks will engage in more
risky behaviors (Ayanian & Cleary, 1999; Strecher, Kreuter, & Kobrin, 1995; Weinstein
1998) such as concurrent dual use of ENDS products and combustible cigarettes (Chen et
al., 2016; Chen & Kaphingst, 2011; Hwang et al., 2019; Krosnick et al., 2017; McCubbin
et al., 2017). It is important to note that the participants in the “all other users” group
were also current or past smokers/vapers and yet significant differences in ENDS health
risk perceptions between them and the current dual users were found. The differences in
ENDS risk perceptions between the current dual users and the “all other users” group in
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our sample are likely of a lower magnitude than what would be expected if one were to
compare current dual users to never smokers/vapers on risk ratings. Future studies that
compare larger samples of dual users versus exclusive smokers/vapers and never users
would help to better assess the relationship between smoking/vaping status and health
perceptions.
Interestingly, there was no significant association between perceptions of health
risk associated with ENDS use and overall health risk scores. However, examination of
the individual components of the overall health risk indicated that perception of one’s
health status was a significant predictor of ENDS risk perceptions. These findings are
consistent with the Health Belief Model (HBM) of health behavior which states that
perceptions regarding risks of getting seriously ill and the ability to overcome illness can
influence the practice of health behaviors (Becker, 1974). Such findings suggest that
providers who can capitalize on the patient’s sensitivity to their health status may be able
to shape the patient’s health risk perceptions and prompt behavior change.
Based on the results from this study, medical practitioners can be more mindful in
discussing the negative health outcomes of dual using among those who have a chronic
respiratory condition and currently smoke and vape. Since this population often requires
frequent medical care and hospital visits, it would be worthwhile to implement change in
respiratory medical standards, whereby patients should be routinely asked about their
vaping habits and educated about the negative health effects of vaping, specific to their
illness. The association between health perceptions and smoking/vaping status
demonstrated in our study and the fact that health perceptions are modifiable, suggests
that provider advice about smoking/vaping-related health risks may influence behavioral
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change. Although increasing patient knowledge about the adverse health consequences
associated with ENDS use may not be sufficient by itself to change patient behavior,
understanding that one’s respiratory symptoms and health risks can be magnified by
smoking and using ENDS products is a first step in making healthy behavioral choices.
Finally, this study sought to examine demographic and psychosocial risk factors
associated with ENDS health risk perceptions. Results indicated that gender, ethnicity,
geographic region of residence, race, number of friends who vape, and smoking/vaping
status were all significantly related to ENDS Risk Perceptions. However, age, income
level, education level, relationship status, and number of friends who smoked were not
significantly associated with ENDS Risk Perceptions. These findings suggest that study
participants who identified as male/transman, Hispanic/Latino, from the South and
Midwest, and of a minority race were more likely to report lower risk perceptions
associated with ENDS use. Social influences were also important in determining health
risk perceptions. Participants who had one or more friends who vaped were more likely
to perceive ENDS use as being less harmful to their health. These higher risk groups
should be targeted for messaging about the health risks associated with ENDS use.
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Clinical Implications
As discussed above, the clinical implications that can be extrapolated from this
study relate to how smoking and vaping is addressed in medical settings among patients
with chronic respiratory conditions. The results from this study and previous studies have
established that this population is in frequent contact with medical providers to manage
their respiratory symptoms. Given this increased contact, it is critical that vaping
behaviors be regularly addressed with the patient during routine medical visits. Along
with the warnings against cigarette smoking, providers should also discuss the dangers of
vaping. Likewise, it would be prudent for medical providers to not advice the use of ecigarettes as a form of smoking cessation aid at this time without an explicit plan to
eventually quit all forms of smoking and vaping. These recommendations can be put into
action by first identifying patients at risk of initiating ENDS use and then providing these
patients with educational pamphlets on the negative health effects of vaping and/or dual
use to prompt discussion about ENDS use. As health risk perceptions can be modified,
and perceptions of risk are associated with smoking/vaping behaviors, increasing patient
awareness of their health risks is an important step in promoting abstinence from ENDS
and tobacco products.
As it relates to psychotherapeutic interventions, mental health practitioners can
utilize this information to bolster smoking cessation psychoeducation by sharing the
negative health effects of dual using for smoking cessation. Since it is suggested that
individuals are more likely to begin using ENDS as a method of smoking cessation, but
often end up continuing to use both cigarettes and ENDS products, it is vital to provide
education about the FDA approved behavioral and pharmacological methods of smoking
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cessation. Motivational interviewing techniques may also be helpful in reducing patient
ambivalence about quitting and increasing motivation for behavioral change. In addition,
practitioners should emphasize that ENDS initiation while smoking cigarettes may be
counterproductive not only to quitting but also in creating worse respiratory effects for
the patient.
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Limitations and Directions for Future Research
There are some methodological issues inherent to the current study, which limit
the definitiveness of the conclusions drawn. First, the study is cross-sectional in design,
such that the directionality of the relationship between many of the participants’
pulmonary-specific characteristics and their health risk perceptions associated with
ENDS cannot be entirely established. Future research should include a longitudinal
approach to better understand directionality of these relationships. Another limitation to
the current study was that the primary outcomes were based on self-reports. Although the
validity of self-reported smoking measures appears to be valid (Caraballo et al., 2004;
Japuntich et al., 2009; Ramo et al. 2011; Wetter et al., 1994;), the validity of self-reported
vaping measures has yet to be investigated. Moreover, only current or former
smokers/vapers who have a respiratory illness were included in this study to examine
perceptions related to ENDS use in this high-risk sample. This eligibility criteria resulted
in a less than desirable sample size, preventing the more in-depth assessment of the risk
and protective factors of ENDS use among those with respiratory illnesses. Likewise, the
subsamples of smoker/vaper groups were unexpectedly small which contributed to the
grouping of all but one group into a heterogeneous group for the purposes of analysis.
The findings from this current study move us toward a better understanding of
smoking and vaping among individuals with respiratory illnesses. Nonetheless, future
research should seek to obtain further information via a nation-wide survey that includes
individuals with respiratory illnesses who do not smoke or use ENDS products. Likewise,
it would be worthwhile to explore the reasons for why individuals believe vaping is an
acceptable method of smoking cessation and ways to alter this perception.

87

REFERENCES

Adkison, S. E., O'Connor, R. J., Bansal-Travers, M., Hyland, A., Borland, R., Yong, H.
H., Cummings, K. M., McNeill, A., Thrasher, J. F., Hammond, D., & Fong, G. T.
(2013). Electronic nicotine delivery systems: international tobacco control fourcountry survey. American journal of preventive medicine, 44(3), 207–215.
https://doi.org/10.1016/j.amepre.2012.10.018
Agency for Toxic Substances and Disease Registry (ATSDR). (2007). Toxicological
profile for Acrolein. U.S. Department of Health and Human Services.
(USDHHS).
https://wwwn.cdc.gov/TSP/ToxProfiles/ToxProfiles.aspx?id=557&tid=102
Ajzen, I. (1991). The theory of planned behavior. Organizational behavior and human
decision processes, 50(2), 179-211.
Ajzen, I. (1985). From intentions to actions: A theory of planned behavior. Action in
control (pp.11-39). Springer, Berlin, Heidelberg.
Allen, J. G., Flanigan, S. S., LeBlanc, M., Vallarino, J., MacNaughton, P., Stewart, J. H.,
& Christiani, D. C. (2016). Flavoring Chemicals in E-Cigarettes: Diacetyl, 2,3Pentanedione, and Acetoin in a Sample of 51 Products, Including Fruit-, Candy-,
and Cocktail-Flavored E-Cigarettes. Environmental health perspectives, 124(6),
733–739. https://doi.org/10.1289/ehp.1510185

88

Alton, D., Eng, L., Lu, L., Song, Y., Su, J., Farzanfar, D., Mohan, R., Krys, O., Mattina,
K., Harper, C., Liu, S., Yoannidis, T., Milne, R., Brown, M. C., Vennettilli, A.,
Hope, A. J., Howell, D., Jones, J. M., Selby, P., Xu, W., Giuliani, M. E. (2018).
Perceptions of Continued Smoking and Smoking Cessation Among Patients with
Cancer. Journal of oncology practice, 14(5), e269–e279.
https://doi.org/10.1200/JOP.17.00029
Alzahrani, T., Pena, I., Temesgen, N., & Glantz, S. A. (2018). Association Between
Electronic Cigarette Use and Myocardial Infarction. American journal of
preventive medicine, 55(4), 455–461.
https://doi.org/10.1016/j.amepre.2018.05.004
American Lung Association (ALA). (2020, May 27). Lung Function Tests. Retrieved
from https://www.lung.org/lung-health-diseases/lung-procedures-and-tests/lungfunction-tests
American Lung Association (ALA). (2021). Overall Tobacco Trends. Retrieved from
https://www.lung.org/research/trends-in-lung-disease/tobacco-trendsbrief/overall-tobacco-trends
American Lung Association (ALA). (2021). Lung Health & Diseases. Retrieved from
https://www.lung.org/lung-health-diseases
Amiri, P., Mohammadzadeh-Naziri, K., Abbasi, B., Cheraghi, L., Jalali-Farahani, S.,
Momenan, A. A., & Azizi, F. (2019). Smoking habits and incidence of
cardiovascular diseases in men and women: findings of a 12 year follow up
among an urban Eastern-Mediterranean population. BMC public health, 19(1), 110. https://doi.org/10.1186/s12889-019-7390-0

89

Antoniewicz, L., Bosson, J. A., Kuhl, J., Abdel-Halim, S. M., Kiessling, A., Mobarrez,
F., & Lundbäck, M. (2016). Electronic cigarettes increase endothelial progenitor
cells in the blood of healthy volunteers. Atherosclerosis, 255, 179–185.
https://doi.org/10.1016/j.atherosclerosis.2016.09.064
Ashford, K., Wiggins, A., Butler, K., Ickes, M., Rayens, M. K., & Hahn, E. (2016). eCigarette Use and Perceived Harm Among Women of Childbearing Age Who
Reported Tobacco Use During the Past Year. Nursing research, 65(5), 408–414.
https://doi.org/10.1097/NNR.0000000000000176
ATSDR. (2010). Toxicological profile for ethylene glycol. U.S. Department of Health and
Human services (USDHHS). https://www.atsdr.cdc.gov/ToxProfiles/tp96.pdf
Awad, M., & Awan, O. (2020, July 13). The Signs of Vaping Lung Disease. Retrieved
from httpswww.hackensackmeridianhealth.org/HealthU/2020/07/13/the-signs-ofvaping-lung-disease/
Awasthi, S., Gupta, S., Maurya, N., Tripathi, P., Dixit, P., & Sharma, N. (2012).
Environmental risk factors for persistent asthma in Lucknow. Indian journal of
pediatrics, 79(10), 1311–1317. https://doi.org/10.1007/s12098-012-0817-6
Ayanian, J. Z., & Cleary, P. D. (1999). Perceived risks of heart disease and cancer among
cigarette smokers. JAMA, 281(11), 1019–1021.
https://doi.org/10.1001/jama.281.11.1019
Ayers, J. W., Leas, E. C., Allem, J. P., Benton, A., Dredze, M., Althouse, B. M., Cruz, T.
B., & Unger, J. B. (2017). Why do people use electronic nicotine delivery systems
(electronic cigarettes)? A content analysis of Twitter, 2012-2015. PloS one, 12(3),
e0170702. https://doi.org/10.1371/journal.pone.0170702

90

Balakumar, P., & Kaur, J. (2009). Is nicotine a key player or spectator in the induction
and progression of cardiovascular disorders? Pharmaco- logical Research, 60,
361–368. http://dx.doi.org/10.1016/j.phrs.2009.06.005
Barrington-Trimis, J. L., Urman, R., Leventhal, A. M., Gauderman, W. J., Cruz, T. B.,
Gilreath, T. D., Howland, S., Unger, J. B., Berhane, K., Samet, J. M., &
McConnell, R. (2016). E-cigarettes, Cigarettes, and the Prevalence of Adolescent
Tobacco Use. Pediatrics, 138(2), e20153983. https://doi.org/10.1542/peds.20153983
Baeza-Loya, S., Viswanath, H., Carter, A., Molfese, D. L., Velasquez, K. M., Baldwin, P.
R., Thompson-Lake, D. G., Sharp, C., Fowler, J. C., De La Garza, R., 2nd, &
Salas, R. (2014). Perceptions about e-cigarette safety may lead to e-smoking
during pregnancy. Bulletin of the Menninger Clinic, 78(3), 243–252.
https://doi.org/10.1521/bumc.2014.78.3.243
Beaglehole, R., Bates, C., Youdan, B., & Bonita, R. (2019). Nicotine without smoke:
fighting the tobacco epidemic with harm reduction. The Lancet, 394(10200), 718720. https://doi.org/10.1016/S0140-6736(19)31884-7
Becker, M. H. (1974). The Health Belief Model and Sick Role Behavior. Health
Education Monographs, 2(4), 409–419. https://doi.org/10.1177/10901981740027
Behar, R. Z., Luo, W., Lin, S. C., Wang, Y., Valle, J., Pankow, J. F., & Talbot, P. (2016).
Distribution, quantification and toxicity of cinnamaldehyde in electronic cigarette
refill fluids and aerosols. Tobacco control, 25(Suppl 2), ii94–ii102.
https://doi.org/10.1136/tobaccocontrol-2016-053224

91

Bekki, K., Uchiyama, S., Ohta, K., Inaba, Y., Nakagome, H., & Kunugita, N. (2014).
Carbonyl compounds generated from electronic cigarettes. International journal
of environmental research & public health, 11(11), 11192–11200.
https://doi.org/10.3390/ijerph111111192
Best, C., Haseen, F., Currie, D., Ozakinci, G., MacKintosh, A. M., Stead, M., Eadie, D.,
MacGregor, A., Pearce, J., Amos, A., Frank, J., & Haw, S. (2017). Relationship
between trying an electronic cigarette and subsequent cigarette experimentation in
Scottish adolescents: a cohort study. Tobacco control, 27(4), 373–378. Advance
online publication. https://doi.org/10.1136/tobaccocontrol-2017-053691
Bhatnagar, A. (2016). E-cigarettes and cardiovascular disease risk: Evaluation of
evidence, policy implications, and recommendations. Current Cardiovascular
Risk Reports, 10, 24. http://dx.doi.org/10.1007/s12170- 016-0505-6
Bhatta, D. N., & Glantz, S. A. (2020). Association of E-Cigarette Use with Respiratory
Disease Among Adults: A Longitudinal Analysis. American journal of preventive
medicine, 58(2), 182–190. https://doi.org/10.1016/j.amepre.2019.07.028
Bjur, K. A., Cannon, B. C., Fine, A. L., Ritter, M. J., Schueler, K. E., & Nemergut, M. E.
(2017). Propylene Glycol Toxicity in Adolescent with Refractory Myoclonic
Status Epilepticus. Case reports in pediatrics, 2017, 2979486.
https://doi.org/10.1155/2017/2979486
Blaha, M. J. (2021). 5 Vaping Facts You Need to Know. Retrieved from
https://www.hopkinsmedicine.org/health/wellness-and-prevention/5-truths-youneed-to-know-about-vaping

92

Bold, K. W., Krishnan-Sarin, S., & Stoney, C. M. (2018). E-cigarette use as a potential
cardiovascular disease risk behavior. American Psychologist, 73(8), 955-967.
http://dx.doi.org.portal.lib.fit.edu/10.1037/amp0000231
Bronars, C., Patten, C., Koller, K., Hatsukami, D., Flanagan, C. A., Decker, P. A.,
Hanson, A., Wolfe, A., Hughes, C., Benowitz, N., Murphy, N. J., & Thomas, T.
(2018). Perceived risks and reasons to smoke cigarettes during pregnancy among
Alaska native women. Ethnicity & health, 23(1), 33–42.
https://doi.org/10.1080/13557858.2016.1246425
Brose, L. S., Hitchman, S. C., Brown, J., West, R., & McNeill, A. (2015). Is the use of
electronic cigarettes while smoking associated with smoking cessation attempts,
cessation and reduced cigarette consumption? A survey with a 1‐year follow‐up.
Addiction, 110(7), 1160–1168. https://doi.org/10.1111/add.12917
Bullen, C., Howe, C., Laugesen, M., McRobbie, H., Parag, V., Williman, J., & Walker,
N. (2013). Electronic cigarettes for smoking cessation: a randomized controlled
trial. The Lancet, 382(9905), 1629–1637. https://doi.org/10.1016/S01406736(13)61842-5
Cameron, J. M., Howell, D. N., White, J. R., Andrenyak, D. M., Layton, M. E., & Roll, J.
M. (2014). Variable and potentially fatal amounts of nicotine in e-cigarette
nicotine solutions. Tobacco control, 23(1), 77–78.
https://doi.org/10.1136/tobaccocontrol-2012-050604

93

Canistro, D., Vivarelli, F., Cirillo, S., Babot Marquillas, C., Buschini, A., Lazzaretti, M.,
Marchi, L., Cardenia, V., Rodriguez-Estrada, M. T., Lodovici, M., Cipriani, C.,
Lorenzini, A., Croco, E., Marchionni, S., Franchi, P., Lucarini, M., Longo, V.,
Della Croce, C. M., Vornoli, A., Colacci, A., Paolini, M. (2017). E-cigarettes
induce toxicological effects that can raise the cancer risk. Scientific reports, 7(1),
2028. https://doi.org/10.1038/s41598-017-02317-8
Caraballo, R. S., Giovino, G. A., & Pechacek, T. F. (2004). Self-reported cigarette
smoking vs. serum cotinine among U.S. adolescents. Nicotine & tobacco
research: official journal of the Society for Research on Nicotine and Tobacco,
6(1), 19–25. https://doi.org/10.1080/14622200310001656821
Carnevale, R., Sciarretta, S., Violi, F., Nocella, C., Loffredo, L., Perri, L., Peruzzi, M.,
Marullo, A. G., De Falco, E., Chimenti, I., Valenti, V., Biondi-Zoccai, G., &
Frati, G. (2016). Acute Impact of Tobacco vs Electronic Cigarette Smoking on
Oxidative Stress and Vascular Function. Chest, 150(3), 606–612.
Cataldo, J. K., Dubey, S., & Prochaska, J. J. (2010). Smoking cessation: an integral part
of lung cancer treatment. Oncology, 78(5-6), 289-301.
https://doi.org/10.1159/000319937
Centers for Disease Control and Prevention (CDC). (2010). Pulmonary Diseases: How
Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for SmokingAttributable Disease: A Report of the Surgeon General. National Center for
Chronic Disease Prevention and Health Promotion; Office on Smoking and
Health. Atlanta (GA): Centers for Disease Control and Prevention.
https://www.ncbi.nlm.nih.gov/books/NBK53021/

94

Centers for Disease Control and Prevention (CDC). (2010) Behavioral Risk Factor
Surveillance System (BRFSS) Survey Data. Atlanta, Georgia: U.S. Department of
Health and Human Services (USDHHS).
Centers for Disease Control and Prevention (CDC). (2017). Percentage of adults who
ever used an E-cigarette and percentage who currently use E-cigarettes, by age
group – National Health Interview Survey, United States, 2016. MWR Morb
Mortal Wkly Rep, 66(33), 892. http://dx.doi.org/10.15585/mmwr.mm6633a6
Centers for Disease Control and Prevention (CDC). (2017) Behavioral Risk Factor
Surveillance System (BRFSS) Survey Data. Atlanta, Georgia: U.S. Department of
Health and Human Services (USDHHS).
Centers for Disease Control and Prevention (CDC). (2019) Behavioral Risk Factor
Surveillance System (BRFSS) Survey Data. Atlanta, Georgia: U.S. Department of
Health and Human Services (USDHHS).
Centers for Disease Control and Prevention (CDC). (2020, March 23). Dual Use of
Tobacco Products. Retrieved from
https://www.cdc.gov/tobacco/campaign/tips/diseases/dual-tobacco-use.html
Centers for Disease Control and Prevention (CDC). (2020, August 21). Common Asthma
Triggers. Retrieved from https://www.cdc.gov/asthma/triggers.html
Centers for Disease Control (CDC). (2020, November 27). EVALI; Outbreak of Lung
Injury Associated with the Use of E-Cigarette, or Vaping, Products. Retrieved
from https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lungdisease.html#

95

Chatham-Stephens, K., Law, R., Taylor, E., Melstrom, P., Bunnell, R., Wang, B., &
Schier, J. G. (2014). Calls to Poison Centers for Exposures to Electronic
Cigarettes—United States, September 2010–February 2014. MMWR. Morbidity
and mortality weekly report, 63(13), 292.
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6313a4.htm
Chen, L. S., & Kaphingst, K. A. (2011). Risk perceptions and family history of lung
cancer: differences by smoking status. Public health genomics, 14(1), 26–34.
https://doi.org/10.1159/000294151
Chen, L. S., Kaphingst, K. A., Tseng, T. S., & Zhao, S. (2016). How are lung cancer risk
perceptions and cigarette smoking related? -testing an accuracy hypothesis.
Translational cancer research, 5(Suppl 5), S964–S971.
https://doi.org/10.21037/tcr.2016.10.75
Choi, K., & Forster, J. (2013). Characteristics associated with awareness, perceptions,
and use of electronic nicotine delivery systems among young US Midwestern
adults. American journal of public health, 103(3), 556–561.
Choi, H., Schmidbauer, N., Spengler, J., & Bornehag, C. G. (2010). Sources of propylene
glycol and glycol ethers in air at home. International journal of environmental
research and public health, 7(12), 4213–4237.
https://doi.org/10.3390/ijerph7124213

96

Clark, E. M., Huang, J., Roth, D. L., Schulz, E., Williams, B. R., & Holt, C. L. (2017).
The relationship between religious beliefs and behaviors and changes in spiritual
health locus of control over time in a national sample of African Americans.
Mental health, religion & culture, 20(5), 449–463.
https://doi.org/10.1080/13674676.2017.1356274
Conner, M., Grogan, S., Simms-Ellis, R., Flett, K., Sykes-Muskett, B., Cowap, L.,
Lawton, R., Armitage, C. J., Meads, D., Torgerson, C., West, R., & Siddiqi, K.
(2017). Do electronic cigarettes increase cigarette smoking in UK adolescents?
Evidence from a 12-month prospective study. Tobacco control, 27(4), 365–372.
Advance online publication. https://doi.org/10.1136/tobaccocontrol-2016-053539
Cooper, M., Harrell, M. B., Pérez, A., Delk, J., & Perry, C. L. (2016). Flavorings and
Perceived Harm and Addictiveness of E-cigarettes among Youth. Tobacco
regulatory science, 2(3), 278–289. https://doi.org/10.18001/TRS.2.3.7
Delnevo, C. D., Giovenco, D. P., Steinberg, M. B., Villanti, A. C., Pearson, J. L., Niaura,
R. S., & Abrams, D. B. (2016). Patterns of Electronic Cigarette Use Among
Adults in the United States. Nicotine & tobacco research: official journal of the
Society for Research on Nicotine and Tobacco, 18(5), 715–719.
https://doi.org/10.1093/ntr/ntv237
Dewantoro, D., Kerr, D. M., & Delles, C. (2018). A survey evaluating healthcare
professionals’ knowledge and perceptions of electronic cigarettes. Heart 2018;
104: A4-A5. http://dx.doi.org/10.1136/heartjnl-2018-SCF.11

97

Doran, N., Brikmanis, K., Petersen, A., Delucchi, K., Al-Delaimy, W. K., Luczak, S.,
Myers, M., & Strong, D. (2017). Does e-cigarette use predict cigarette escalation?
A longitudinal study of young adult non-daily smokers. Preventive medicine, 100,
279–284. https://doi.org/10.1016/j.ypmed.2017.03.023
Doyle, T., Palmer, S., Johnson, J., Babyak, M. A., Smith, P., Mabe, S., Welty-Wolf, K.,
Martinu, T., & Blumenthal, J. A. (2013). Association of anxiety and depression
with pulmonary-specific symptoms in chronic obstructive pulmonary disease.
International journal of psychiatry in medicine, 45(2), 189–202.
https://doi.org/10.2190/PM.45.2.g
Duffy, S. A., Khan, M. J., Ronis, D. L., Fowler, K. E., Gruber, S. B., Wolf, G. T., &
Terrell, J. E. (2008). Health behaviors of head and neck cancer patients the first
year after diagnosis. Head & Neck: Journal for the Sciences and Specialties of the
Head and Neck, 30(1), 93-102. https://doi.org/10.1002/hed.20665
East, K., Hitchman, S. C., Bakolis, I., Williams, S., Cheeseman, H., Arnott, D., &
McNeill, A. (2018). The Association Between Smoking and Electronic Cigarette
Use in a Cohort of Young People. The Journal of adolescent health: official
publication of the Society for Adolescent Medicine, 62(5), 539–547.
https://doi.org/10.1016/j.jadohealth.2017.11.301
Fairchild, A. L., Bayer, R., & Lee, J. S. (2019). The E-Cigarette Debate: What Counts as
Evidence? American journal of public health, 109(7), 1000–1006.
https://doi.org/10.2105/AJPH.2019.305107

98

Ferrer, R., Klein, W., Lerner, J., Reyna, V., & Keltner, D. (2016). Emotions and health
decision making. Behavioral economics and public health, 101-132.
https://doi.org/10.1093/med/9780199398331.003.0004
Fishbein, M., & Ajzen, I. (1975). Belief, Attitude, Intention, and Behavior: An
Introduction to Theory and Research. Reading, MA: Addison-Wesley.
Flora, J. W., Wilkinson, C. T., Wilkinson, J. W., Lipowicz, P. J., Skapars, J. A.,
Anderson, A., & Miller, J. H. (2017). Method for the Determination of Carbonyl
Compounds in E-Cigarette Aerosols. Journal of chromatographic science, 55(2),
142–148. https://doi.org/10.1093/chromsci/bmw157
Food and Drug Administration (FDA). (2020, September 17). Vaporizers, E-Cigarettes,
and other Electronic Nicotine Delivery Systems (ENDS). Retrieved from
https://www.fda.gov/tobacco-products/products-ingredientscomponents/vaporizers-e-cigarettes-and-other-electronic-nicotine-deliverysystems-ends
Forum of International Respiratory Societies (FIRS). (2017). The Global Impact of
Respiratory Disease – Second Edition. Sheffield, European Respiratory Society.
https://www.who.int/gard/publications/The_Global_Impact_of_Respiratory_Dise
ase.pdf
Foulds, J., Veldheer, S., & Berg, A. (2011). Electronic cigarettes (e-cigs): views of
aficionados and clinical/public health perspectives. International journal of
clinical practice, 65(10), 1037–1042. https://doi.org/10.1111/j.17421241.2011.02751.x

99

Franks, A. M., Hawes, W. A., McCain, K. R., & Payakachat, N. (2017). Electronic
cigarette use, knowledge, and perceptions among health professional students.
Currents in pharmacy teaching & learning, 9(6), 1003–1009.
https://doi.org/10.1016/j.cptl.2017.07.023
Garcia-Arcos, I., Geraghty, P., Baumlin, N., Campos, M., Dabo, A. J., Jundi, B.,
Cummins, N., Eden, E., Grosche, A., Salathe, M., & Foronjy, R. (2016). Chronic
electronic cigarette exposure in mice induces features of COPD in a nicotinedependent manner. Thorax, 71(12), 1119–1129. https://doi.org/10.1136/thoraxjnl2015-208039
Gellatly, S., Pavelka, N., Crue, T., Schweitzer, K. S., Day, B. J., Min, E., Numata, M.,
Voelker, D. R., Scruggs, A., Petrache, I., & Hong, W. C. (2020). Nicotine-Free ECigarette Vapor Exposure Stimulates IL6 and Mucin Production in Human
Primary Small Airway Epithelial Cells. Journal of Inflammation Research, 13,
175-185. http://dx.doi.org.portal.lib.fit.edu/10.2147/JIR.S244434
Geiss, O., Bianchi, I., & Barrero-Moreno, J. (2016). Correlation of volatile carbonyl
yields emitted by e-cigarettes with the temperature of the heating coil and the
perceived sensorial quality of the generated vapors. International journal of
hygiene and environmental health, 219(3), 268–277.
https://doi.org/10.1016/j.ijheh.2016.01.004

100

Ghosh, A., Coakley, R. D., Ghio, A. J., Muhlebach, M. S., Esther, C. R., Jr, Alexis, N. E.,
& Tarran, R. (2019). Chronic E-Cigarette Use Increases Neutrophil Elastase and
Matrix Metalloprotease Levels in the Lung. American journal of respiratory and
critical care medicine, 200(11), 1392–1401. https://doi.org/10.1164/rccm.2019030615OC
Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2021). Global strategy
for the diagnosis, management, and prevention of chronic obstructive pulmonary
disease. (2021 report). https://goldcopd.org/wp-content/uploads/2020/11/GOLDREPORT-2021-v1.1-25Nov20_WMV.pdf
Gomes, R., Liteplo, R. G., Meek, M. E., & World Health Organization. (2002). Ethylene
glycol:human health aspects. World Health Organization.
https://www.who.int/ipcs/publications/cicad/en/cicad45.pdf
González López, A., & Amérigo Cuervo-Arango, M. (2008). Relationship among values,
beliefs, norms and ecological behavior. Psicothema, 20(4), 623–629.
Gotts, J. E., Jordt, S. E., McConnell, R., & Tarran, R. (2019). What are the respiratory
effects of e-cigarettes? BMJ (Clinical research ed.), 366, l5275.
https://doi.org/10.1136/bmj.l5275
Gravely, S., Fong, G. T., Cummings, K. M., Yan, M., Quah, A. C., Borland, R., Yong, H.
H., Hitchman, S. C., McNeill, A., Hammond, D., Thrasher, J. F., Willemsen, M.
C., Seo, H. G., Jiang, Y., Cavalcante, T., Perez, C., Omar, M., & Hummel, K.
(2014). Awareness, trial, and current use of electronic cigarettes in 10 countries:
Findings from the ITC project. International journal of environmental research
and public health, 11(11), 11691–11704. https://doi.org/10.3390/ijerph111111691

101

Grando, S. A. (2014). Connections of nicotine to cancer. Nature Reviews Cancer, 14,
419–429. http://dx.doi.org/10.1038/nrc3725
Gravely, S., Thrasher, J. F., Cummings, K. M., Ouimet, J., McNeill, A., Meng, G.,
Lindblom, E. N., Loewen, R., O'Connor, R. J., Thompson, M. E., Hitchman, S.
C., Hammond, D., Heckman, B. W., Borland, R., Yong, H. H., Elton-Marshall,
T., Bansal-Travers, M., Gartner, C., & Fong, G. T. (2019). Discussions between
health professionals and smokers about nicotine vaping products: results from the
2016 ITC Four Country Smoking and Vaping Survey. Addiction (Abingdon,
England), 114 Suppl 1, 71–85. https://doi.org/10.1111/add.14527
Gillman, I. G., Kistler, K. A., Stewart, E. W., & Paolantonio, A. R. (2016). Effect of
variable power levels on the yield of total aerosol mass and formation of
aldehydes in e-cigarette aerosols. Regulatory toxicology and pharmacology
(RTP), 75, 58–65. https://doi.org/10.1016/j.yrtph.2015.12.019
Hajek, P., Phillips-Waller, A., Dunja, P., Francesca, P., Myers, S. K., Natalie, B.,
Jinshuo, L., Parrott, S., Sasieni, P., Dawkins, L., Ross, L., Maciej, G., Wu, Q., &
McRobbie, H. J. (2019). A Randomized Trial of E-Cigarettes versus NicotineReplacement Therapy. The New England Journal of Medicine, 380(7), 629-637.
http://dx.doi.org.portal.lib.fit.edu/10.1056/NEJMoa1808779
Harrell, M. B., Weaver, S. R., Loukas, A., Creamer, M., Marti, C. N., Jackson, C. D.,
Eriksen, M. P. (2017). Flavored e-cigarette use: characterizing youth, young adult,
and adult users. Preventive medicine reports, 5, 33-40.
https://doi.org/10.1016/j.pmedr.2016.11.001

102

Hartmann-Boyce, J., McRobbie, H., Bullen, C., Begh, R., Stead, L. F., & Hajek, P.
(2016). Electronic cigarettes for smoking cessation. The Cochrane database of
systematic reviews, 9(9), CD010216.
https://doi.org/10.1002/14651858.CD010216.pub3
Herrington, J. S., & Myers, C. (2015). Electronic cigarette solutions and resultant aerosol
profiles. Journal of chromatography 1418, 192–199.
https://doi.org/10.1016/j.chroma.2015.09.034
Hogg J. C. (2004). Pathophysiology of airflow limitation in chronic obstructive
pulmonary disease. Lancet, 364(9435), 709–721. https://doi.org/10.1016/S01406736(04)16900-6
Hua, M., Alfi, M., & Talbot, P. (2013). Health-related effects reported by electronic
cigarette users in online forums. Journal of medical Internet research, 15(4), e59.
https://doi.org/10.2196/jmir.2324
Hua, M., Sadah, S., Hristidis, V., & Talbot, P. (2020). Health Effects Associated with
Electronic Cigarette Use: Automated Mining of Online Forums. Journal of
medical Internet research, 22(1), e15684. https://doi.org/10.2196/15684
Huang, J., Kim, Y., Vera, L., & Emery, S. L. (2016). Electronic Cigarettes Among
Priority Populations: Role of Smoking Cessation and Tobacco Control Policies.
American journal of preventive medicine, 50(2), 199–209.
https://doi.org/10.1016/j.amepre.2015.06.032

103

Huang, J., Feng, B., Weaver, S. R., Pechacek, T. F., Slovic, P., & Eriksen, M. P. (2019).
Changing perceptions of harm of e-cigarette vs cigarette use among adults in 2
US national surveys from 2012 to 2017. JAMA network open, 2(3),
https://doi.org/10.1001/jamanetworkopen.2019.1047
Hunter, C. L., Goodie, J. L., Oordt, M. S., & Dobmeyer, A. C. (2017). Integrated
behavioral health in primary care: Step-by-step guidance for assessment and
intervention- Second Edition. American Psychological Association.
Hwang, Y. I., Park, Y. B., Yoon, H. K., Kim, T. H., Yoo, K. H., Rhee, C. K., Park, J. H.,
Jang, S. H., Park, S., Kim, J. H., Park, J., & Jung, K. S. (2019). Male current
smokers have low awareness and optimistic bias about COPD: field survey results
about COPD in Korea. International journal of chronic obstructive pulmonary
disease, 14, 271–277. https://doi.org/10.2147/COPD.S189859
Hynninen, M. J., Pallesen, S., & Nordhus, I. H. (2007). Factors affecting health status in
COPD patients with co-morbid anxiety or depression. International journal of
chronic obstructive pulmonary disease, 2(3), 323–328
Jaiswal, S. J., Pilarski, J. Q., Harrison, C. M., & Fregosi, R. F. (2013). Developmental
nicotine exposure alters AMPA neurotransmission in the hypoglossal motor
nucleus and pre-Botzinger complex of neonatal rats. The Journal of neuroscience:
the official journal of the Society for Neuroscience, 33(6), 2616–2625.
https://doi.org/10.1523/JNEUROSCI.3711-12.2013
Janz, N. K., & Becker, M. H. (1984). The Health Belief Model: a decade later. Health
education quarterly, 11(1), 1–47. https://doi.org/10.1177/109019818401100101

104

Japuntich, S. J., Piper, M. E., Schlam, T. R., Bolt, D. M., & Baker, T. B. (2009). Do
smokers know what we're talking about. The construct validity of nicotine
dependence questionnaire measures. Psychological Assessment, 21(4), 595-607.
http://dx.doi.org.portal.lib.fit.edu/10.1037/a0017312
Jensen, R. P., Strongin, R. M., & Peyton, D. H. (2017). Solvent Chemistry in the
Electronic Cigarette Reaction Vessel. Scientific reports, 7, 42549.
https://doi.org/10.1038/srep42549
Jensen, R. P., Luo, W., Pankow, J. F., Strongin, R. M., & Peyton, D. H. (2015). Hidden
formaldehyde in e-cigarette aerosols. The New England journal of medicine,
372(4), 392–394. https://doi.org/10.1056/NEJMc1413069
John Hopkins Medicine. (2021). Health: Pulmonary Function Tests. Retrieved from
https://www.hopkinsmedicine.org/health/treatment-tests-andtherapies/pulmonary-function-tests
Kan, M. P. H., & Fabrigar, L. R. (2017). Theory of planned behavior. Encyclopedia of
personality and individual differences, 1-8. https://doi.org/10.1007/978-3-31928099-8_1191-1
Kanchongkittiphon, W., Gaffin, J. M., & Phipatanakul, W. (2014). The indoor
environment and inner-city childhood asthma. Asian Pacific journal of allergy
and immunology, 32(2), 103–110.
Kanchustambham, V., Saladi, S., Rodrigues, J., Fernandes, H., Patolia, S., & Santosh, S.
(2017). The knowledge, concerns and healthcare practices among physicians
regarding electronic cigarettes. Journal of community hospital internal medicine
perspectives, 7(3), 144–150. https://doi.org/10.1080/20009666.2017.1343076

105

Kava, C. M., Hannon, P. A., & Harris, J. R. (2020). Peer Reviewed: Use of Cigarettes
and E-Cigarettes and Dual Use Among Adult Employees in the US Workplace.
Preventing chronic disease, 17. http://dx.doi.org/10.5888/pcd17.190217
King, B. A., Patel, R., Nguyen, K. H., & Dube, S. R. (2015). Trends in awareness and use
of electronic cigarettes among US adults, 2010-2013. Nicotine & tobacco
research: official journal of the Society for Research on Nicotine and Tobacco,
17(2), 219–227. https://doi.org/10.1093/ntr/ntu191
US Preventive Services Task Force. (2021). Interventions for Tobacco Smoking
Cessation in Adults, Including Pregnant Persons: US Preventive Services Task
Force Recommendation Statement. JAMA, 325(3), 265-279.
https://doi.org/10.1001/jama.2020.25019
Kreiss, K., Gomaa, A., Kullman, G., Fedan, K., Simoes, E. J., & Enright, P. L. (2002).
Clinical bronchiolitis obliterans in workers at a microwave-popcorn plant. The
New England journal of medicine, 347(5), 330–338.
https://doi.org/10.1056/NEJMoa020300
Krosnick, J. A., Malhotra, N., Mo, C. H., Bruera, E. F., Chang, L., Pasek, J., & Thomas,
R. K. (2017). Perceptions of health risks of cigarette smoking: A new measure
reveals widespread misunderstanding. PloS one, 12(8), e0182063.
https://doi.org/10.1371/journal.pone.0182063

106

Kosmider, L., Sobczak, A., Fik, M., Knysak, J., Zaciera, M., Kurek, J., & Goniewicz, M.
L. (2014). Carbonyl compounds in electronic cigarette vapors: effects of nicotine
solvent and battery output voltage. Nicotine & tobacco research: official journal
of the Society for Research on Nicotine and Tobacco, 16(10), 1319–1326.
https://doi.org/10.1093/ntr/ntu078
Kucharska, M., Wesołowski, W., Czerczak, S., & Soćko, R. (2016). Testing of the
composition of e-cigarette liquids - Manufacturer-declared vs. true contents in a
selected series of products. Medycyna Pracy, 67(2), 239–253.
https://doi.org/10.13075/mp.5893.00365
Kumral, T. L., Salturk, Z., Yildirim, G., Uyar, Y., Berkiten, G., & Inan, M. (2016). How
does electronic cigarette smoking affect sinonasal symptoms and nasal
mucociliary clearance? B-ENT, 12(1), 17-21.
Landry, R. L., Groom, A. L., Vu, T. T., Stokes, A. C., Berry, K. M., Kesh, A., Hart, J. L.,
Walker, K. L., Giachello, A. L., Sears, C. G., McGlasson, K. L., Tompkins, L. K.,
Mattingly, D. T., Robertson, R. M., & Payne, T. J. (2019). The role of flavors in
vaping initiation and satisfaction among U.S. adults. Addictive behaviors, 99,
106077. https://doi.org/10.1016/j.addbeh.2019.106077
Levy, D. T., Yuan, Z., & Li, Y. (2017). The Prevalence and Characteristics of E-Cigarette
Users in the U.S. International journal of environmental research and public
health, 14(10), 1200. https://doi.org/10.3390/ijerph14101200
Lim, T. Y., Poole, R. L., & Pageler, N. M. (2014). Propylene glycol toxicity in children.
The journal of pediatric pharmacology and therapeutics: JPPT: the official
journal of PPAG, 19(4), 277–282. https://doi.org/10.5863/1551-6776-19.4.277

107

Lippi, G., Favaloro, E. J., Meschi, T., Mattiuzzi, C., Borghi, L., & Cervel- lin, G. (2014).
E-cigarettes and cardiovascular risk: Beyond science and mysticism. Thrombosis
& Hemostasis, 40(1), 60–65. http://dx.doi.org/ 10.1055/s-0033-1363468
Loukas, A., Marti, C. N., Cooper, M., Pasch, K. E., & Perry, C. L. (2018). Exclusive ecigarette use predicts cigarette initiation among college students. Addictive
behaviors, 76, 343–347. https://doi.org/10.1016/j.addbeh.2017.08.023
Lupien, S. J., McEwen, B. S., Gunnar, M. R., & Heim, C. (2009). Effects of stress
throughout the lifespan on the brain, behavior and cognition. Nature reviews.
Neuroscience, 10(6), 434–445. https://doi.org/10.1038/nrn2639
Maillé, A. R., Koning, C. J., Zwinderman, A. H., Willems, L. N., Dijkman, J. H.,
Kaptein, A.A. (1997). The development of the 'Quality-of-life for Respiratory
Illness Questionnaire (QOL-RIQ)': a disease-specific quality-of-life questionnaire
for patients with mild to moderate chronic non-specific lung disease. Respiratory
medicine, 91(5), 297–309. https://doi.org/10.1016/s0954-6111(97)90034-2
Martin, E. M., Clapp, P. W., Rebuli, M. E., Pawlak, E. A., Glista-Baker, E., Benowitz, N.
L., Jaspers, I. (2016). E-cigarettes use results in suppression of immune and
inflammatory response genes in nasal epithelial cells similar to cigarette smoke.
American Journal of Physiology Lung Cellular and Molecular Physiology,
311(1), L135–L144. http://dx.doi.org/10.1152/ajplung.00170.2016
Mayo Clinic. (2020, July 28). Sleep apnea. Retrieved from
https://www.mayoclinic.org/diseases-conditions/sleep-apnea/symptomscauses/syc-20377631

108

McCauley, L., Markin, C., & Hosmer, D. (2012). An unexpected consequence of
electronic cigarette use. Chest, 141(4), 1110–1113. doi.org/10.1378/chest.11-1334
McConnell, R., Barrington-Trimis, J. L., Wang, K., Urman, R., Hong, H., Unger, J.,
Samet, J., Leventhal, A., & Berhane, K. (2017). Electronic Cigarette Use and
Respiratory Symptoms in Adolescents. American journal of respiratory and
critical care medicine, 195(8), 1043–1049. https://doi.org/10.1164/rccm.2016040804OC
McCubbin, A., Fallin-Bennett, A., Barnett, J., & Ashford, K. (2017). Perceptions and use
of electronic cigarettes in pregnancy. Health education research, 32(1), 22-32.
https://doi.org/10.1093/her/cyw059
McMillen, R. C., Gottlieb, M. A., Shaefer, R. M., Winickoff, J. P., & Klein, J. D. (2015).
Trends in Electronic Cigarette Use Among U.S. Adults: Use is Increasing in Both
Smokers and Nonsmokers. Nicotine & tobacco research: official journal of the
Society for Research on Nicotine and Tobacco, 17(10), 1195–1202.
https://doi.org/10.1093/ntr/ntu213
McNeill, A. D., Brose, L. S., Calder, R., Bauld, L., & Robson, D. J. (2018). Evidence
reviews of e-cigarettes and heated tobacco products 2018: A report commissioned
by Public Health England. Public Health England (PHE).
https://www.gov.uk/government/publications/e-cigarettes-and-heated-tobaccoproducts-evidence-review
McNeill, A. (2016). Should Clinicians Recommend E-cigarettes to Their Patients Who
Smoke? Yes. The Annals of Family Medicine, 14(4), 300-301.
https://doi.org/10.1370/afm.1962

109

Miravitlles, M., Anzueto, A., Legnani, D., Forstmeier, L., & Fargel, M. (2007). Patient's
perception of exacerbations of COPD--the PERCEIVE study. Respiratory
medicine, 101(3), 453–460. https://doi.org/10.1016/j.rmed.2006.07.010
Miravitlles, M., & Ribera, A. (2017). Understanding the impact of symptoms on the
burden of COPD. Respiratory research, 18(1), 67.
https://doi.org/10.1186/s12931-017-0548-3
Mishra, A., Chaturvedi, P., Datta, S., Sinukumar, S., Joshi, P., & Garg, A. (2015).
Harmful effects of nicotine. Indian journal of medical and pediatric oncology,
36(1), 24–31. https://doi.org/10.4103/0971-5851.151771
Moheimani, R. S., Bhetraratana, M., Yin, F., Peters, K. M., Gornbein, J., Araujo, J. A., &
Middlekauff, H. R. (2017). Increased Cardiac Sympathetic Activity and Oxidative
Stress in Habitual Electronic Cigarette Users: Implications for Cardiovascular
Risk. JAMA cardiology, 2(3), 278–284.
https://doi.org/10.1001/jamacardio.2016.5303
Monteagudo, M., Rodríguez-Blanco, T., Llagostera, M., Valero, C., Bayona, X., Ferrer,
M., Miravitlles, M. (2013). Factors associated with changes in quality of life of
COPD patients: a prospective study in primary care. Respiratory medicine,
107(10), 1589–1597. https://doi.org/10.1016/j.rmed.2013.05.009
Muthumalage, T., Lamb, T., Friedman, M. R., & Rahman, I. (2019). E-cigarette flavored
pods induce inflammation, epithelial barrier dysfunction, and DNA damage in
lung epithelial cells and monocytes. Scientific reports, 9(1), 19035.
https://doi.org/10.1038/s41598-019-51643-6

110

National Academies of Sciences, Engineering, and Medicine (NASEM). (2018). Public
Health Consequences of E-Cigarettes. Washington, DC: The National Academies
Press. https://doi.org/10.17226/24952
National Center for Health Statistics (NCHS). (2018). National Health Interview Survey
(NHIS) Survey Data. Hyattsville, Maryland: U.S. Department of Health and
Human Services (USDHHS), Centers for Disease Control and Prevention (CDC).
National Center for Health Statistics (NCHS). (2019). National Health Interview Survey
(NHIS) Survey Data. Hyattsville, Maryland: U.S. Department of Health and
Human Services (USDHHS), Centers for Disease Control and Prevention (CDC).
National Center for Health Statistics (NCHS). (2020). National Health Interview Survey
(NHIS) Survey Data. Hyattsville, Maryland: U.S. Department of Health and
Human Services (USDHHS), Centers for Disease Control and Prevention (CDC).
National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI).
(2020, October 6). How the Lungs Work. Retrieved from
https://www.nhlbi.nih.gov/health-topics/how-lungs-work
National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI).
(n.d.). Interstitial Lung Diseases. Retrieved from
https://www.nhlbi.nih.gov/health-topics/interstitial-lung-diseases
National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI).
(n.d.). Sleep Apnea. Retrieved from https://www.nhlbi.nih.gov/healthtopics/sleep-apnea

111

National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI).
(2020, November 17). COPD. Retrieved from https://www.nhlbi.nih.gov/healthtopics/copd
National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI).
(2020, December 3). Asthma. Retrieved from https://www.nhlbi.nih.gov/healthtopics/asthma
National Institutes of Health (NIH) U.S. National Library of Medicine. (2021, April 2).
MedlinePlus; Medical Encyclopedia: Lung Disease. Retrieved from
https://medlineplus.gov/ency/article/000066.htm
National Institutes of Health (NIH) U.S. National Library of Medicine. (2021, February
5). MedlinePlus; Health Topics: Asthma. Retrieved from
https://medlineplus.gov/asthma.html#summary
National Institutes of Health (NIH) U.S. National Library of Medicine. (2018, August).
Environmental health & toxicology information - Respiratory Tract. Retrieved
from https://toxtutor.nlm.nih.gov/10-003.html
National Institute for Occupational Safety and Health (NIOSH). (2011, May 12). The
Emergency Response Safety & Health Database: Systemic Agent: ETHYLENE
GLYCOL. Retrieved from
https://www.cdc.gov/niosh/ershdb/emergencyresponsecard_29750031.html
National Institute for Occupational Safety and Health (NIOSH). (2017). Flavoringsrelated lung disease: Exposure to Flavoring Chemicals. Retrieved from
https://www.cdc.gov/niosh/topics/flavorings/exposure.html

112

Ninot, G., Soyez, F., & Préfaut, C. (2013). A short questionnaire for the assessment of
quality of life in patients with chronic obstructive pulmonary disease:
psychometric properties of VQ11. Health and quality of life outcomes, 11, 179.
https://doi.org/10.1186/1477-7525-11-179
Ofei-Dodoo, S., Kellerman, R., Nilsen, K., Nutting, R., & Lewis, D. (2017). Family
Physicians' Perceptions of Electronic Cigarettes in Tobacco Use Counseling.
Journal of the American Board of Family Medicine: JABFM, 30(4), 448–459.
https://doi.org/10.3122/jabfm.2017.04.170084
Ofei-Dodoo, S., Wipperman, J., Nutting, R., Gilchrist, K., & Kellerman, R. (2020).
Changes in Family Physicians' Perceptions of Electronic Cigarettes in Tobacco
Use Counseling Between 2016 and 2019. Kansas journal of medicine, 13, 311–
317. https://doi.org/10.17161/kjm.vol13.13877
Owusu, D., Massey, Z., & Popova, L. (2020). An experimental study of messages
communicating potential harms of electronic cigarettes. PLoS One, 15 (10)
http://dx.doi.org.portal.lib.fit.edu/10.1371/journal.pone.0240611
Park S.H., Lee L., Shearston J.A., Weitzman M. (2017). Patterns of electronic cigarette
use and level of psychological distress. PLoS ONE 12(3): e0173625.
https://doi.org/10.1371/journal.pone.0173625
Pepper, J. K., Ribisl, K. M., Emery, S. L., & Brewer, N. T. (2014). Reasons for starting
and stopping electronic cigarette use. International journal of environmental
research and public health, 11(10), 10345–10361.
https://doi.org/10.3390/ijerph111010345

113

Peters, E. N., Harrell, P. T., Hendricks, P. S., O'Grady, K. E., Pickworth, W. B., & Vocci,
F. J. (2015). Electronic cigarettes in adults in outpatient substance use treatment:
Awareness, perceptions, use, and reasons for use. The American journal on
addictions, 24(3), 233–239. https://doi.org/10.1111/ajad.12206
Phillips, E., Wang, T. W., Husten, C. G., Corey, C. G., Apelberg, B. J., Jamal, A., ... &
King, B.A. (2017). Tobacco product use among adults—United States, 2015.
MMWR. Morbidity and mortality weekly report, 66(44), 1209.
http://dx.doi.org/10.15585/mmwr.mm6644a2
Piper, M. E., Baker, T. B., Benowitz, N. L., & Jorenby, D. E. (2020). Changes in Use
Patterns Over 1 Year Among Smokers and Dual Users of Combustible and
Electronic Cigarettes. Nicotine & tobacco research: official journal of the Society
for Research on Nicotine and Tobacco, 22(5), 672–680.
https://doi.org/10.1093/ntr/ntz065
Pisinger, C., & Døssing, M. (2015). A systematic review of health effects of electronic
cigarettes. Preventive medicine, 69, 248–260.
https://doi.org/10.1016/j.ypmed.2014.10.009
Ponizovskiy, V., Grigoryan, L., Kühnen, U., & Boehnke, K. (2019). Social Construction
of the Value-Behavior Relation. Frontiers in psychology, 10, 934.
https://doi.org/10.3389/fpsyg.2019.00934
Popova, L., Owusu, D., Weaver, S. R., Kemp, C. B., Mertz, C. K., Pechacek, T. F., &
Slovic, P. (2018). Affect, risk perception, and the use of cigarettes and ecigarettes: a population study of US adults. BMC public health, 18(1), 1-15.
https://doi.org/10.1186/s12889-018-5306-z

114

Price, D., Small, M., Milligan, G., Higgins, V., Gil, E. G., & Estruch, J. (2013). Impact of
night-time symptoms in COPD: a real-world study in five European countries.
International journal of chronic obstructive pulmonary disease, 8, 595.
https://doi.org/10.2147/COPD.S48570
Prior, A., Fenger-Grøn, M., Larsen, K. K., Larsen, F. B., Robinson, K. M., Nielsen, M.
G., Christensen, K. S., Mercer, S. W., & Vestergaard, M. (2016). The Association
Between Perceived Stress and Mortality Among People with Multimorbidity: A
Prospective Population-Based Cohort Study. American journal of epidemiology,
184(3), 199–210. https://doi.org/10.1093/aje/kwv324
Putzhammer, R., Doppler, C., Jakschitz, T., Heinz, K., Förste, J., Danzl, K., & Bernhard,
D. (2016). Vapours of US and EU market leader electronic cigarette brands and
liquids are cytotoxic for human vascular endothelial cells. PloS one, 11(6),
e0157337. https://doi.org/10.1371/journal.pone.0157337
Quinto, K. B. (2013). Environmental tobacco smoke exposure in children aged 3-19
years with and without asthma in the United States, 1999-2010 (No. 2013). US
Department of Health and Human Services, Centers for Disease Control and
Prevention, National Center for Health Statistics.
Rakofsky, J. J., & Dunlop, B. W. (2019). Nothing to sneeze at: Upper respiratory
infections and mood disorders. Current Psychiatry, 18(7), 29-34.
Ramo, D. E., Hall, S. M., & Prochaska, J. J. (2011). Reliability and validity of selfreported smoking in an anonymous online survey with young adults. Health
Psychology, 30(6), 693-701. http://dx.doi.org.portal.lib.fit.edu/10.1037/a0023443

115

Regan, A. K., Promoff, G., Dube, S. R., & Arrazola, R. (2013). Electronic nicotine
delivery systems: adult use and awareness of the 'e-cigarette' in the USA. Tobacco
control, 22(1), 19–23. https://doi.org/10.1136/tobaccocontrol-2011-050044
Roche, N., Chavannes, N. H., & Miravitlles, M. (2013). COPD symptoms in the
morning: impact, evaluation and management. Respiratory research, 14(1), 112.
https://doi.org/10.1186/1465-9921-14-112
Romijnders, K., Beijaert, M., van Osch, L., De Vries, H., Talhout, R. (2018a). Tobacco
cigarette use versus electronic cigarette use: determinants of smoking and vaping
behavior. Tobacco Induced Diseases, 16(1), 235.
https://doi.org/10.18332/tid/84216
Romijnders, K. A., Van Osch, L., De Vries, H., & Talhout, R. (2018b). Perceptions and
reasons regarding e-cigarette use among users and non-users: a narrative literature
review. International journal of environmental research and public health, 15(6),
1190. https://doi.org/10.3390/ijerph15061190
Rowell, T. R., & Tarran, R. (2015). Will chronic e-cigarette use cause lung disease?
American Journal of Physiology Lung Cellular and Molecular Physiology, 309,
L1398–L1409. http://dx.doi.org/10.1152/ajplung .00272.2015
Royal College of Physicians of London. (2016). Nicotine without smoke: tobacco harm
reduction. Royal College of Physicians of London. Retrieved from
https://www.rcplondon.ac.uk/projects/outputs/nicotine-without-smoke-tobaccoharm-reduction

116

Russ, T. C., Stamatakis, E., Hamer, M., Starr, J. M., Kivimäki, M., & Batty, G. D.
(2012). Association between psychological distress and mortality: individual
participant pooled analysis of 10 prospective cohort studies. BMJ (Clinical
research ed.), 345, e4933. https://doi.org/10.1136/bmj.e4933
Rutten, L. J., Blake, K. D., Agunwamba, A. A., Grana, R. A., Wilson, P. M., Ebbert, J.
O., Okamoto, J., & Leischow, S. J. (2015). Use of E-Cigarettes Among Current
Smokers: Associations Among Reasons for Use, Quit Intentions, and Current
Tobacco Use. Nicotine & tobacco research: official journal of the Society for
Research on Nicotine and Tobacco, 17(10), 1228–1234.
https://doi.org/10.1093/ntr/ntv003
Sajja, R. K., Rahman, S., & Cucullo, L. (2015). Drugs of abuse and blood-brain barrier
endothelial dysfunction: A focus on the role of oxidative stress. Journal of
Cerebral Blood Flow and Metabolism, 36, 539–554.
http://dx.doi.org/10.1177/0271678X15616978
Salloum, R. G., Huo, J., Lee, J. H., Lee, J., Dallery, J., George, T., & Warren, G. (2019).
Tobacco and E-cigarette use among cancer survivors in the United States. PloS
one, 14(12), e0226110. https://doi.org/10.1371/journal.pone.0226110
Salamanca, J. C., Munhenzva, I., Escobedo, J. O., Jensen, R. P., Shaw, A., Campbell, R.,
Luo, W., Peyton, D. H., & Strongin, R. M. (2017). Formaldehyde Hemiacetal
Sampling, Recovery, and Quantification from Electronic Cigarette Aerosols.
Scientific reports, 7(1), 11044. https://doi.org/10.1038/s41598-017-11499-0

117

Sales, M., A. J., Chatkin, J. M., Godoy, I., Pereira, L., Castellano, M., Tanni, S. E.,
Almeida, A.Á., Chatkin, G., Silva, L., Gonçalves, C., Botelho, C., Santos, U. P.,
Viegas, C., Sestelo, M. R., Meireles, R., Correa, P., Oliveira, M., Reichert, J.,
Lima, M. S., Silva, C. (2019). Update on the approach to smoking in patients with
respiratory diseases. Brazilian Journal of Pulmonology, 45(3), e20180314.
https://doi.org/10.1590/1806-3713/e20180314
Sardari Nia, P., Weyler, J., Colpaert, C., Vermeulen, P., Van Marck, E., & Van Schil, P.
(2005). Prognostic value of smoking status in operated non-small cell lung cancer.
Lung cancer, 47(3), 351-359. https://doi.org/10.1016/j.lungcan.2004.08.011
Samiei-Siboni, F., Alimoradi, Z., Atashi, V., Alipour, M., & Khatooni, M. (2019).
Quality of Life in Different Chronic Diseases and Its Related Factors.
International journal of preventive medicine, 10, 65.
https://doi.org/10.4103/ijpvm.IJPVM_429_17
Schlueter, D. F., Rasberry, C. N., Buckley, R., Mast, D. K., Cheung, K., Luna, P. J.,
Robin, L., Greenberg, C., & Langenfeld, N. A. (2011). Secondhand Tobacco
Smoke Exposure Among School-Aged Youth Enrolled in School-Based Asthma
Management Programs: A Mixed Methods Analysis. Journal of Asthma &
Allergy Educators, 2(4), 173–180. https://doi.org/10.1177/2150129711408305
Schwartz, S. H. (1992). Universals in the content and structure of values: Theoretical
advances and empirical tests in 20 countries. Advances in experimental social
psychology (Vol. 25, pp. 1-65). Academic Press. https://doi.org/10.1016/S00652601(08)60281-6

118

Sharapova, S. R., Singh, T., Agaku, I. T., Kennedy, S. M., & King, B. A. (2018). Patterns
of E-cigarette Use Frequency-National Adult Tobacco Survey, 2012-2014.
American journal of preventive medicine, 54(2), 284–288.
https://doi.org/10.1016/j.amepre.2017.09.015
Soneji, S., Barrington-Trimis, J. L., Wills, T. A., Leventhal, A. M., Unger, J. B., Gibson,
L. A., Yang, J., Primack, B. A., Andrews, J. A., Miech, R. A., Spindle, T. R.,
Dick, D. M., Eissenberg, T., Hornik, R. C., Dang, R., & Sargent, J. D. (2017).
Association Between Initial Use of E-Cigarettes and Subsequent Cigarette
Smoking Among Adolescents and Young Adults: A Systematic Review and
Meta-analysis. JAMA pediatrics, 171(8), 788–797.
https://doi.org/10.1001/jamapediatrics.2017.1488
Spears, C. A., Jones, D. M., Weaver, S. R., Yang, B., Pechacek, T. F., & Eriksen, M. P.
(2019). Electronic nicotine delivery system (ENDS) use in relation to mental
health conditions, past-month serious psychological distress and cigarette
smoking status. Addiction 114(2), 315–325. https://doi.org/10.1111/add.14464
Strecher, V. J., Kreuter, M. W., & Kobrin, S. C. (1995). Do cigarette smokers have
unrealistic perceptions of their heart attack, cancer, and stroke risks? Journal of
behavioral medicine, 18(1), 45–54. https://doi.org/10.1007/BF01857704
Strine, T. W., Chapman, D. P., Balluz, L. S., Moriarty, D. G., & Mokdad, A. H. (2008).
The associations between life satisfaction and health-related quality of life,
chronic illness, and health behaviors among U.S. community-dwelling adults.
Journal of community health, 33(1), 40–50. https://doi.org/10.1007/s10900-0079066-4

119

Substance Abuse and Mental Health Services Administration (SAMHSA). (2017).
Results from the 2016 national survey on drug use and health: detailed tables.
Rockville, MD: Substance Abuse and Mental health Services Administration,
Center for Behavioral Health Statistics and Quality.
https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUHDetTabs-2016.pdf
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F.
(2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and
Mortality Worldwide for 36 Cancers in 185 Countries. CA: Cancer Journal for
Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
Sutfin, E. L., Reboussin, B. A., Debinski, B., Wagoner, K. G., Spangler, J.,Wolfson, M.
(2015). The Impact of Trying Electronic Cigarettes on Cigarette Smoking by
College Students: A Prospective Analysis. American journal of public health,
105(8), e83–e89. https://doi.org/10.2105/AJPH.2015.302707
Swartz, J. A., & Jantz, I. (2014). Association between nonspecific severe psychological
distress as an indicator of serious mental illness and increasing levels of medical
multimorbidity. American journal of public health, 104(12), 2350–2358.
https://doi.org/10.2105/AJPH.2014.302165
Traboulsi, H., Cherian, M., Mira, A. R., Preteroti, M., Bourbeau, J., Smith, B. M.,
Eidelman, D. H., & Baglole, C. J. (2020). Inhalation Toxicology of Vaping
Products and Implications for Pulmonary Health. International Journal of
Molecular Sciences, 21(10), 3495.
http://dx.doi.org.portal.lib.fit.edu/10.3390/ijms21103495

120

Truth Initiative. (2019, June). Tobacco Nation: An Ongoing Crisis. Examining the health
and policy disparities of U.S. states with the highest smoking rates. Retrieved
from https://truthinitiative.org/tobacconation
Tsiligianni, I., Kocks, J., Tzanakis, N., Siafakas, N., & van der Molen, T. (2011). Factors
that influence disease-specific quality of life or health status in patients with
COPD: a review and meta-analysis of Pearson correlations. Primary care
respiratory journal: journal of the General Practice Airways Group, 20(3), 257–
268. https://doi.org/10.4104/pcrj.2011.00029
Tweed, J. O., Hsia, S. H., Lutfy, K., & Friedman, T. C. (2012). The endocrine effects of
nicotine and cigarette smoke. Trends in Endocrinology and Metabolism, 23, 334 –
342. http://dx.doi.org/10.1016/j.tem .2012.03.006
Tyc, V. L., Lensing, S., Vukadinovich, C., & Hovell, M. F. (2013). Smoking restrictions
in the homes of children with cancer. American Journal of Health Behavior,
37(4), 440–448. https://doi.org/10.5993/AJHB.37.4.2
United States Department of Health and Human Services (USDHHS). (2010). How
tobacco smoke causes disease: The biology and behavioral basis for smokingattributable disease: A report of the Surgeon General. Atlanta, GA: U.S.
Department of Health and Human Services, Centers for Disease Control and
Prevention, National Center for Chronic Disease Prevention and Health
Promotion, Office on Smoking and Health.
https://www.ncbi.nlm.nih.gov/books/NBK53017/

121

USDHHS. (2014). The health consequences of smoking-50 years of progress: A report of
the Surgeon General. Atlanta, GA: U.S. Department of Health and Human
Services, Centers for Disease Control and Prevention, National Center for
Chronic Disease Prevention and Health Promotion, Office on Smoking and
Health. www.ncbi.nlm.nih.gov/books/NBK179276/pdf/Bookshelf_NBK.pdf
USDHHS. (2016). E-cigarette use among youth and young adults: A report of the
surgeon general. Atlanta, GA: U.S. Department of Health and Human Services,
Centers for Disease Control and Prevention, National Center for Chronic Disease
Prevention and Health Promotion, Office on Smoking and Health. https://ecigarettes.surgeongeneral.gov/documents/2016_SGR_Full_Report_non-508.pdf
USDHHS. (2020). Smoking Cessation: A Report of the Surgeon General. Atlanta, GA:
U.S. Department of Health and Human Services, Centers for Disease Control and
Prevention, National Center for Chronic Disease Prevention and Health
Promotion, Office on Smoking and Health.
https://www.hhs.gov/sites/default/files/2020-cessation-sgr-full-report.pdf
Vancampfort, D., Koyanagi, A., Ward, P. B., Veronese, N., Carvalho, A. F., Solmi, M.,
Mugisha, J., Rosenbaum, S., De Hert, M., & Stubbs, B. (2017). Perceived Stress
and Its Relationship with Chronic Medical Conditions and Multimorbidity
Among 229,293 Community-Dwelling Adults in 44 Low- and Middle-Income
Countries. American journal of epidemiology, 186(8), 979–989.
https://doi.org/10.1093/aje/kwx159

122

Van Den Bosch, G. E., Merkus, P. J., Buysse, C. M., Boehmer, A. L., Vaessen-Verberne,
A. A., Van Veen, L. N., Hop, W. C., & de Hoog, M. (2012). Risk factors for
pediatric intensive care admission in children with acute asthma. Respiratory
care, 57(9), 1391–1397. https://doi.org/10.4187/respcare.01325
Vardavas, C. I., Anagnostopoulos, N., Kougias, M., Evangelopoulou, V., Connolly, G.
N., & Behrakis, P. K. (2012). Short-term pulmonary effects of using an electronic
cigarette: impact on respiratory flow resistance, impedance, and exhaled nitric
oxide. Chest, 141(6), 1400–1406. https://doi.org/10.1378/chest.11-2443
Varughese, S., Teschke, K., Brauer, M., Chow, Y., van Netten, C., & Kennedy, S. M.
(2005). Effects of theatrical smokes and fogs on respiratory health in the
entertainment industry. American journal of industrial medicine, 47(5), 411–418.
https://doi.org/10.1002/ajim.20151
Villarroel, M. A., Cha, A. E., & Vahratian, A. (2020). Electronic cigarette use among US
adults. https://www.cdc.gov/nchs/products/databriefs/db365.htm
Wagena, E. J., Arrindell, W. A., Wouters, E. F., & van Schayck, C. P. (2005). Are
patients with COPD psychologically distressed? The European respiratory
journal, 26(2), 242–248. https://doi.org/10.1183/09031936.05.00010604
Wang, P., Chen, W., Liao, J., Matsuo, T., Ito, K., Fowles, J., Shusterman, D., Mendell,
M., & Kumagai, K. (2017). A Device-Independent Evaluation of Carbonyl
Emissions from Heated Electronic Cigarette Solvents. PloS one, 12(1), e0169811.
https://doi.org/10.1371/journal.pone.0169811

123

Wang, T. W., Gentzke, A., Sharapova, S., Cullen, K. A., Ambrose, B. K., & Jamal, A.
(2018). Tobacco Product Use Among Middle and High School Students - United
States, 2011-2017. MMWR. Morbidity and mortality weekly report, 67(22), 629–
633. https://doi.org/10.15585/mmwr.mm6722a3
Wang, Z., May, S. M., Charoenlap, S., Pyle, R., Ott, N. L., Mohammed, K., & Joshi, A.
Y. (2015). Effects of secondhand smoke exposure on asthma morbidity and health
care utilization in children: a systematic review and meta-analysis. Annals of
Allergy, Asthma & Immunology, 115(5), 396-401.
https://doi.org/10.1016/j.anai.2015.08.005
Weaver, S. R., Majeed, B. A., Pechacek, T. F., Nyman, A. L., Gregory, K. R., & Eriksen,
M. P. (2016). Use of electronic nicotine delivery systems and other tobacco
products among USA adults, 2014: results from a national survey. International
journal of public health, 61(2), 177-188. https://doi.org/10.3390/ijerph14010010
Weinstein N. D. (1998). Accuracy of smokers' risk perceptions. Annals of behavioral
medicine:a publication of the Society of Behavioral Medicine, 20(2), 135–140.
https://doi.org/10.1007/BF02884459
Wetter, D. W., Smith, S. S., Kenford, S. L., Jorenby, D. E., Fiore, M. C., Hurt, R. D.,
Offord, K. P., & Baker, T. B. (1994). Smoking outcome expectancies: Factor
structure, predictive validity, and discriminant validity. Journal of Abnormal
Psychology, 103(4), 801-811. http://dx.doi.org.portal.lib.fit.edu/10.1037/0021843X.103.4.801

124

World Health Organization (WHO). (2009). Global health risks: mortality and burden of
disease attributable to selected major risks. World Health Organization.
World Health Organization (WHO). (2021). Chronic respiratory diseases. Retrieved from
https://www.who.int/health-topics/chronic-respiratory-diseases#tab=tab_1
Xie, W., Kathuria, H., Galiatsatos, P., Blaha, M. J., Hamburg, N. M., Robertson, R. M.,
Bhatnagar, A., Benjamin, E. J., & Stokes, A. C. (2020). Association of Electronic
Cigarette Use with Incident Respiratory Conditions Among US Adults From 2013
to 2018. JAMA network open, 3(11), e2020816.
https://doi.org/10.1001/jamanetworkopen.2020.20816
Yi-Fong, V., Hu, L. Y., Yeh, C. M., Chiang, H. L., Shen, C. C., Chou, K. T., & Liu, C. J.
(2017). Chronic obstructive pulmonary disease associated with increased risk of
bipolar disorder. Chronic respiratory disease, 14(2), 151-160.
https://doi.org/10.1177/1479972316680846
Zhu, S. H., Gamst, A., Lee, M., Cummins, S., Yin, L., & Zoref, L. (2013). The use and
perception of electronic cigarettes and snus among the U.S. population. PloS one,
8(10), e79332. https://doi.org/10.1371/journal.pone.0079332
Zhu, S. H., Zhuang, Y. L., Wong, S., Cummins, S. E., & Tedeschi, G. J. (2017). Ecigarette use and associated changes in population smoking cessation: evidence
from US current population surveys. BMJ (Clinical research ed.), 358, j3262.
https://doi.org/10.1136/bmj.j3262

125

Table 1
Frequency for Psychosocial Variables
Variable
Medical Health Condition
Arthritis
Cancer
Chronic fatigue syndrome
Chronic pain
Diabetes
Gastrointestinal (GI) disorder
Heart Disease
HIV Disease (AIDS)
Hypertension (high blood pressure)
Kidney Disease
Multiple Sclerosis
Parkinson’s Disease
Stroke
Traumatic brain injury or other brain-related injury
Any physical disability (e.g., quadriplegia, paraplegia, etc.)
Other Medical Condition
Eczema
High cholesterol
Mental Health Condition
Anxiety
Bipolar Disorder
Depression (including dysthymia)
Obsessive Compulsive Disorder (OCD)
Post-Traumatic Stress Disorder (PTSD)
Personality Disorder
Schizophrenia
Sleep Disorder (e.g., insomnia)
Developmental Disability (ADHD, Learning Disorder, etc.)
Neurocognitive Disorder (Dementia, MCI, etc.)
Alcohol abuse
Drug abuse
Health-Related Quality of Life (QoL)
Respiratory illness has negatively impacted (worsened) QoL
Respiratory illness has not impacted QoL (no change)

126

n

%

96
42
44
60
42
46
34
3
57
20
13
6
13
8
4
2
1
1

35.56%
15.56%
16.30%
22.22%
15.56%
17.04%
12.59%
1.11%
21.11%
7.41%
4.81%
2.22%
4.81%
2.96%
1.48%
0.74%
0.37%
0.37%

126
55
78
33
27
15
12
61
19
9
25
9

46.67%
20.37%
28.89%
12.22%
10.00%
5.56%
4.44%
22.59%
7.04%
3.33%
9.26%
3.33%

200
56

74.07%
20.74%

Respiratory illness has positively impacted (improved) QoL

Table 2
Frequency of Respiratory Illness Variables
Variable
Respiratory Condition
Acute Respiratory Distress Syndrome (ARDS)
Asthma
Bronchiectasis
Bronchiolitis Obliterans
Chronic Obstructive Pulmonary Disease (COPD)
Coronavirus Disease 2019 (COVID-19)
Cystic Fibrosis
Diffuse Panbronchiolitis
E-cigarette or Vaping product use Associated Lung Injury
(EVALI)
Interstitial Lung Disease (ILD); including Pulmonary
Fibrosis
Lung Cancer
Sleep Apnea (central, obstructive, or mixed)
Pulmonary Edema
Pulmonary Embolism
Pulmonary Hypertension
Severe Acute Respiratory Syndrome (SARS)
Tuberculosis
Onset of Illness
Illness diagnosed before smoking/vaping
Smoking/vaping before illness was diagnosed
Don’t know / Not sure
Pulmonary Function Test (PFT)
Yes
No
Don’t know / Not sure
Currently Use Prescribed Inhaler
Yes
No
Severe attack over past 12 months

127

14

5.19%

n

%

47
111
78
34
88
12
18
32

17.41%
41.11%
28.89%
12.59%
32.59%
4.44%
6.67%
11.85%

26

9.63%

22

8.15%

15 5.56%
29 10.74%
5 1.85%
12 4.44%
15 5.56%
10 3.70%
5 1.85%
96 35.56%
149 55.70%
25 9.26%
205 75.93%
50 18.52%
15 5.56%
191 70.74%
79 29.23%

Yes
No
ER/Urgent Care Visit over past 12 moths

149 55.19%
121 44.81%

Yes

168 62.22%

No

102 37.78%

Routine Medical Visit for Resp. Illness over past 12 months
Yes

212 78.52%

No

58 21.48%

Table 3
Frequency of Health Risk Variables
Health Status
n
General Health
Excellent - Good
127
Fair - Terrible
143
Respiratory Health
Excellent - Good
111
Fair – Terrible
159
Perceived Stress Level
n
How often have you felt unable to control the important things in your
life?
Never - Almost Never
123
Sometimes
114
Fairly Often - Very Often
33
How often have you felt confident about your ability to handle personal
problems?
Very Often - Fairly Often
74
Sometimes
104
Almost Never - Never
92
How often have you felt things were going your way?
Very Often - Fairly Often
64
Sometimes
103
Almost Never - Never
103
How often have you felt difficulties were so high you could not overcome
them?
Never - Almost Never
122
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%
47.04%
52.96%
41.11%
58.89%
%

45.56%
42.22%
12.22%

27.41%
38.52%
34.08%
20.71%
38.15%
38.15%

45.18%

Sometimes
Fairly Often - Very Often
Symptom Severity

95 35.19%
53 19.63%
n
%

Chest pain/tightness
None - Mild
Moderate - Severe
Coughing
None - Mild
Moderate - Severe
Difficulty breathing in
None - Mild
Moderate - Severe
Fatigue
None - Mild
Moderate - Severe
Frequent need to clear throat
None - Mild
Moderate - Severe
Heavy/rapid breathing
None - Mild
Moderate - Severe
Itchy/dry throat
None - Mild
Moderate - Severe
Phlegm production
None - Mild
Moderate - Severe
Recurrent colds
None - Mild
Moderate - Severe
Shortness of breath
None - Mild
Moderate - Severe
Sleeping issues
None - Mild
Moderate - Severe
Stuffed sinus/runny nose
None - Mild
Moderate – Severe
Weight loss/gain
None - Mild
Moderate - Severe
Wheezing
None - Mild
Moderate - Severe

182 67.41%
88 32.59%
143 52.96%
127 47.04%
167 61.85%
103 38.15%
135 50.00%
135 50.00%
156 57.78%
114 42.22%
155 57.41%
115 42.59%
169 62.59%
101 37.41%
147 54.44%
123 45.56%
196 72.59%
74 27.41%
154 57.04%
116 42.96%
149 55.19%
121 44.81%
157 58.15%
113 48.85%
183 67.78%
87 32.22%
170 62.96%
100 37.04%
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Difficulty/Impairment with Daily Activities (Functioning)
Bathing/Showering
None - Mild difficulty
Moderate - Severe difficulty
Eating/Swallowing
None - Mild difficulty
Moderate - Severe difficulty
Getting Dressed
None - Mild difficulty
Moderate - Severe difficulty
Going Up Stairs
None - Mild difficulty
Moderate - Severe difficulty
Lifting a Heavy Object
None - Mild difficulty
Moderate - Severe difficulty
Running a Short Distance
None - Mild difficulty
Moderate - Severe difficulty
Sleeping/Resting
None - Mild difficulty
Moderate - Severe difficulty
Shopping
None - Mild difficulty
Moderate - Severe difficulty
Toileting
None - Mild difficulty
Moderate - Severe difficulty

n

%

199 73.70%
71 26.30%
188 69.63%
82 30.37%
212 78.52%
58 21.48%
174 64.44%
96 35.56%
166 61.48%
104 38.52%
135 50.00%
135 50.00%
184 68.15%
86 31.85%
182 67.41%
88 32.59%
197 72.96%
73 27.04%

Table 4
Summary Statistics for Health Risk Factors & Overall Health Risk
Variable
M
SD
n SEM Min
Max Skewness Kurtosis
Health Status
3.56 1.94 270 0.12 0.00
8.00
0.47
-0.47
Stress Level
7.46 2.61 270 0.16 0.00 16.00
-0.37
1.21
Symptom Severity
30.01 12.17 270 0.74 0.00 60.00
-0.36
-0.32
Level of
15.97 10.14 270 0.62 0.00 40.00
0.02
-1.16
Functioning
Overall Health Risk 57.00 21.65 270 1.32 8.00 107.00
-0.16
-0.54
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Table 5
Demographic and Psychosocial variables according to ENDS Health Risk Perceptions
ENDS Health Risk Perceptions

AGE
Older
Younger

Higher Risk
n (%)

Lower Risk
n (%)

68 (25.2%)
55 (20.4%)

71 (26.3%)
76 (28.1%)

GENDER
Female
Male

66 (24.4%)
57 (21.1%)

55 (20.4%)
92 (34.1%)

INCOME
High Income
Low Income

68 (25.2%)
55 (20.4%)

95 (35.2%)
52 (19.3%)

EDUCATION
More educated
Less educated

46 (17.0%)
77 (28.5%)

58 (21.5%)
89 (33.0%)

RELATIONSHIP STATUS
Relationship
Single
ETHNICITY
Hispanic
Non-Hispanic
GEOGRAPHIC REGION
Other Regions
South/Midwest

76 (28.1%)
47 (17.4%)
46 (17.0%)
77 (28.5%)
63 (23.3%)
60 (22.2%)

FRIENDS WHO SMOKE
0
1 or more

23 (8.5%)
100 (37.0%)

16 (5.9%)
131 (48.5%)

60 (22.2%)
63 (23.3%)
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1.04

1

.307

6.50

1

.011*

2.07

1

.150

0.05

1

.826

1.70

1

.192

4.03

1

.045*

4.16

1

.041*

7.40

1

.007*

2.71

1

.100

13.92

1

< .001*

0.48

1

.490

56 (20.7%)
91 (33.7%)
46 (17.0%)
101 (37.4%)

OVERALL HEALTH RISK
Lower
Higher

p

74 (27.4%)
73 (27.0%)

20 (7.4%)
103 (38.1%)

29 (10.7%)
94 (34.8%)

df

103 (38.1%)
44 (16.3%)

RACE
Minority
White

FRIENDS WHO VAPE
0
1 or more

χ2

10 (3.7%)
137 (50.7%)
79 (29.3%)
68 (25.2%)

Note. * Indicates significance at p < .05

Table 6
Results for Linear Regression with Health Risk Factors
Variable
B
SE
95% CI
(Intercept)
19.15 1.42
[16.34, 21.95]
Health Status
0.70 0.20
[0.30, 1.10]
Stress Level
-0.01 0.15
[-0.31, 0.29]
Symptom Severity
0.03 0.04
[-0.05, 0.12]
Level of Functioning
-0.03 0.05
[-0.13, 0.07]
2
Note. Results: F (4, 265) = 4.01, p = .004, R = 0.06
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β
0.00
0.22
-0.00
0.06
-0.05

t
13.46
3.42
-0.06
0.78
-0.56

p
< .001
< .001
.956
.437
.578

APPENDIX A
LETTER OF INFORMATION AND INFORMED CONSENT
Primary Investigator:
Sarah A. Sebban, M.S.
Department of Psychology, Florida Institute of Technology
Email: SSebban2018@my.fit.edu
Co-Investigator:
Vida L. Tyc, PhD.
Department of Psychology, Florida Institute of Technology
Email: VTyc@fit.edu
Purpose of the Study
The purpose of this study is to learn more about Electronic Nicotine Delivery System
(ENDS) (i.e., e-cigarettes, vapes) use among individuals with chronic respiratory
illnesses (asthma, COPD, etc.). ENDS are battery-operated devices that usually resembles
a cigarette, but do not involve the burning of tobacco. They are also known as e-cigs, ecigars, vapes, vape pens, and other names. If you do not use e-cigarettes, we will ask for
your opinions about them. This information will help us to better understand factors
related to e-cigarette use among those with respiratory illnesses.
Eligibility
In order to participate, you must be 18 years of age or older, be able to read and write
English fluently, have been diagnosed with a respiratory illness by a medical
professional, and be a current or past smoker of any combustible tobacco product (i.e.,
cigarettes, cigarillos, cigars, blunts, bidis, or any other tobacco product), and/or a current
or past ENDS user. Participants who use ENDS devices with or without nicotine are
eligible to participate; those who only use ENDS devices containing cannabis products
(e.g., THC, CBD oil, etc.) are not eligible for this study.
Procedures of the Study
If you are eligible, you will be asked to complete a survey online. The survey will consist
of questions that ask about your past and current smoking and vaping behaviors, as well
as your medical and mental health history. You will be able to adjust any of your
responses by pressing the “Back” button to return to the previously completed page. We
estimate that the questionnaire will take approximately 15 minutes to complete.
Compensation
At the end of the survey, you will be given the choice to provide your email address to be
entered into a drawing to win one of four $50 gift cards.
Potential Risks and Benefits
The risks of participating in this study are minimal and unlikely. However, you will be
asked questions about your smoking and vaping behaviors as well as your respiratory
health which you may find stressful. You may choose not to respond to any question that
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makes you feel uncomfortable and are free to discontinue your participation at any point
during the study. While it is unlikely, there is also a risk of loss of privacy. We will keep
your study records private and confidential, and all data will be de-identified and kept in
a database that only researchers have access to. There will be no direct benefits to you by
taking part in this study. However, the information obtained from this study may be used
to help other smokers and vapers in the future.
Discontinuation of the Study
Participation in this study is voluntary. You are under no obligation to participate in this
study, and you are free to discontinue the study at any time without consequences to you.
There is no penalty for not participating. You may refuse to answer any questions that we
ask you. If you decide to withdraw from the study, the information provided by you will
not be retained.
Confidentiality
Your responses will be kept confidential. No identifying information will be collected
during this survey. All data collected will be entered into a HIPAA-compliant database
and stored on a password-protected server located in the Department of Psychology at
Florida Institute of Technology. Only authorized researchers will have access to this
information.
Questions?
Any questions about study participation may be directed to Sarah A. Sebban (Principal
Investigator) at SSebban2018@my.fit.edu.
This study has been reviewed and approved by the Florida Institute of Technology’s
Institutional Review Board. If you have any ethical questions or concerns about the
study, these may be directed to:
Dr. Jignya Patel, Chair for the Institutional Review Board
Institutional Review Board Office, School of Psychology
150 W. University Blvd
Melbourne, Florida, 32901
Phone: 321-674-7347
Email: FIT_IRB@fit.edu
Consent
In order to keep your information confidential, your name and signature are not
required. Please indicate your choice below. Should you choose to participate, you will
be directed automatically to the survey.
o I have read the information presented above about a study being conducted by
Sarah A. Sebban (Principal Investigator) of the School of Psychology at Florida
Institute of Technology. I am 18 years or older, and I understand that I may
withdraw from the study at any time. I agree to participate in this study.
o I have read the information presented about this study and I do not wish to
participate.
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APPENDIX B
Survey
Qualifying Information:
1. Are you 18 years of age or older?
a. Yes
b. No
2. Are you able to read and write English fluently?
a. Yes
b. No
3. Have you ever been told by a doctor, nurse, or other health professional that you have
a respiratory, pulmonary, or lung disease/illness (e.g., asthma, COPD, emphysema,
chronic bronchitis, interstitial lung disease, sleep apnea, etc.)?
a. Yes
b. No
4. Do you still have this respiratory, pulmonary, or lung disease/illness?
a. Yes
b. No
5. Have you smoked at least 100 cigarettes (including cigarillos, cigars, blunts, biddies,
or any other tobacco products) in your lifetime? 1 pack = 20 cigarettes, thus 5 packs =
100 Cigarettes
a. Yes (score=1)
b. No (score=0)
6. Have you ever used an electronic nicotine delivery system (ENDS) product
(including electronic cigarettes, e-cigarettes, e-cigs, vapes, e-hookahs, hookah pens,
or vape pens) even once in your lifetime? NOTE: If you have only used ENDS
devices containing cannabis products, please select ‘No’
a. Yes (score=1)
b. No (score=0)
7. Did you answer ‘Yes’ to either question 5 or 6 above?
a. Yes
b. No
8. Within the last 30 days, how often have you smoked cigarettes?
a. Nearly Every Day (score=1)
b. Some Days (score=1)
c. I have not smoked any cigarette product within the last 30 days (score=0)
9. Within the last 30 days, how often have you used an electronic nicotine delivery
system (ENDS)/vaping product?
a. Nearly Every Day (score=1)
b. Some Days (score=1)
c. I have not used any ENDS product within the last 30 days (score=0)

Demographics:
10. What is your current age?
a. 18-24 years old
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b. 25-34 years old
c. 35-44 years old
d. 45-54 years old
e. 55-64 years old
f. 65-74 years old
g. 75 years or older
11. What sexual orientation do you identify with?
a. Heterosexual (i.e., attracted to other sex)
b. Homosexual (i.e., attracted to same sex)
c. Bisexual
d. Asexual
e. Pansexual
f. Other: ____________________
12. What gender do you identify with?
a. Female
b. Male
c. Transwoman (MTF)
d. Transman (FTM)
e. Gender Fluid
f. Other: ___________________
13. What is your race?
a. White/Caucasian
b. Black/African American
c. Asian
d. American Indian/Alaskan Native
e. Hawaiian Native/Other Pacific Islander
f. Biracial/Multiracial
g. Other: __________________
14. What is your ethnicity?
a. Hispanic/Latino
b. Non-Hispanic/Latino
15. How would you describe the area you currently live in?
a. Urban/City
b. Rural/Country
16. What geographic region do you currently reside in?
a. Northeast: Maine, New Hampshire, Vermont, Massachusetts, Rhode Island,
Connecticut, New York, New Jersey, and Pennsylvania.
b. Midwest: Ohio, Indiana, Illinois, Michigan, Wisconsin, Minnesota, Iowa,
Missouri, North Dakota, South Dakota, Nebraska, and Kansas.
c. South: Delaware, Maryland, District of Columbia, Virginia, West Virginia,
North Carolina, South Carolina, Georgia, Florida, Kentucky, Tennessee,
Alabama, Mississippi, Arkansas, Louisiana, Oklahoma, and Texas.
d. West: Montana, Idaho, Wyoming, Colorado, New Mexico, Arizona, Utah,
Nevada, Washington, Oregon, California, Alaska, and Hawaii.
e. N/A, I live outside of the United States:
*What country do you currently live in? _________
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17. What is your current relationship status?
a. Single
b. In a relationship
c. Married
d. Divorced
e. Widowed
18. What is your highest level of education completed?
a. I did not graduate high school
b. High School Diploma/GED
c. Technical Degree/Certificate
d. Associate Degree
e. Bachelor’s Degree
f. Master’s Degree
g. Doctoral Degree
19. What is your approximate individual total annual income (before taxes)?
a. $0-$19,000
b. $20,000-$39,000
c. $40,000-$59,000
d. $60,000-$79,000
e. $80,000-$99,000
f. $100,000-$119,000
g. $120,000 and over
20. What is your current occupational status?
a. Employed full-time
b. Employed part-time
c. On disability
d. Retired
e. Unemployed
f. Student

Psychosocial:
21. Has a doctor, nurse, or other healthcare professional EVER told you that you had any
of the following chronic medical health conditions? [Please select all that apply]
a. Arthritis (rheumatoid arthritis, gout, lupus, fibromyalgia, etc.)
b. Cancer
c. Chronic fatigue syndrome
d. Chronic pain
e. Diabetes
f. Gastrointestinal (GI) disorder (Crohn’s disease, ulcerative colitis, irritable
bowel syndrome, or bowel incontinence)
g. Heart Disease (heart attack, congestive heart failure, angina, etc.)
h. HIV Disease (AIDS)
i. Hypertension (high blood pressure)
j. Kidney Disease
k. Multiple Sclerosis
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l. Parkinson’s Disease
m. Stroke
n. Traumatic brain injury or other brain-related injury
o. Any physical disability (e.g., quadriplegia, paraplegia, amputation, etc.)
p. Other: ________________________
22. Have you EVER been informed by a health professional that you have any of the
following mental health conditions? [Please select all that apply]
a. Anxiety
b. Bipolar Disorder
c. Depression (including dysthymia)
d. Obsessive Compulsive Disorder (OCD)
e. Post-Traumatic Stress Disorder (PTSD)
f. Personality Disorder
g. Schizophrenia
h. Sleep Disorder (e.g., insomnia)
i. Developmental Disability (ADHD, Learning Disorder, Autism Spectrum
Disorder, etc.)
j. Neurocognitive Disorder (Dementia, MCI, etc.)
k. Alcohol abuse
l. Drug abuse
m. Other: ________________________
23. Please rate the impact that your respiratory illness has had on the quality of your life.
a. My respiratory illness has negatively impacted (worsened) my quality of life
b. My respiratory illness has not impacted my quality of life (no change)
c. My respiratory illness has positively impacted (improved) my quality of life

Cigarette Smoking Status and History:
24. For how many years have you smoked cigarettes?
a. Years: ________
b. N/A, I have never smoked cigarettes
25. Does your spouse/partner currently smoke cigarettes?
a. Yes
b. No
c. N/A (No spouse / partner)
26. How many of your close friends currently smoke cigarettes?
a. 0
b. 1-2
c. 3 or more
27. Do you feel that you smoke cigarettes to manage/cope with stress?
a. Yes
b. No
c. N/A, I have never smoked cigarettes
28. Do you feel that your smoking habits have changed since/due to COVID-19?
a. No, my smoking habits have not changed since COVID-19
b. Yes, I started smoking cigarettes since the start of COVID-19
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c. Yes, I smoke more since COVID-19
d. Yes, I smoke less since COVID-19
e. N/A, I have never smoked cigarettes
ENDS Smoking Status and History:
29. If you use or have ever used e-cigarettes/vaping products, how much nicotine is
typically in your e-liquid?
a. Nicotine amount: _______________
b. None, my e-cigarettes/vaping product does not contain any nicotine
c. Not sure
d. N/A, I have never used e-cigarettes/vaping products
30. Have you ever used an e-cigarette/vaping product to inhale other substances, such as
CBD oil, alcohol, etc.?
a. Yes
b. No
c. N/A, I have never used e-cigarettes/vaping products
31. For how many years have you used e-cigarettes/vaping products?
a. Years: ________
b. N/A, I have never used e-cigarettes/vaping products
32. What are the reasons you have used, or might consider using, e-cigarettes/vaping
products? [Please select all that apply]
a. Friend or family member used
b. Help with quitting other tobacco products, such as cigarettes
c. E-cigarettes cost less than other tobacco products, such as cigarettes
d. E-cigarettes are easier to get than other tobacco products, such as cigarettes
e. Famous people on TV or in movies use e-cigarettes
f. E-cigarettes are less harmful to my health than cigarettes
g. E-cigarettes are available in a variety of flavors, such as mint, candy, fruit,
chocolate, etc.
h. E-cigarettes can be used discreetly in areas where other products, such as
cigarettes, are not allowed
i. E-cigarettes do not leave a bad smell or taste like cigarettes do
j. It is more socially acceptable to use e-cigarettes in my environment
k. Some other reason: __________________
l. N/A, I would never consider using e-cigarettes
33. For those who do not currently vape, do you intend to start using e-cigarettes/vaping
products?
a. Yes, within the next month
b. Yes, within the next 6 months
c. Yes, within the next year
d. Yes, sometime in the future
e. No, I do not have any intentions to start using e-cigarettes/vaping products
f. N/A, I already currently use e-cigarettes/vaping products
34. Does your spouse/partner currently use e-cigarettes/vape?
a. Yes
b. No
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c. N/A (No spouse/partner)
35. How many of your close friends currently use e-cigarettes/vape?
a. 0
b. 1-2
c. 3 or more
36. Do you feel that you use e-cigarettes/vaping products to manage or cope with stress?
a. Yes
b. No
c. N/A, I have never used e-cigarettes/vaping products
37. Do you feel that your use of e-cigarettes/vaping products have changed since/due to
COVID-19?
a. No, my vaping habits have not changed since COVID-19
b. Yes, I started using e-cigarettes since the start of COVID-19
c. Yes, I vape more since COVID-19
d. Yes, I vape less since COVID-19
e. N/A, I have never used e-cigarettes/vaping products

Respiratory Health Status and History
38. Please select the respiratory, pulmonary, or lung disease/illness you have been
diagnosed with. [Select all that apply]
a. Acute Respiratory Distress Syndrome (ARDS)
b. Asthma
c. Bronchiectasis
d. Bronchiolitis Obliterans
e. Chronic Obstructive Pulmonary Disease (COPD); including emphysema or
chronic bronchitis
f. Coronavirus Disease 2019 (COVID-19)
g. Cystic Fibrosis
h. Diffuse Panbronchiolitis
i. E-cigarette or Vaping product use Associated Lung Injury (EVALI)
j. Interstitial Lung Disease (ILD); including Pulmonary Fibrosis
k. Lung Cancer
l. Sleep Apnea (central, obstructive, or mixed)
m. Pulmonary Edema
n. Pulmonary Embolism
o. Pulmonary Hypertension
p. Severe Acute Respiratory Syndrome (SARS)
q. Tuberculosis
r. Other: _____________
39. Was your respiratory illness diagnosed before you started smoking or vaping?
a. Yes
b. No, I smoked/vaped first
c. Don’t know / Not sure
40. Have you ever been given a breathing test (Pulmonary Function Test) to assess your
breathing problems?
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a. Yes
b. No
c. Don’t know / Not sure
41. During the past 12 months, have you visited an emergency room or urgent care center
because of your respiratory, pulmonary, or lung disease/illness?
a. Yes
b. No
42. During the past 12 months, have you seen a doctor, nurse, or other healthcare
professional for a routine checkup of your respiratory, pulmonary, or lung
disease/illness?
a. Yes
b. No
43. Do you currently take/use medication for your respiratory, pulmonary, or lung
disease/illness?
a. Yes
b. No
44. Do you currently use any type of medically prescribed inhaler?
a. Yes
b. No
45. During the past 12 months, have you had an episode of severe symptom
exacerbation/attack?
a. Yes
b. No
46. During the past 3 months, have you used the kind of PRESCRIPTION inhaler that
gives QUICK relief from symptoms during an exacerbation/attack?
a. Yes
b. No
47. During the past 30 days, how many days did you take a preventative medication (i.e.,
maintenance inhaler) to PREVENT a symptom exacerbation/attack from occurring?
a. Never
b. 1 to 14 days
c. 15 to 24 days
d. 25 to 30 days
ENDS Health Risk Perceptions
*Please complete the following questions regardless of if you smoke OR vape.
48. E-cigarettes are harmful to one’s health.
a. Strongly Agree (score=3)
b. Agree (score=2)
c. Disagree (score=1)
d. Strongly Disagree (score=0)
49. Do you believe the use of e-cigarettes/vaping is less harmful, equally harmful, or
more harmful for people with pulmonary/respiratory problems than smoking regular
cigarettes?
a. Less harmful (score=0)
b. As harmful (score= 1)
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c. More harmful (score=2)
50. Compared to people your age without pulmonary/respiratory problems, do you
believe it is less harmful, equally harmful, or more harmful for people with
pulmonary/respiratory problems to use e-cigarettes?
a. Less harmful (score=0)
b. As harmful (score= 1)
c. More harmful (score=2)
51. Using e-cigarettes would lead to serious health problems for someone like me in the
next few months.
a. Strongly Agree (score=3)
b. Agree (score=2)
c. Disagree (score=1)
d. Strongly Disagree (score=0)
52. Using e-cigarettes would lead to serious health problems for someone like me, down
the road (in the long-term future).
a. Strongly Agree (score=3)
b. Agree (score=2)
c. Disagree (score=1)
d. Strongly Disagree (score=0)
53. People with pulmonary/respiratory problems should not use e-cigarettes.
a. Strongly Agree (score=3)
b. Agree (score=2)
c. Disagree (score=1)
d. Strongly Disagree (score=0)
54. E-cigarettes are a safer alternative to regular cigarettes.
a. Strongly Agree (score=0)
b. Agree (score=1)
c. Disagree (score=2)
d. Strongly Disagree (score=3)
55. Do you believe that breathing in second-hand vapors from e-cigarettes is less
harmful, equally as harmful, or more harmful than breathing in second-hand cigarette
smoke?
a. Less harmful (score=0)
b. As harmful (score= 1)
c. More harmful (score=2)
56. Inhaling vapors from e-cigarettes can harm one’s health.
a. Strongly Agree (score=3)
b. Agree (score=2)
c. Disagree (score=1)
d. Strongly Disagree (score=0)
57. Use of e-cigarettes is:
a. Less harmful to me than regular cigarettes (score=0)
b. As harmful to me as regular cigarettes (score=1)
c. More harmful to me than regular cigarettes (score=2)
58. I am hesitant to use e-cigarettes because of possible health risks.
a. Strongly Agree (score=3)
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b. Agree (score=2)
c. Disagree (score=1)
d. Strongly Disagree (score=0)
59. My respiratory/pulmonary symptoms will worsen if I use e-cigarettes.
a. Strongly Agree (score=3)
b. Agree (score=2)
c. Disagree (score=1)
d. Strongly Disagree (score=0)
60. The benefits of using e-cigarettes far outweigh the risks.
a. Strongly Agree (score=0)
b. Agree (score=1)
c. Disagree (score=2)
d. Strongly Disagree (score=3)
61. My risk of becoming ill from using e-cigarettes is low.
a. Strongly Agree (score=0)
b. Agree (score=1)
c. Disagree (score=2)
d. Strongly Disagree (score=3)

Smoking Cessation Perceptions Regarding ENDS
62. E-cigarettes/vaping products could help me OR others quit smoking regular cigarettes
(i.e., e-cigarettes are an effective method of smoking cessation).
a. Strongly Agree (score=3)
b. Agree (score=2)
c. Disagree (score=1)
d. Strongly Disagree (score=0)
63. E-cigarettes/vaping products could help me OR others reduce the number of
cigarettes smoked.
a. Strongly Agree (score=3)
b. Agree (score=2)
c. Disagree (score=1)
d. Strongly Disagree (score=0)

Healthcare Provider Communication:
64. Have any of your healthcare providers ever discussed the risks of smoking with you?
a. Never (score=0)
b. Once or Twice (score=1)
c. Frequently (score=2)
65. Have any of your healthcare providers ever discussed the risks of vaping with you?
a. Never (score=0)
b. Once or Twice (score=1)
c. Frequently (score=2)
66. Have any of your healthcare providers advised you to use typical smoking cessation
interventions, such as Nicotine Replacement Therapy (patch, lozenge, gum, nasal

143

spray), Non-Nicotine Replacement Therapy (Chantix, Wellbutrin, Elavil), or
Behavioral Counseling (therapy) to quit smoking or reduce the number of cigarettes
smoked?
a. Never (score=0)
b. Once or Twice (score=1)
c. Frequently (score=2)
67. Have any of your healthcare providers advised the use of e-cigarettes/vaping products
to quit cigarette smoking or reduce the number of cigarettes smoked?
a. Never (score=2)
b. Once or Twice (score=1)
c. Frequently (score=0)

Health Risk Variables:
(A) Health Status
68. Would you say your general health is:
a. Excellent (score=0)
b. Good (score=1)
c. Fair (score=2)
d. Poor (score=3)
e. Terrible (score=4)
69. Would you say your respiratory health is:
a. Excellent (score=0)
b. Good (score=1)
c. Fair (score=2)
d. Poor (score=3)
e. Terrible (score=4)

(B) Stress Level
70. In the last month, how often have you felt that you were unable to control the
important things in your life?
a. Never (score=0)
b. Almost Never (score=1)
c. Sometimes (score=2)
d. Fairly Often (score=3)
e. Very Often (score=4)
71. In the last month, how often have you felt confident about your ability to handle your
personal problems?
a. Never (score=4)
b. Almost Never (score=3)
c. Sometimes (score=2)
d. Fairly Often (score=1)
e. Very Often (score=0)
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72. In the last month, how often have you felt things were going your way?
a. Never (score=4)
b. Almost Never (score=3)
c. Sometimes (score=2)
d. Fairly Often (score=1)
e. Very Often (score=0)
73. In the last month, how often have you felt difficulties were piling up so high that you
could not overcome them?
a. Never (score=0)
b. Almost Never (score=1)
c. Sometimes (score=2)
d. Fairly Often (score=3)
e. Very Often (score=4)

(C) Respiratory Symptom Severity
74. Thinking about your respiratory illness symptoms, please rate the frequency/severity
of each symptom listed below:
None Slight Mild Moderate Moderately Severe Severe
Chest pain/tightness
0
1
2
3
4
5
Coughing
0
1
2
3
4
5
Difficulty breathing in
0
1
2
3
4
5
Fatigue

0

1

2

3

4

5

Frequent need to clear
throat
Heavy/rapid breathing

0

1

2

3

4

5

0

1

2

3

4

5

Itchy/dry throat

0

1

2

3

4

5

Phlegm production

0

1

2

3

4

5

Recurrent colds

0

1

2

3

4

5

Shortness of breath

0

1

2

3

4

5

Sleeping issues

0

1

2

3

4

5

Stuffed sinus/runny nose

0

1

2

3

4

5

Weight loss/gain

0

1

2

3

4

5

Wheezing

0

1

2

3

4

5
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(D) Level of Functioning
75. As it pertains to your respiratory illness, please rate your typical level of difficulty/
impairment with completing each activity below.
No
Slight
Mild
Moderate Moderately Severe
difficulty difficulty difficulty difficulty
Severe
difficulty
difficulty
Bathing/showering
0
1
2
3
4
5
Eating/swallowing
0
1
2
3
4
5
Getting dressed
0
1
2
3
4
5
Going up stairs
0
1
2
3
4
5
Lifting a heavy object
0
1
2
3
4
5
Running a short
0
1
2
3
4
5
distance
Sleeping/resting
0
1
2
3
4
5
Shopping
0
1
2
3
4
5
Toileting
0
1
2
3
4
5
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